cytarabine has been researched along with Leukemia, Myeloid in 1086 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 310 (28.55) | 18.7374 |
| 1990's | 379 (34.90) | 18.2507 |
| 2000's | 333 (30.66) | 29.6817 |
| 2010's | 57 (5.25) | 24.3611 |
| 2020's | 7 (0.64) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L; Peng, S; Wang, Y; Wu, J; Yang, Y; Zhang, X; Zhao, M; Zheng, M | 1 |
| Amsberg, GV; Dyshlovoy, SA; Kantemirov, A; Lebedev, T; Prassolov, V; Shyrokova, E; Smirnova, P; Spirin, P; Vagapova, E; Zhidkov, M | 1 |
| Chen, S; Feng, L; Hao, C; Lao, Y; Li, B; Liu, N; Mack, R; Peng, M; Shao, X; Song, J; Sun, X; Wang, S; Wang, T; Wei, W; Wu, Y; Yin, L; Zhang, J; Zhang, L | 1 |
| Gao, W; Hu, J; Jiang, J; Wan, M; Wang, L | 1 |
| Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H | 1 |
| Bergman, AM; Cloos, J; Comijn, EM; Jansen, G; Jaramillo, AC; Kaspers, GJL; Peters, GJ | 1 |
| Jaramillo, S; Schlenk, RF | 1 |
| Alonzo, T; Beckman, A; Berman, JN; Brodersen, L; Chisholm, K; Druley, T; Gamis, A; Gerbing, R; Heerema-McKenney, A; Hijiya, N; Hirsch, B; Hitzler, J; Kolb, EA; Loken, M; O'Brien, M; Raimondi, S; Schore, R; Taub, J; Tong, S; Viola, S; Wang, YC | 1 |
| Heisel, RW; Lim, SH; Mascara, GP; Oleksiuk, LM; Sutton, RR; Weber, DR; Winger, DG | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
| Inokuchi, K; Kitano, T; Miyake, K; Miyake, N; Omori, I; Yamaguchi, H | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Chan, S; Farshchi Zarabi, S; Gupta, V; Khalaf, D; Lutynski, A; Minden, MD; Rostom, A; Rydlewski, A; Schimmer, AD; Schuh, AC; Sibai, H; Yee, KWL | 1 |
| Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K | 1 |
| Becker, PS; Chiarella, MT; Estey, EH; Hendrie, PC; Louie, AC; McDaniel, EN; Medeiros, BC; Orlowski, KF; Othus, M; Percival, MM; Scott, BL; Walter, RB | 1 |
| Cetkovský, P; Mayer, J; Novák, J; Pecherková, P; Petečuková, V; Ráčil, Z; Šálek, C; Schwarz, J; Vydra, J; Žák, P | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| Creutzig, U; de Haas, V; Flasinski, M; Klusmann, JH; Reinhardt, D; Reinhardt, K; Scheibke, K; van der Velden, VHJ; Verwer, F; von Neuhoff, C; Zimmermann, M; Zwaan, CM | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| Kajimura, Y; Matsuguma, M; Nakamura, Y; Tanaka, M; Tanaka, Y; Tanizawa, Y; Tokunaga, Y; Yamamoto, K; Yujiri, T | 1 |
| Chen, Y; Cheng, N; Feng, Y; Lai, W; Liu, J; Zhang, L | 1 |
| Stone, RM | 1 |
| Cao, X; Cen, J; Chen, Z; Gu, W; Li, M; Liu, Y; Xiang, L; Xie, X; Zhen, X | 1 |
| Côté, S; Momparler, LF; Momparler, RL | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Chen, F; Liu, J; Peng, M; Zhao, X | 1 |
| Amadori, S; Berneman, Z; De Fabritiis, P; de Witte, T; Falzetti, F; Fazi, P; Guimaraes, JE; Halkes, CJ; Ho, AD; Karrasch, M; Latagliata, R; Lübbert, M; Magro, D; Marie, JP; Muus, P; Salih, HR; Selleslag, D; Specchia, G; Stasi, R; Suciu, S; Thomas, X; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Abraham, R; Barkoh, BA; Luthra, R; Medeiros, LJ; Mehrotra, M; Mishra, BM; Patel, KP; Ravandi, F; Sargent, RL | 1 |
| Brandt, M; Choi, S; Cortes, J; Faderl, S; Garcia-Manero, G; Ghanem, H; Huang, X; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S | 1 |
| Estey, EH; Pagel, JM; Sandhu, RK; Ueda, M; Walter, RB; Xie, H | 1 |
| Bradtke, J; Jung, R; Krumbholz, M; Metzler, M; Reinhardt, D; Stachel, D | 1 |
| Ancelet, LR; Compton, BJ; Gibbins, JD; Hermans, IF; Painter, GF; Petersen, TR; Weinkove, R | 1 |
| Lan, FM; Li, HM | 1 |
| Aoki, K; Aotsuka, N; Arai, Y; Atsuta, Y; Kato, K; Kondo, T; Kouzai, Y; Nakamae, H; Nakaseko, C; Onishi, Y; Ota, S; Ozawa, Y; Takahashi, S; Takami, A; Takeda, J; Yamaguchi, H | 1 |
| Adachi, S; Goto, H; Horibe, K; Ito, E; Iwamoto, S; Kinoshita, A; Koh, K; Kudo, K; Moritake, H; Nakahata, T; Nakayama, H; Saito, AM; Shimada, A; Taga, T; Takahashi, H; Taki, T; Tawa, A; Terui, K; Toki, T; Tomizawa, D; Watanabe, T | 1 |
| Bosse, RC; Chaplin, DJ; Cogle, CR; Drusbosky, L; Meacham, A; Purich, DL; Siemann, DW; Walter, GA; Wasserstrom, B; Wise, E | 1 |
| Bone, E; Burnett, A; Davidson, A; Gilmour, M; Hills, R; Knapper, S; Vyas, P; Zabkiewicz, J | 1 |
| Afanasyev, B; Arcese, W; Bacigalupo, A; Beelen, D; Ciceri, F; Giebel, S; Gülbas, Z; Koc, Y; Labopin, M; Mohty, M; Nagler, A; Piemontese, S; Polge, E; Rubio, MT; Santarone, S; Savani, BN; Schmid, C; Tischer, J; Wu, D | 1 |
| Chen, JR; Jia, XH; Li, YJ; Wang, H; Wang, JY; Xie, SY; Yi, YJ | 1 |
| Braun, JT; Freter, CE; Lionberger, JM; Petruska, PJ; Ramlal, R; Schoen, MW; Woelich, SK | 1 |
| Canning, C; DeAngelo, DJ; Galinsky, I; Janosova, A; Ritz, J; Soiffer, RJ; Stone, RM | 1 |
| Bousema, MT; Hayes, DP; Kardaun, SH; Kramer, MH; Timmer-de Mik, L | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Eddington, JK; Keefer, LK; Kosak, KM; Maciag, AE; Saavedra, JE; Shami, PJ; Udupi, V | 1 |
| Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| Anensen, N; Bruserud, Ø; Bø, TH; Gjertsen, BT; Jonassen, I; Kalland, KH; Stordrange, L; Øyan, AM | 1 |
| Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W | 1 |
| Fathi, AT; Karp, JE | 1 |
| de Bont, ES; Kamps, WA; Koetse, HA; Rings, EH; Stellaard, F; Tissing, WJ; van Vliet, MJ | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Luong, TM; McHayleh, W; Natale, J; Raptis, A; Redner, RL; Schlesselman, JJ; Sehgal, R | 1 |
| Einsele, H; Grigoleit, GU; Kapp, M; Mielke, S; Stuhler, G; Tan, SM; Topp, MS; Unzicker, C | 1 |
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
| Faderl, S | 1 |
| Rowe, JM | 1 |
| Baruchel, A; Clavel, J; Nacka, F; Pérel, Y; Tandonnet, J | 1 |
| Ai, HS; Dong, Z; Guo, M; Hu, KX; Huang, YJ; Liu, GX; Qiao, JH; Qiao, JX; Sun, QY; Sun, WJ; Sun, XD; Wang, DH; Wei, L; Yu, CL | 1 |
| Prenkert, M; Strid, H; Tidefelt, U; Uggla, B | 1 |
| Andreeff, M; Carter, BZ; Coombes, KR; Kantarjian, HM; Koller, E; Kornblau, SM; Mak, DH; Qiu, YH; Ravandi, F; Thomas, DA; Zhang, N | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| Ashcroft, J; Moreton, P; Parrish, C | 1 |
| Guan, XQ; Huang, LB; Ke, ZY; Luo, XQ; Xu, L; Zhang, XL; Zhang, YC | 1 |
| Lowe, SW; Pardee, TS; Zuber, J | 1 |
| Gerhard, B; Harasym, TO; Hogge, DE; Kim, HP; Mayer, LD | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Hsiao, PF; Lin, J; Wu, YH | 1 |
| Gocek, E; Liu, CG; Liu, X; Studzinski, GP; Wang, X | 1 |
| Alonzo, TA; Arceci, RJ; Barnard, D; Doyle, J; Gamis, AS; Gerbing, RB; Hilden, JM; Loew, TW; Massey, G; Perentesis, J; Ravindranath, Y; Sharma, M; Smith, FO; Sorrell, AD; Taub, J | 1 |
| Artz, A; Campbell, NP; Daugherty, C; Gajria, D; Godley, LA; Green, M; Gurbuxani, S; Huo, D; Hyjek, E; Larson, RA; Larson, SM; Odenike, O; Sipkins, D; Stock, W; Thirman, M; Van Besien, K; Weiner, H; Zhang, Y | 1 |
| Apfelbaum, SM; Burbage, M; Kircher, S; Kirsch, K; Lofwall, M; Passik, S; Zacny, J | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Minden, MD; Murray, C; Nixon, S; Saini, L; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Arora, S; Azorsa, DO; Bogenberger, JM; Braggio, E; Buechel, ME; Chaudhuri, L; Chow, D; Demuth, T; Gonzales, IM; Hagelstrom, RT; Mesa, RA; Slack, J; Tibes, R; Yin, HH | 1 |
| Alonzo, TA; Arceci, RJ; Barnard, D; Gamis, AS; Gerbing, RB; Hathaway, L; Hilden, JM; Loew, TW; Ravindranath, Y; Smith, FO; Sorrell, AD; Taub, JW; Woods, WG | 1 |
| Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A | 1 |
| Chi, M; Estey, E; Lin, A; McQuary, A; Othus, M | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, SH; Kim, YK; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, J; Shin, MG; Sohn, SK; Won, JH | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Andreeff, M; Cragg, LH; Feldman, E; Grant, S; Kramer, L; Murgo, A; Roberts, J; Roboz, G; Tombes, MB; Winning, M | 1 |
| Wheatley, K | 1 |
| Andreeff, M; Champlin, R; Estey, E; Hu, W; Jackson, CE; Jiang, S; Konopleva, M; Reed, JC; Snell, V; Weidner, D; Zhang, X; Zhao, S | 1 |
| Gibson, AD | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Belleri, M; Presta, M; Ribatti, D; Vacca, A | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H | 1 |
| Sekeres, MA; Stone, R | 1 |
| Barbui, T; Bassan, R; Buelli, M; Chiodini, B; Giussani, U; Lerede, T; Oldani, E; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Andreu, R; Benlloch, L; Cervera, J; de la Rubia, J; García, I; Jarque, I; Jiménez, C; Martín, G; Martínez, J; Mollá, S; Moscardó, F; Regadera, A; Sanz, G; Sanz, M | 1 |
| Afanasiev, BV; Andreeff, M; Hu, W; Konoplev, S; Konopleva, M; Zaritskey, AY | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Tay, J | 1 |
| Creutzig, U; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Pieters, R; Slater, RM; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Benner, A; Breitruck, J; Döhner, H; Döhner, K; Fröhling, S; Kreitmeier, S; Schlenk, RF; Tobis, K | 1 |
| Anderson, JE; Appelbaum, FR; Balcerzak, SP; Chen, IM; Head, D; Johnson, DB; Kopecky, KJ; Luthardt, FW; Norwood, TH; O'Donnell, MR; Willman, CL | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Carroll, AJ; Davey, FR; Dodge, RK; Edwards, CG; Feldman, EJ; Koduru, PR; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Patil, SR; Pettenati, MJ; Rao, KW; Schiffer, CA; Stone, RM; Watson, MS | 1 |
| Barge, RM; Honders, MW; Veuger, MJ; Willemze, R | 1 |
| Beelen, D; Flasshove, M; Kasimir-Bauer, S; Noppeney, R; Scheulen, ME; Seeber, S | 1 |
| Aledo, A; Alonzo, TA; Buxton, AB; Kobrinsky, NL; Lange, BJ; Woods, WG | 1 |
| Alvarez, R; Beran, M; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, AM | 1 |
| Grant, S; Wang, S; Wang, Z | 1 |
| Ravindranath, Y | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Appelbaum, FR; Banker, DE; Li, HY; Willman, CL; Zager, RA | 1 |
| Black, JH; Frankel, AE; Hogge, DE; McCubrey, JA; Ramage, J; Willingham, MC | 1 |
| Björkholm, M; Brinch, L; Evensen, S; Gruber, A; Gustavsson, B; Hedenus, M; Juliusson, G; Liliemark, J; Löfvenberg, E; Nesthus, I; Paul, C; Simonsson, B; Sjo, M; Stenke, L; Tangen, JM; Tidefelt, U; Udén, AM | 1 |
| Elhamri, M; Le, QH; Tavernier, E; Thomas, X | 1 |
| Estey, EH; Thall, PF | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Holowiecki, J; Jamroziak, K; Konopka, L; Kuliczkowski, K; Maj, S; Marianska, B; Mazur, G; Robak, T; Wierzbowska, A; Wrzesien-Kus, A; Zawilska, K | 1 |
| Arber, DA; Dagis, A; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, AP; Niland, JC; O'Donnell, MR; Parker, P; Rodriguez, R; Slovak, ML; Snyder, DS; Somlo, G; Spielberger, RT; Stein, AS; Vora, N; Wang, S | 1 |
| Ali, R; Kimya, Y; Ozan, U; Ozçelik, T; Ozkalemkaş, F; Ozkocaman, V; Tunali, A | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Baer, MR; Barcos, M; Blumenson, L; Ferrone, S; Ford, LA; McElwain, BK; Mortazavi, A; Slack, JL; Stewart, CC; Wetzler, M | 1 |
| Robak, T | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Knau, A; Mitrou, PS; Napieralski, S; Nowak, D; Weidmann, E | 1 |
| Bagg, A; Carroll, M; Scialla, TJ; Simpson, SE; Xu, Q | 1 |
| Pandit, SR; Raheem, MA | 1 |
| Aulitzky, W; Bodenstein, H; Ehninger, G; Gramatzki, M; Helm, G; Link, H; Pascheberg, U; Repp, R; Schaekel, U; Sonnen, R; Soucek, S; Thiede, C; Wandt, H | 1 |
| Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC | 1 |
| Burnett, AK; Chang, J; Chopra, R; Ewing, JC; Kell, WJ; Morgenstern, GR; Robertson, JD; Ryder, D; Scarffe, JH | 1 |
| Allen, SL; Archer, KJ; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; de la Chapelle, A; Kolitz, JE; Larson, RA; Marcucci, G; Moore, JO; Powell, BL; Ruppert, AS; Tanner, SM; Vardiman, JW; Whitman, SP | 1 |
| Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y | 1 |
| He, XY; Kalaycio, M; Lichtin, A; Pohlman, B; Rybicki, L | 1 |
| Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG | 1 |
| Cros, E; Dumontet, C; El Jafaari, A; Galmarini, CM; Graham, K; Jordheim, L; Mackey, JR; Thomas, X | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Hovi, L; Jonmundsson, G; Lie, SO; Mellander, L | 1 |
| Bron, AJ; Lochhead, J; Salmon, JF | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Benner, A; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Grimminger, W; Gunzer, U; Haas, R; Hartmann, F; Hensel, M; Pezzutto, A; Pralle, H; Preiss, J; Schlenk, RF; Weber, C; Weber, W | 1 |
| Burnett, AK; Chopra, R; Clark, RE; Culligan, D; Hunter, A; Kell, WJ; Milligan, DW; Prentice, AG; Rohatiner, A; Yin, JA | 1 |
| Ito, Y; Katagiri, T; Nakajima, A; Ohyashiki, K; Shimamoto, T | 1 |
| Chng, WJ | 1 |
| Bernell, P; Björkholm, M; Celsing, F; Dahl, IM; Dybedal, I; Gahrton, G; Hast, R; Hellström-Lindberg, E; Lerner, R; Lindberg, G; Linder, O; Löfvenberg, E; Nilsson-Ehle, H; Oberg, G; Ohm, L; Paul, C; Samuelsson, J; Tangen, JM; Tidefelt, U; Turesson, I; Wahlin, A; Wallvik, J; Winquist, I | 1 |
| Okamoto, Y; Pui, CH; Razzouk, BI; Ribeiro, RC; Shenep, JL; Srivastava, DK | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Andretta, C; Camera, A; Ciancia, R; Della Cioppa, P; Picardi, M; Rinaldi, CR; Rossi, M; Rotoli, B; Selleri, C; Villa, MR; Volpicelli, M | 1 |
| Abboud, CN; Bennett, JM; Dewald, G; Friedenberg, W; Hayes, FA; Liesveld, JL; Makary, AZ; Neuberg, D; Paietta, E; Rowe, JM; Tallman, MS; Wiernik, PH | 1 |
| Depil, S; Quesnel, B; Saudemont, A; Vereecque, R | 1 |
| Creutzig, U; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Reinhardt, D; Varwig, D | 1 |
| Bagrintseva, K; Eichenlaub, S; Ellwart, JW; Hiddemann, W; Kohl, TM; Schnittger, S; Schwab, R; Spiekermann, K | 1 |
| Aslan, D; Cetin, M; Hiçsönmez, G; Ozyürek, E; Tuncer, AM; Unal, S; Yenicesu, I | 1 |
| Brien, B; Chang, H; Minden, MD; Patterson, B; Salma, F; Yi, QL | 1 |
| Björkholm, M; Höglund, M; Juliusson, G; Karlsson, K; Löfgren, C; Möllgård, L; Paul, C; Tidefelt, U | 1 |
| Ahlgren, T; Billström, R; Brune, M; Hedenus, M; Höglund, M; Markevärn, B; Nilsson, B; Sallerfors, B; Simonsson, B; Stockelberg, D; Wahlin, A | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Graf, M; Hecht, K; Nuessler, V; Pelka-Fleischer, R; Pfister, K; Reif, S; Schmetzer, H | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Ahn, HS; Choi, HS; Han, KS; Kang, HJ; Shin, HY | 1 |
| Andreeff, M; Hu, SX; Konopleva, M; Marini, FC; McQueen, T; Ruvolo, PP; Tacke, F; Xu, HJ; Zhao, S | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| Grazide, S; Jaffrézou, JP; Laurent, G; Lerouge, S; Terrisse, AD | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Aström, M; Björkholm, M; Hast, R; Hedenius, M; Lerner, R; Liliemark, J; Löfgren, C; Nilsson, I; Paul, C; Rödjer, S; Simonsson, B; Stockelberg, D; Tidefelt, U | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Carroll, AJ; Davey, FR; Edwards, CG; Koduru, PR; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Ruppert, AS; Stamberg, J | 1 |
| Altundag, K; Altundag, O; Celik, I; Kars, A; Turker, A | 1 |
| Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Santana, VM; Srivastava, DK | 1 |
| Chaoui, D; Faussat, AM; Legrand, O; Majdak, P; Marie, JP; Perrot, JY; Tang, R | 1 |
| Baer, MR; Bloomfield, CD; George, SL; Kolitz, JE; Larson, RA; Lee, EJ | 1 |
| Auvrignon, A; Baruchel, A; Couillaud, G; Dalle, JH; Gandemer, V; Lamagnere, JP; Leblanc, T; Leverger, G; Mèchinaud, F; Michel, G; Pautard, B; Perel, Y; Piguet, Ch; Schmitt, C; Vannier, JP | 1 |
| Haferlach, T; Hiddemann, W; Kern, W; Schnittger, S; Schoch, C; Voskova, D | 1 |
| Cros, E; Dumontet, C; Galmarini, CM; Graham, K; Mackey, JR; Thomas, X | 1 |
| Boccadoro, M; Campa, E; Campana, S; Dellacasa, C; Ferrero, D; Foli, C | 1 |
| Gotoh, A; Nakajima, A; Ohyashiki, JH; Ohyashiki, K; Sashida, G; Shin-Ya, K; Sumi, M; Tauchi, T | 1 |
| Quesnel, B; Saudemont, A; Vereecque, R | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Aschan, J; Dugas, M; Hahn, J; Hegenbart, U; Holler, E; Kolb, HJ; Ledderose, G; Niederwieser, D; Ringdén, O; Schleuning, M; Schmid, C | 1 |
| Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, KF; Brighton, T; Cannell, P; Catalano, J; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Joshua, D; Juneja, S; Koutts, J; Leahy, M; Lowenthal, RM; Matthews, JP; Schwarer, AP; Szer, J; Taylor, K; Young, GA | 1 |
| Blazek, B; Cerná, Z; Gajdos, P; Hak, J; Hrstková, H; Hrusák, O; Jabali, Y; Kopecná, L; Michalová, K; Procházková, D; Ptoszková, H; Sedlácek, P; Smísek, P; Starý, J; Timr, P; Tousovská, K; Vávra, V | 1 |
| Baccarani, M; Gaitani, S; Malagola, M; Martinelli, G; Piccaluga, PP; Rondoni, M; Visani, G | 1 |
| Braess, J; Fiegl, M; Hiddemann, W; Lorenz, I; Schneiderat, P; Schoch, C | 1 |
| Batlle, M; Besalduch, J; Brunet, S; Bueno, J; Carreras, E; Esteve, J; Feliu, E; Guàrdia, R; Julià, A; Llorente, A; Montserrat, E; Oriol, A; Pedro, C; Ribera, JM; Sánchez, JM; Sierra, J; Tormo, M; Vilà, JM; Vivancos, P | 1 |
| Holyoake, TL; McQuaker, IG; Osborne, WL; Parker, AN | 1 |
| Abrahams, L; du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Böhmer, FD; Kirsch, C; Klinger, R; Scholl, S | 1 |
| Abdel-Latif, ME; Ariffin, H; Ariffin, WA; Chan, LL; Lin, HP | 1 |
| Gaziev, D; Grafone, T; Isidori, A; Malagola, M; Martinelli, G; Ottaviani, E; Piccaluga, PP; Santini, V; Sparaventi, G; Tosi, P; Tura, S; Visani, G | 1 |
| Cros, E; Dumontet, C; Galmarini, CM; Jordheim, L | 1 |
| Hokland, P; Stentoft, J; Østergaard, M | 1 |
| Feuring-Buske, M; Frankel, AE; Gerhard, B; Hogge, DE | 1 |
| Brown, CA; Hashem, B; Lane, JE; Lesher, JL; Marzec, T | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Allen, SL; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Hoke, E; Hurd, DD; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Shea, TC; Vardiman, JW; Velez-Garcia, E | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Broekhuizen, R; Cloos, J; Creutzig, U; Fleischhack, G; Haarman, EG; Hubeek, I; Huismans, DR; Kaspers, GJ; Litvinova, E; Peters, GJ; Zwaan, CM | 1 |
| Amrein, PC; Baer, MR; Bloomfield, CD; Davey, FR; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Schiffer, CA | 1 |
| Benderra, Z; Chaoui, D; Faussat, AM; Legrand, O; Marie, JP; Perrot, JY; Sayada, L | 1 |
| Kalaycio, M | 1 |
| Celik, I; Cetinkaya, YS; Gonen, C; Haznedaroglu, I | 1 |
| Gale, RE; Grandage, VL; Khwaja, A; Linch, DC | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E | 1 |
| Naito, K; Ohnishi, K | 1 |
| Forestier, E; Frost, BM; Gustafsson, G; Hellebostad, M; Jonsson, OG; Kanerva, J; Larsson, R; Lönnerholm, G; Nygren, P; Palle, J; Schmiegelow, K | 1 |
| Brandwein, J; Chun, K; Gupta, V; Minden, M; Schuh, A; Wells, R; Yi, QL | 1 |
| Baran, W; Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Kiebiński, M; Krawczyńska, A; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Mazur, G; Pluta, A; Robak, T; Wach, M; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
| Cedrone, M; Chierichini, A; Diverio, D; Foà, R; Lo Coco, F; Mariani, G; Pasquini, L; Pelosi, E; Peschle, C; Riccioni, R; Rossini, A; Saulle, E; Testa, U; Vitale, A | 1 |
| Fonatsch, C; Gaiger, A; Jäger, U; Kainz, B; Schwarzinger, I; Sperr, WR | 1 |
| Chau, WK; Chen, CC; Gau, JP; Ho, CH; Hsu, HC; Kwang, WK; Lee, KD; Tzeng, CH; Yang, CF; Yang, MH; You, JY; Yu, YB | 1 |
| Baer, MR; Ford, LA; Greco, WR; Minderman, H; O'Loughlin, KL; Pendyala, L; Smith, PF; Sweeney, KG; Wetzler, M | 1 |
| Botton, Sd; Chelghoum, Y; Dhedin, N; Dombret, H; Dreyfus, F; Elhamri, M; Fenaux, P; Guerci, A; Le, Q; Michallet, M; Pautas, C; Pigneux, A; Raffoux, E; Reman, O; Revel, Td; Thiebaut, A; Thomas, X; Travade, P; Troncy, J; Vekhoff, A | 1 |
| Avet-Loiseau, H; Chevallier, P; Dubruille, V; Garand, R; Guillaume, T; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, P; Roland, V; Vigouroux, S | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP | 1 |
| Armata, J; Balcerska, A; Balwierz, W; Chybicka, A; Dluzniewska, A; Kowalczyk, J; Matysiak, M; Ochocka, M; Radwanska, U; Rokicka-Milewska, R; Sonta-Jakimczyk, D; Wachowiak, J; Wysocki, M | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
| Becton, D; Camitta, B; Carroll, A; Chang, M; Civin, C; Dahl, G; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, HJ | 1 |
| Lemez, P; Urbánek, V | 1 |
| Brychtova, Y; Buchtova, I; Doubek, M; Mayer, J; Palasek, I | 1 |
| Horácek, JM; Jebavý, L; Malý, J; Praus, R; Pudil, R; Strasová, A; Tichý, M; Zák, P | 1 |
| Schiffer, CA | 2 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Berger, MS; Cheng, SC; Cortes-Franco, JE; Estey, EH; Giles, FJ; Leopold, LH | 1 |
| Hasle, H; Hokland, P; Lund, B; Nyvold, CG; Østergaard, M | 1 |
| Braess, J; Fiegl, M; Hiddemann, W; Lorenz, I; Waxenberger, K | 1 |
| Bloomfield, CD | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Beason, K; Hughson, M; Kozlov, I; Yu, C | 1 |
| Ball, ED; Bashey, A; Carrier, E; Castro, JE; Corringham, S; Hassidim, K; Holman, P; Ihasz, A; Keese, K; Lane, TA; Liu, L; Medina, B | 1 |
| Hasz, DE; Largaespada, DA; Mao, Z; Morgan, K; Yin, B | 1 |
| Stiefelhagen, P | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Cros, E; Dumontet, C; Galmarini, CM; Jordheim, L; Thomas, X | 1 |
| Broekhuizen, R; Cloos, J; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Kuik, DJ; Meijerink, JP; Peters, GJ; Pieters, R; Stam, RW; van Wering, ER; Zwaan, CM | 1 |
| Barbé, G; Bertrand, Y; Bleyzac, N; Brunet, AS; Freydière, AM; Galambrun, C; Pages, MP; Ploton, C; Pondarré, C | 1 |
| Sekeres, MA | 1 |
| Beran, M; Cortes, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Koller, C; Kwari, M; O'Brien, S; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Bennett, J; Cripe, LD; Gordon, MS; Litzow, MR; Neuberg, D; O'brien, TE; Paietta, E; Rader, K; Rowe, JM; Tallman, MS | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Agis, H; Böhm, A; Florian, S; Hauswirth, AW; Krauth, MT; Samorapoompichit, P; Sonneck, K; Sperr, WR; Valent, P | 1 |
| Huang, S; Li, AP; Liu, QZ; Mao, WG; Shen, Q; Ye, J; Zhou, JW; Zou, CP | 1 |
| de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K | 1 |
| Andreeff, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Jeha, S; King, I; O'brien, SM; Sznol, M; Thomas, D; Verstovsek, S; Wierda, W; Yee, KW | 1 |
| Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W | 1 |
| Abildgaard, L; Abrahamsson, J; Ellebaek, E; Gustafsson, G; Hasle, H; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Hanada, R; Horibe, K; Kobayashi, R; Tawa, A; Tsuchida, M; Tsukimoto, I | 1 |
| Belloc, F; Lacombe, F; Pigneux, A; Praloran, V; Tabrizi, R; Vial, JP | 1 |
| Ito, M; Kamijo, A; Maruta, I; Mizuno, Y; Onishi, H; Onose, M; Saito, H; Yamada, T | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Bruserud, Ø; Ersvaer, E; Gjertsen, BT; Skavland, J; Ulvestad, E | 1 |
| Dickins, RA; Kogan, SC; Largaespada, DA; Lowe, SW; Yin, B | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Marcucci, G | 1 |
| Braess, J; Haferlach, T; Holdenrieder, S; Mueller, S; Nagel, D; Schalhorn, A; Seidel, D; Stieber, P | 1 |
| Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Ludwig, WD; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Serve, HL; Staib, P; Tchinda, J; Wörmann, B | 1 |
| Abe, S; Funato, T; Harigae, H; Ishizawa, K; Kaku, M; Kameoka, J; Sasaki, T; Takahashi, S; Tomiya, Y; Yamada-Fujiwara, M; Yamamoto, J; Yokoyama, H | 1 |
| Antonioli, E; Baccini, M; Bosi, A; Gianfaldoni, G; Leoni, F; Mannelli, F | 1 |
| Hanada, R; Kigasawa, H; Kinoshita, A; Tabuchi, K; Tomizawa, D; Tsuchida, M; Tsukimoto, I | 1 |
| Asai, O; Dobashi, N; Minami, J; Ogasawara, Y; Osawa, H; Saito, T; Takahara, S; Takei, Y; Usui, N; Yamaguchi, Y; Yano, S | 1 |
| Baran, Y; Gunduz, U; Ural, AU | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Brandalise, SR; Matsuda, EI; Nowill, AE; Oliveira, SN; Rodrigues, PC; Viana, MB; Yunes, JA | 1 |
| Hamaki, T; Harima, A; Hoshi, K; Kajiwara, K; Kodo, H; Kozai, Y; Mizusawa, M; Yamada, K | 1 |
| Adamo, F; Amadori, S; Beeldens, F; Berneman, Z; de Witte, T; Fazi, P; Fillet, G; Jehn, U; Lefrère, F; Leone, G; Mandelli, F; Marie, JP; Montanaro, M; Muus, P; Nobile, F; Ricciuti, F; Rizzoli, V; Suciu, S; Thomas, X; Willemze, R | 1 |
| Braess, J; Fiegl, M; Hiddemann, W; Juergens, M | 1 |
| Clementino, NC; Fagundes, EM; Glória, AB; Guimarães, JP; Pedroso, ER; Quintão, JS; Rocha, V; Viana, MB | 1 |
| Creutzig, U; Dworzak, M; Graf, N; Hermann, J; Lehrnbecher, T; Niemeyer, CM; Reinhardt, D; Reiter, A; Ritter, J; Stary, J; Zimmermann, M | 1 |
| Adams, JA; Liu, JA; Morris, KL | 1 |
| Li, JY; Qian, SX; Qiu, HR; Shen, RL; Wu, YJ; Zhang, JF; Zhang, SJ; Zhou, HF | 1 |
| Baek, JH; Kim, DH; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Sohn, SK; Yang, DH | 1 |
| Berdel, WE; Bisping, G; Brandts, C; Büchner, T; Hilberg, F; Kienast, J; Kolkmeyer, A; Kulimova, E; Mesters, RM; Müller-Tidow, C; Munzert, G; Oelmann, E; Roth, GJ; Schwäble, J; Serve, H; Stefanic, M; Steffen, B | 1 |
| Gonzalez-Carrillo, ML; Jaramillo, P; Manzano, C; Morales-Toquero, A; Reyes-Núñez, V; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Ahmad, I; André, M; Bennani, J; Bron, D; Dargent, JL; Meuleman, N; Ngirabacu, MC; Ravoet, C; Ysebrant, L | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Albitar, M; Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Giles, FJ; Kantarjian, H; Kornblau, S; Pierce, S; Ravandi, F; Thomas, D; Verstovsek, S; Wierda, W | 1 |
| Arnaud, P; Botton, Sd; Bourhis, JH; Castaigne, S; Cordonnier, C; Corront, B; de Revel, T; Dombret, H; Elhamri, M; Fenaux, P; Gardin, C; Le, QH; Michallet, M; Pautas, C; Preudhomme, C; Quesnel, B; Raffoux, E; Reman, O; Terré, C; Thomas, X | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Kantarjian, HM | 1 |
| Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG | 1 |
| Burnett, AK; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, D; Prentice, AG; Wheatley, K | 1 |
| Roboz, GJ | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Carluccio, P; Giannoccaro, M; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G; Spinosa, G | 1 |
| Dombret, H; Thomas, X | 1 |
| Ainoon, O; Cheong, SK; Fazlina, N; Hamidah, H; Hamidah, NH; Jamal, R; Maha, A; Zarina, AL; Zulkifli, SZ | 1 |
| Haferlach, C; Hiddemann, W; Schnittger, S; Weisser, M | 1 |
| Demirel, YN; Fatih, T; Mesut, A; Selim, Y; Yuksel, P | 1 |
| Jiang, YQ; Li, JY; Lu, H; Qian, SX; Shen, YF; Tian, T; Wu, HX; Xu, W; Zhang, SJ | 1 |
| Burnett, AK; Gale, RE; Hills, RK; Linch, DC; Mead, AJ; Wheatley, K | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Arcaro, A; Doepfner, KT; Spertini, O | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Freijs, A; Jonsson, N; Karlsson, MO; Kristensen, J; Larsson, R; Lindhagen, E; Nygren, P; Quartino, A | 1 |
| Genev, ED; Grudeva-Popova, JG; Lazarova, A; Mumdjiev, IN; Spasova, MI; Stoyanova, AA | 1 |
| Cogburn, J; Cualing, H; Khalil, F; Miles, L | 1 |
| Forghieri, F; Luppi, M; Morselli, M; Potenza, L | 1 |
| Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Han, JH; Lilly, M; Lim, YP; Loh, SL; Pan, M; Tai, YC; Xie, Z; Zhou, J | 1 |
| Buck, SA; Chen, Q; Diakiw, AE; Dombkowski, AA; Ge, Y; LaFiura, KM; Matherly, LH; Payton, SG; Salagrama, S; Taub, JW | 1 |
| Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ | 1 |
| Grebe, G; Lira, P | 1 |
| Cadman, E; Rauscher, F | 1 |
| Miller, DR; Miller, LP; Tan, CT | 1 |
| Spiers, AS | 1 |
| Benjamin, RS; Bodey, GP; Brown, NS; Carter, CJ; Freireich, EJ; Hester, J; Ho, DH; McCredie, K | 1 |
| Grianti, C; Izzi, T; Moretti, L; Muretto, P | 1 |
| Büchner, T; Hiddemann, W; Kamanabroo, D; Schulte, H; Urbanitz, D; van de Loo, J | 1 |
| Andreeff, M; Arlin, Z; Büchner, T; Clarkson, BD; Hiddemann, W; Wörmann, B | 1 |
| Hossfeld, DK; Kubaschinski, G; Nowrousian, MR; Schaefer, UW; Schmidt, CG | 1 |
| Dantas, M; Drebing, C; Glode, LM; Koeppler, H; Robinson, WA; Thomas, MR | 1 |
| Cuttner, J; Holland, JF; Paciucci, PA | 1 |
| Ahmann, GB; Armitage, JO; Fyfe, MA; Gingrich, RD; Klassen, LW; Kugler, JW; Patil, SR; Tewfik, HH | 1 |
| Bennett, J; Golomb, H; Higby, D; Kirshner, J; Preisler, HD; Raza, A; Richman, C; Weiner, R; Winton, L; Woll, J | 1 |
| Burke, PJ; Vaughan, WP | 1 |
| Aherne, GW; Johnston, A; Lister, TA; Piall, EM; Slevin, ML | 1 |
| Costanzo, C; Kubota, K; Preisler, HD | 1 |
| Saito, Y; Uzuka, Y | 1 |
| Turnbull, AL; Watkins, SM; Williams, JR | 1 |
| Killmann, SA; Nielsen, HR | 1 |
| Kato, Y; Kawashima, K; Ohno, R; Yamada, K | 1 |
| Amar, M; Bernard, JF; Brousse, N; Chastang, C; Desaint, B; Herrera, A; Mancilla, F; Renoux, M; Solal-Celigny, P; Vroclans, M | 1 |
| De Vassal, F; Dorval, T; Gaget, H; Goldschmidt, E; Lemaigre, G; Machover, D; Misset, JL; Rappaport, H; Ribaud, P; Schwarzenberg, L | 1 |
| Komatsu, M; Saito, Y; Takahash, H; Uzuka, Y | 1 |
| Boogaerts, MA; De Bock, R; Dekker, AW; Peetermans, M; Punt, K; Tricot, G; Verwilghen, RL | 1 |
| Baker, LH; Balcerzak, SP; Chen, TT; Coltman, CA; Hester, JP; Morrison, FS; Stephens, RL; Waddell, CC | 1 |
| Darlow, S; Hamblin, TJ; Mufti, GJ; Nightingale, A; Oscier, DG | 1 |
| Gandara, DR; George, CB; Mansour, RP; Redmond, J | 1 |
| Aiba, K; Chinen, T; Kobayashi, T; Kuraishi, Y; Mashizu, N; Meguro, S; Nagamine, D; Ozeki, H; Takasaki, N; Yokoyama, K | 1 |
| Hatakeyama, S; Okeda, R; Suzuki, K; Takemura, T | 1 |
| Fischer, P; Haas, O; Paietta, E; Schwarzmeier, JD | 1 |
| Fontebuoni, A; Izzi, T; Lucarelli, G; Talevi, N | 1 |
| Cervantes, F; Grañena, A; Montserrat, E; Ribera, JM; Rozman, C | 1 |
| Lotem, J; Sachs, L | 4 |
| Borisov, BN; Fedorov, NA; Oan', NF; Sevast'ianova, MG; Skotnikova, OI | 1 |
| Adamson, JW; Arlin, ZA; Clarkson, BD; Fialkow, PJ; Kempin, SJ; Najfeld, V; Singer, JW | 1 |
| Lilleyman, JS | 1 |
| Ansell, JE; Bhawan, J; Pechet, L | 1 |
| Ascari, E; Cresci, R; Mazzini, G; Montecucco, CM; Riccardi, A | 1 |
| Chervenick, PA; Hopen, G; Johnson, BL; Mondino, BJ | 1 |
| Bloomfield, CD; Peterson, BA | 1 |
| Efira, A; Mattelaer, MA; Spiro, TE; Stryckmans, P | 1 |
| Mejer, J | 2 |
| Astaldi, G; Baccarani, M; Bagnara, GP; Biagini, G; Brunelli, MA; Laschi, R | 1 |
| Kondrak, R; Wedrychowicz, A | 1 |
| Hitzig, WH; Plüss, HJ | 1 |
| Jones, SP; Paterson, AR; Sawyer, WH; Wiley, JS | 1 |
| Sharp, JC | 1 |
| Ogier, C; Reizenstein, P | 1 |
| Hasegawa, K; Hida, K; Kano, Y; Kasahara, T; Okamura, J; Sakamoto, S; Sasaki, H; Takaku, F; Tsukada, T | 1 |
| Hoffbrand, AV; Taheri, MR; Wickremasinghe, RG | 1 |
| Elford, HL; Gill, S; Howell, SB | 1 |
| Dabich, L | 1 |
| Stuart, J | 1 |
| Moloney, WC; Rosenthal, DS | 1 |
| Kondrat'eva, NA; Kovaleva, LG; Kruglova, GV; Makhonova, LA; Volkova, MA | 1 |
| Cherepanova, VV; Gliasova, GA; Isaev, VG; Kaporskaia, TS; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Baer, MR; Bloomfield, CD; Brunetto, VL; Christiansen, NP; Frankel, SR; Herzig, GP; Mrózek, K | 1 |
| Escudier, SM; Seymour, JF | 1 |
| Fukuda, R; Ichikawa, Y; Kawada, H; Kobayashi, N; Nagao, T; Yonekura, S | 1 |
| Im, T; Inoue, T; Okuda, K; Park, K; Tatsumi, N | 1 |
| Ikebuchi, K; Irie, S; Matsudaira, T; Matsuishi, E; Okamoto, SI; Shimane, M; Shirafuji, N; Takahashi, S; Tani, K; Tsuruta, T | 1 |
| Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL | 1 |
| Böckmann, A; Büchner, T; Hiddemann, W; Reuter, C; Schleyer, E; Wörmann, B; Zühlsdorf, M | 1 |
| Kharbanda, S; Kufe, D; Yuan, ZM | 2 |
| Jehn, U | 1 |
| Andrews, R; Begent, RH; Boshoff, C; Holden, L; Newlands, ES; Oliver, RT; Ong, J; Rustin, GJ; Skelton, M | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Davison, G; Jacobs, P; Kelly, S; McLellan, G; Pillay, Y | 1 |
| Löwenberg, B; Nooter, K; Sonneveld, P; te Boekhorst, PA; van Kapel, J | 1 |
| Pallister, CJ; Singer, CR; Smith, JG; Smith, MA | 1 |
| Hu, ZB; McCulloch, EA; Minden, MD | 2 |
| Behm, FG; Boyett, JM; Hancock, ML; Krance, RA; Mahmoud, HH; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Sandlund, JT | 1 |
| Creutzig, U; Harbott, J; Löffler, H; Ludwig, WD; Riehm, H; Ritter, J; Schellong, G; Sperling, C; Zimmermann, M | 1 |
| Appelbaum, FR; Buckner, CD; Chauncey, T; Demirer, T; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R; Weaver, CH | 1 |
| Estey, E; Freireich, EJ; Kantarjian, H; Keating, M; Marlton, P; O'Brien, S; Pierce, S | 1 |
| Bleiberg, I; Fabian, I; Kashman, Y; Lishner, M; Rudi, A; Shur, I | 1 |
| Andersen, JW; Bennett, JM; Cassileth, PA; Hayes, FA; Mazza, JJ; Oette, D; Paietta, E; Rowe, JM; Stadtmauer, EA; Wiernik, PH | 1 |
| Fuchigami, K; Izumikawa, K; Kohno, T; Kuriyama, K; Maeda, T; Mori, H; Nagai, K; Nakamura, H; Tomonaga, M | 1 |
| Capizzi, RL; Fleming, RA; Oliver, LK; Omura, GA; Peterson, BA; Rosner, GL; Schiffer, CA; Silver, RT; Smith, SJ; Weiss, RB | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Asou, N; Fujimoto, K; Hiraoka, A; Kobayashi, T; Kuriyama, K; Ohno, R; Saito, H; Tanimoto, M; Teshima, H; Yoshida, M | 1 |
| Johnson, PR; Liu Yin, JA | 1 |
| Bhalla, K; Huang, Y; Ibrado, AM; Mahoney, ME; Tang, C; Tourkina, E | 1 |
| Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| McCulloch, EA; Minden, MD; Yang, GS | 1 |
| Clausen, N; Ellegaard, J; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Blenis, J; Kharbanda, S; Kufe, D; Rubin, E; Saleem, A; Sukhatme, V | 1 |
| Jedlicková, A; Jelínek, J; Lemez, P; Lukásová, M; Palecek, A; Sajdová, J; Vítek, A; Vorlová, Z | 1 |
| Kataoka, S; Kawai, H; Mashima, T; Naito, M; Tsuruo, T | 1 |
| Lemez, P | 1 |
| Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Copplestone, JA; Morgenstern, GR; Norfolk, DR; Williamson, LM; Williamson, P; Wimperis, JZ | 1 |
| Archimbaud, E; Cordonnier, C; Dreyfus, F; Fenaux, P; Jaubert, J; Leblond, V; Michallet, M; Thomas, X; Travade, P; Troussard, X | 1 |
| Büchner, T; Hiddemann, W; Reuter, C; Wörmann, B; Zühlsdorf, M | 1 |
| Cepelák, V; Cetkovský, P; Koza, V; Vít, L | 1 |
| Atkins, CD | 1 |
| Cetkovský, P; Koza, V | 1 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| Champlin, R; Gajewski, J; Ho, W; Lee, M; Schiller, G; Territo, M | 1 |
| Cianfriglia, M; Eisterer, W; Gotwald, M; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J; Zabernigg, A | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, VS; Ray, S; Tang, C | 1 |
| Cassileth, PA; Friedenberg, WR; Hocking, WG; Marx, JJ; Mazza, JJ; Mercier, RJ; Miller, HJ; Raich, PC; Reding, DJ; Schloesser, LL | 1 |
| Götzl, M; Gsur, A; Kyrle, PA; Lechner, K; Pirker, R; Zöchbauer, S | 1 |
| Jack, FR; Summerfield, GP | 1 |
| Kataoka, S; Naito, M; Tomida, A; Tsuruo, T | 1 |
| Conley, NS; Doughney, KB; Durkin, WJ; Favis, GR; Siddiqui, T; Smith, AE; Weiss, R | 1 |
| Cherepanova, VV; Isaev, VG; Kaporskaia, TS; Kliasova, GA; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Chatterjee, R; Franklin, IM; Goldstone, AH; Hutchinson, RM; Kelsey, SM; Linch, DC; McMillan, AK; Milligan, DW; Newland, AC; Salooja, N | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Belloc, F; Bernard, P; Boisseau, MR; Dumain, P; Lacombe, F; Makhoul, PC; Puntous, M; Reiffers, J; Saux, MC | 1 |
| Buschfort, C; Müller, MR; Rajewsky, MF; Seeber, S; Seiler, F; Thomale, J | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dubosc-Marchenay, N; Dumain, P; Fabères, C; Lacombe, F; Marit, G; Montastruc, M; Puntous, M | 1 |
| Emoto, Y; Kharbanda, S; Kisaki, H; Kufe, D; Saleem, A | 1 |
| Berg, DT; Davis, RB; Frei, E; Mayer, RJ; McIntyre, OR; Moore, JO; Omura, GA; Powell, BL; Schiffer, CA; Schulman, P | 1 |
| Bishop, JF | 2 |
| Bozeman, P; Hurwitz, C; Jenkins, J; Katz, J; Krance, R; Laver, J; Mahmoud, H; Mirro, J; Shearer, P | 1 |
| Cork, A; Jeha, S; Lockhart, S; Pinkel, D; Plunkett, W; Ramirez, I; Zipf, T | 1 |
| Gewirtz, DA; Grant, S; Jarvis, WD; Pettit, GR; Povirk, LF; Traylor, RS; Turner, AJ | 1 |
| Kolla, SS; Studzinski, GP | 1 |
| Damon, LE; Linker, CA; Ries, CA; Rugo, HS | 1 |
| Amaki, I; Kawashima, K; Kimura, K; Maekawa, T; Masaoka, T; Nagura, E; Ohta, K; Takaku, F; Uchino, H; Yamada, K | 1 |
| Akashi, K; Eto, T; Harada, M; Harada, N; Inaba, S; Niho, Y; Okamura, T; Takamatsu, Y; Teshima, T | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Bhalla, K; Bullock, G; Grant, S; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Tang, C; Tourkina, E | 1 |
| Crespo, P; Delgado, MD; Gómez-Casares, MT; León, J; Lerga, A; Quincoces, AF; Richard, C | 1 |
| Fine, HA; Kufe, DW; Manome, Y; Weichselbaum, RR | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Annaloro, C; Cofrancesco, E; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi Deliliers, G; Mozzana, R; Oriani, A; Pozzoli, E; Soligo, D | 1 |
| Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Bruecher, J; Claudé, R; Hoelzer, D; Martin, H | 1 |
| Chan, JC; Chan, JK; Lam, SY; Wong, KF | 1 |
| Fujimura, T; Iwabuchi, A; Kawakubo, K; Kodama, A; Ohyashiki, JH; Ohyashiki, K; Toyama, K | 1 |
| Aller, P; Mata, F; Rius, C; Vilaboa, N | 1 |
| Barnett, MJ; Elmongy, MB; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD | 1 |
| Darbyshire, PJ; Mann, JR; Sartori, PC; Stevens, MC; Taylor, MH | 1 |
| Brocklebank, AM; Buolamwini, JK; Jamieson, GP; Paterson, AR; Sawyer, WH; Snook, MB; Wiley, JS | 1 |
| Barcos, M; Gartside, P; Kukla, C; Lampkin, B; Lykins, J; Preisler, H; Raza, A; Sheikh, Y; White, M; Yousuf, N | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Lee, JW; Nesbit, ME; Versteeg, C; Wells, RJ; Woods, WG | 1 |
| Mayer, RJ; Stone, RM | 1 |
| Akerman, S; Allen, SL; Barile, B; Budman, DR; DeMarco, LC; Kreis, W; Marsh, JH; Schulman, P; Schuster, MW | 1 |
| Brach, MA; Herrmann, F; Mertelsmann, RH | 2 |
| Hansen, PB; Hippe, E; Johnsen, HE | 1 |
| Harousseau, JL | 1 |
| Andresen, SW; Bergfeld, WF; Thorisdottir, K; Tomecki, KJ | 1 |
| Del Poeta, G; Delaroche, I; Masi, M; Nicoletti, B; Papa, G; Stasi, R; Tedeschi, B; Tribalto, M; Venditti, A; Vernole, P | 1 |
| Asou, N; Hiraoka, A; Imai, K; Kobayashi, T; Kodera, Y; Ohno, R; Takahashi, I; Tanimoto, M; Tomonaga, M; Tsubaki, K | 1 |
| Huberman, E; Kharbanda, S; Kufe, D | 1 |
| Adamczyk-Cioch, MB; Dmoszyńska, A; Hus, I; Hus, M | 1 |
| Caporale, R; Ciolli, S; Leoni, F; Marrani, C; Nozzoli, C; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Béhar, C; Benoit, Y; Bertrand, Y; Boutard, P; Ferster, A; Lutz, P; Manel, AM; Otten, J; Robert, A; Solbu, G; Suciu, S; Tokaji, E; Vilmer, E | 1 |
| Asou, N; Emi, N; Hiraoka, A; Jinnai, I; Kageyama, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Matsuoka, A; Minami, S; Minato, K; Miyawaki, S; Murakami, H; Naoe, T; Oh, H; Ohmoto, E; Ohno, R; Saito, K; Sakamaki, H; Takahashi, I; Tanimoto, M; Tomonaga, M; Tsubaki, K; Yamada, O; Yoshida, M | 1 |
| Dann, EJ; Gillis, S; Rund, D | 1 |
| Grande, M | 1 |
| Buck, SA; Gurney, JG; Matherly, LH; Ravindranath, Y; Stout, ML; Taub, JW | 1 |
| Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
| Larson, RA | 1 |
| Estey, EH; Kantarjian, HM; Keating, MA | 1 |
| Camitta, B; Carroll, A; Chang, MN; Graham-Pole, J; Inoue, S; Krischer, J; Ravindranath, Y; Steuber, CP; Weinstein, HJ; Yeager, AM | 1 |
| Bishop, JF; Bradstock, K; Cobcroft, R; Enno, A; Fox, R; Garson, OM; Gillett, A; Herrmann, R; Joshua, D; Juneja, S; Lowenthal, RM; Matthews, JP; Page, F; Szer, J; Van Der Weyden, M; Wolf, MM; Young, GA | 1 |
| Emoto, Y; Kharbanda, S; Kisaki, H; Kufe, D; Manome, Y | 1 |
| Baruchel, A; Bergeron, C; Bordigoni, P; Esperou-Bourdeau, H; Landman-Parker, J; Leblanc, T; Leverger, G; Michel, G; Nelken, B; Perel, Y; Schaison, G; Thuret, I; Vannier, JP | 1 |
| Bow, EJ; Clinch, JJ; Kilpatrick, MG; Rubinger, M; Schacter, BA; Shore, TB; Sutherland, JA; Williams, GJ | 1 |
| Arthur, DC; Barnard, DR; Buckley, JD; DeSwarte, J; Dusenbery, K; Gold, S; Kalousek, D; Kobrinsky, N; Lange, BJ; Lee, JW; Neudorf, S; Sanders, J; Woods, WG | 1 |
| Amadori, S; Fazi, P; Mandelli, F; Montefusco, E; Petti, MC; Picardi, A; Testi, AM | 1 |
| Brandt, ML; Dorfman, SR; Dreyer, ZE; Murray, JC | 1 |
| Barnett, MJ; Philips, GL; Shepherd, JD | 1 |
| Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Chong, SY; Hahn, JS; Ko, YW; Lee, JW; Lee, S; Min, YH | 1 |
| Belloc, F; Bernard, P; Boisseau, M; Cony-Makhoul, P; Dumain, P; Lacombe, F; Puntous, M; Reiffers, J | 1 |
| Clausen, N; Hasle, H; Jacobsen, BB; Jacobsen, N; Kerndrup, G; Ostergaard, E; Yssing, M | 1 |
| Estey, EH; Freireich, EJ; Ghaddar, HM; Kantarjian, HM; Keating, MJ; Pierce, S | 1 |
| Sonneveld, P | 1 |
| Cremer, F; Döhner, H; Goldschmidt, H; Haas, R; Hunstein, W; Moos, M; Schmohl, D; Schulz, R; Sucker, C | 1 |
| Estey, E; Kuschel, B | 1 |
| Avvisati, G; Broccia, G; Carotenuto, M; Falda, M; Fazi, P; Iacopino, P; Lazzarino, M; Leoni, P; Liso, V; Mandelli, F; Mirto, S; Nobile, F; Nosari, AM; Petti, MC; Pucci, G; Specchia, G; Stasi, R; Tabilio, A | 1 |
| Gray, RG; Rees, JK; Wheatley, K | 1 |
| Abruzzese, E; Amadori, S; Aronica, G; Cecconi, M; Del Poeta, G; Masi, M; Pisani, F; Stasi, R; Venditti, A | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
| Dyson, PG; Juttner, CA; Roberts, MM; To, LB; Willson, K | 1 |
| Emmanoulides, C; Iastrebner, MC; Lee, M; Naeim, F; Schiller, G | 1 |
| Bahl, VK; Meisner, D; Mozersky, RP; Patel, H | 1 |
| Guedez, L; Suresh, A; Tung, F; Zucali, J | 1 |
| Büchner, T; Hiddemann, W; Kern, W; Schleyer, E; Unterhalt, M | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Appelbaum, FR; Balcerzak, SP; Bickers, JN; Grever, M; Head, DR; Hynes, HE; Kingsbury, LL; Kopecky, KJ; Simon, SR; Weick, JK; Welborn, JL | 1 |
| Chim, CS; Kwong, YL | 1 |
| Dan, K; Ogata, K; Yamada, T | 1 |
| Allford, S; Glynne, P; Hamblin, M; Horton, C; Mackay, H; Mehta, J; Powles, R; Prendiville, J; Saso, R; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Archimbaud, E; Auzanneau, G; Cony-Makhoul, P; Cordonnier, C; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Leblond, V; Marie, JP; Thomas, X; Tilly, H; Troussard, X | 1 |
| Attal, M; Blaise, D; Broustet, A; Cony-Makhoul, P; Corront, B; Faberes, C; Gastaut, JA; Hollard, D; Huguet, F; Laurent, G; Maraninchi, D; Marit, G; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM | 1 |
| Capizzi, RL | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Ibrado, AM; Nuñez, G; Ray, S; Tang, C | 1 |
| Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA | 1 |
| Cortés, MA; Hermida, G; Iriondo, A; Mozota, ML; Olalla, I; Ortín, M; Richard, C; Zubizarreta, A | 1 |
| Appelbaum, FR; Banker, DE; Groudine, M; Norwood, T | 1 |
| Büchner, T; Hiddemann, W; Kern, W; Schleyer, E; Unterhalt, M; Wörmann, B | 1 |
| Lemez, P; Maresová, J | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Geissler, K; Gisslinger, H; Haas, OA; Huhmann, IM; Jäger, U; Kalhs, P; Knöbl, P; Korninger, L; Lechner, K; Mannhalter, C; Mitterbauer, G; Pabinger, I; Schwarzinger, I; Watzke, HH | 1 |
| Edwards, JR; Gay, JC; Greer, JP; Hord, JD; Janco, RL; Lukens, JN; McCurley, TL; Wells, RJ; Whitlock, JA | 1 |
| Datta, R; Kharbanda, S; Kufe, D; Saleem, A; Yuan, ZM | 1 |
| Hashimoto, Y; Iwasaki, S; Nakajima, O | 1 |
| Canpolat, C; Jeha, S; Lockhart, S; Pinkel, D; Ramirez, I; Zipf, T | 1 |
| Ahmed, T; Beer, M; Case, DC; Damon, L; Feldman, EJ; Linker, C; Ries, C; Rugo, H; Seiter, K | 1 |
| Büchner, T; Hiddemann, W; Reuter, C; Rolf, C; Schleyer, E; Wörmann, B | 1 |
| Croop, JM; Dunussi-Joannopoulos, K; Ferrara, JL; Krenger, W; Weinstein, HJ | 1 |
| Munshi, NC; Tricot, GJ | 1 |
| Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K | 1 |
| Bouaziz, M; Daoud, J; Elloumi, M; Frikha, M; Gargouri, J; Khanfir, A; Mseddi, S; Souissi, T | 1 |
| Endo, K; Furuyama, K; Harigae, H; Hayashi, N; Munakata, H; Nagai, T; Sassa, S; Yamamoto, M | 1 |
| Bacchi, M; Cavalli, F; Fey, MF; Fopp, M; Gmuer, J; Gratwohl, A; Jacky, E; Schmid, L; Tichelli, A; Tobler, A; Tschopp, L; Von Fliedner, V | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Brinch, L; Evensen, SA; Hedenus, M; Hörnsten, P; Oberg, G; Simonsson, B; Wahlin, A | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Baker, RI; Kyle, PW; Manoharan, A | 1 |
| Cole, N; Gibson, BE | 1 |
| Heitjan, DF | 1 |
| Auf der Landwehr, U; Büchner, T; Hiddemann, W; Jahns-Streubel, G; Reuter, C; Schleyer, E; Unterhalt, M; Wörmann, B | 1 |
| Honma, Y; Niitsu, N; Umeda, M | 1 |
| Becton, DL; Buck, SA; Huang, X; Ravindranath, Y; Stout, ML; Taub, JW; Vega, RA | 1 |
| Rowe, JM; Tallman, MS | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Benner, A; Döhner, H; Fischer, JT; Fischer, K; Gunzer, U; Haas, R; Hartmann, F; Pförsich, M; Pralle, H; Schlenk, RF; Weber, W | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dekker, AW; Jehn, U; Löwenberg, B; Muus, P; Ossenkoppele, G; Schouten, H; Sonneveld, P; Stryckmans, P; Suciu, S; Vellenga, E; Verhoef, GE; Wijermans, P; Zittoun, R | 1 |
| Abgrall, JF; Audhuy, B; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Delain, M; Desablens, B; Francois, S; Guilhot, F; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Lamy, T; Lioure, B; Milpied, N; Pignon, B; Tellier, Z; Witz, F | 1 |
| Ciliberti, C; De Felice, L; Martelli, MP; Mascolo, MG; Petrucci, MT; Petti, MC; Ricciardi, MR; Tafuri, A | 1 |
| Hurwitz, CA; Krance, R; Laver, J; Mirro, J; Shearer, P; Srivastava, DK; Weinstein, HJ | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Bloomfield, CD; Herzig, GP; Peterson, BA; Wolff, SN | 1 |
| de Nully Brown, P; Geisler, CH; Jurlander, J; Pedersen-Bjergaard, J; Victor, MA | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Akiyama, Y; Bessho, R; Furusho, K; Kataoka, A; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, K | 1 |
| Bukh, A; Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Archimbaud, E; Berneman, ZN; de Cataldo, R; Dekker, AW; Fillet, G; Haak, H; Hagemeijer, A; Hayat, M; Löwenberg, B; Solbu, G; Sonneveld, P; Stryckmans, P; Suciu, S; Thyss, A; van der Lelie, J; Visani, G; Zittoun, R | 1 |
| Bishop, JF; Bradstock, K; Lowenthal, RM; Matthews, JP; Young, GA | 1 |
| Löwenberg, B; Rutten, FF; Suciu, S; Uyl-de Groot, CA; Vellenga, E; Willemze, R | 1 |
| Asano, S; Inoue, T; Nagayama, H; Nishiwaki, K; Okamoto, S; Oshima, Y; Takahashi, S; Tani, K; Tojo, A | 1 |
| Ottaviani, E; Pellacani, A; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Annunziata, M; Copia, C; Ferrara, F; Magrin, S; Mele, G; Mirto, S | 1 |
| Büchner, T; Kessler, T; Schumacher, A; van de Loo, J; Wewers, D | 1 |
| Cao, GS; Chang, RL; Conney, AH; Han, ZT; Liu, XJ; Newmark, HL; Sun, JZ; Tian, GF; Yang, RY; Zhu, XX | 1 |
| Almici, C; Caramatti, C; Carlo-Stella, C; Mangoni, L; Rizzoli, V | 1 |
| Appelbaum, FR; Balcerzak, SP; Godwin, JE; Head, DR; Hynes, HE; Kopecky, KJ; Leith, CP; Willman, CL | 1 |
| Bertone, A; Candoni, A; Grattoni, R; Russo, D; Zaja, F | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Amian, A; Cañavate, M; Diéguez, JC; Fernández-Jurado, A; Martino, ML; Moreno, MV; Polo, B; Prados, D; Quesada, JA; Rodríguez, JN | 1 |
| Bowen, DT; Burnett, AK; Darley, RL; Gallagher, AP | 1 |
| Chen, SH; Liang, DC; Liu, HC | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Davey, FR; Lawrence, D; Pettenati, MJ; Qumsiyeh, M; Schiffer, CA; Stamberg, J; Tantravahi, R | 1 |
| Aveiro, F; Bernardo, M; Conduto, A; Costa, I; Cruz, E; Fernandes, JP; Ferreira, G; Gonçalves, AJ; Gouveia, J; Monteiro, A; Neves, A; Nunes, O; Ribeiro, P; Rodrigues, AS; Soares, VH; Sousa, AB; Sousa, M; Veiga, J | 1 |
| Appelbaum, FR; Banker, DE; Groudine, M; Norwood, T; Willman, CL | 1 |
| Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V | 1 |
| Cosson, A; Fenaux, P; Grardel, N; Lepelley, P; Poulain, S; Preudhomme, C | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; Lerede, T; Rambaldi, A | 1 |
| Aul, C; Bartholomäus, A; Bettelheim, P; Büchner, T; Hiddemann, W; Kern, W; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R; Wörmann, B | 1 |
| Alton, P; Elgie, AW; Noordhuis, P; Peters, GJ; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Bruserud, O | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Ferrara, F; Mirto, S; Pinto, A; Zagonel, V | 1 |
| Hagiwara, S; Hirano, N; Miwa, A; Takezako, N; Togawa, A; Yuo, A | 1 |
| Arakawa, M; Chou, T; Emura, I; Ishiguro, T; Kakihara, T; Naito, M; Yoshizawa, H | 1 |
| An, E; Dan, K; Gomi, S; Kamikubo, K; Nomura, T; Ogata, K; Tamura, H; Yamada, T; Yokose, N | 1 |
| Baer, MR; Baumann, H; Bernstein, SH; Bloomfield, CD; Blumenson, L; Fries, KM; Herzig, GP; Slack, JL; Stewart, C; Wetzler, M | 1 |
| Izumi, Y; Sawada, H; Serino, Y; Wake, A; Yamasaki, Y | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Abbruzzese, A; Bianco, AR; Caraglia, M; De Lorenzo, S; Fabbrocini, A; Leardi, A; Musicò, M; Notaro, R; Pepe, S; Pizzi, C; Selleri, C; Tagliaferri, P | 1 |
| Arthur, DC; Berg, DT; Bloomfield, CD; Byrd, JC; Carroll, A; Davey, FR; Lawrence, D; Mayer, RJ; Patil, SR; Pettenati, MJ; Schiffer, CA; Tantravahi, R | 1 |
| Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M | 1 |
| Boiron, JM; Cardinaud, JP; Gbikpi-Benissan, G; Gruson, D; Guisset, O; Hilbert, G; Pigneux, A; Reiffers, J; Texier, J; Vargas, F | 1 |
| Friedenberg, WR | 1 |
| Aul, C; Büchner, T; Eimermacher, H; Grote-Metke, A; Hiddemann, W; Kerkhoff, A; Kern, W; Kubica, U; Kuse, R; Maschmeyer, G; Wörmann, B | 1 |
| Brunner, R; Filipits, M; Lechner, K; Pirker, R; Suchomel, RW; Zöchbauer, S | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Baak, JP; Broxterman, HJ; Eekman, CA; Feller, N; Klumper, E; Kuiper, CM; Ossenkoppele, GJ; Pieters, R; Schuurhuis, GJ; van Heijningen, TH | 1 |
| Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M | 1 |
| De La Rubia, J; Gomis, F; González-García, Y; Jarque, I; Martín, G; Pérez-Sirvent, M; Sanz, MA; Sempere, A; Senent, L | 1 |
| Appelbaum, FR; Bennett, JM; Blume, KG; Cassileth, PA; Harrington, DP; Head, DR; Hurd, DD; Lazarus, HM; Paietta, E; Rowe, JM; Wiernik, PH; Willman, C | 1 |
| Burnett, AK | 2 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Kirch, C; Schröder, JK; Schütte, J; Seeber, S | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Behringer, D; Köhler, G; Lindemann, A; Lübbert, M; Mertelsmann, R; Würthner, JU | 1 |
| Bigas, A; Chernukhin, IV; Delgado, MD; Klenova, EM; León, J | 1 |
| Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Chong, YY; Lee, LH; Wong, GC | 1 |
| Goa, KL; Whittington, R | 1 |
| Altés, A; Brunet, S; Guardia, R; Martino, R; Sierra, J; Sureda, A | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Chang, SC; Hung, CC; Ker, CC; Luh, KT; Sheng, WH | 1 |
| Akiyama, H; Asou, N; Jinnai, I; Kiyoi, H; Kuriyama, K; Minami, S; Miyawaki, S; Motoji, T; Nakano, Y; Naoe, T; Oh, H; Ohno, R; Omoto, E; Saito, H; Saito, K; Shimazaki, C; Ueda, R; Yokota, S | 1 |
| Braess, J; Feuring-Buske, M; Hiddemann, W; Kern, W; Riggert, J; Schleyer, E; Wegendt, C | 1 |
| Kishimoto, Y; Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Morishima, Y; Seto, M; Suzuki, R | 1 |
| Gorin, NC; Labopin, M | 1 |
| Hamaguchi, H; Hara, M; Ito, U; Nagata, K; Tomita, H; Tone, O; Yamamoto, K | 1 |
| Appelbaum, FR; Issa, JP; Kopecky, KJ; Li, Q; Mohan, A; Weick, JK; Willman, CL | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R | 1 |
| Manabe, T; Sadahira, Y; Sugihara, T; Yawata, Y | 1 |
| Cavaliere, M; Clavio, M; Gobbi, M; Miglino, M; Pierri, I; Pietrasanta, D | 1 |
| Bhalla, K; Frankel, AE; Hall, P; Jia, T; Kim, CN; Kreitman, RJ; Tagge, EP; Willingham, MC | 1 |
| Ehninger, G; Illmer, T; Neubauer, A; Nowak, R; Oelschlägel, U; Renner, U; Schaich, M; Subat, S; Ziegs, B | 1 |
| Becton, DL; Buck, SA; Chang, MN; Huang, X; Massey, GV; Matherly, LH; Ravindranath, Y; Stout, ML; Taub, JW; Weinstein, HJ | 1 |
| Archimbaud, E; Bordessoule, D; Cony-Makhoul, P; Cordonnier, C; de Revel, T; Delair, S; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Janvier, M; Leblond, V; Marie, JP; Nicolini, F; Rousselot, P; Simon, M; Stoppa, AM; Thomas, X; Tilly, H; Troussard, X; Vekhoff, A | 1 |
| Avigdor, A; Ben-Bassat, I; Ben-Yehuda, D; Berkowicz, M; Chetrit, A; Gillis, S; Hardan, I; Lossos, I; Raanani, P; Shpilberg, O; Sofer, O | 1 |
| Ahmed, N; Baumforth, KR; Hassan, HT; Laverick, L; Sammons, J | 1 |
| Ferrara, F; Leoni, F; Mele, G; Melillo, L; Mirto, S; Montillo, M; Pinto, A | 1 |
| Kneisl, JS; Lipford, EH; Woodard, WL | 1 |
| Appelbaum, FR; Grever, MR; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; Kraut, EH; Lichtin, A; Nand, S; Samlowski, WE; Vial, RH | 1 |
| Isaev, VG; Khoroshko, ND; Kliasova, GA; Kulikov, SM; Maslova, ER; Ol'shanskaia, IuV; Parovichnikova, EN; Pivnik, AV; Savchenko, VG; Tikhonova, LIu | 1 |
| Gherlinzoni, F; Isidori, A; Lemoli, R; Leopardi, G; Martinelli, G; Motta, M; Pastano, R; Piccaluga, P; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA | 1 |
| Kulkarni, S; Mehta, J; Min, T; Powles, R; Saso, R; Singhal, S; Swansbury, GJ; Treleaven, J | 1 |
| Adachi, K; Asou, N; Hatake, K; Hiraoka, A; Jinnai, I; Kageyama, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Matsuda, S; Minami, S; Miyawaki, S; Oh, H; Ohno, R; Ohtake, S; Omoto, E; Saito, K; Sakamaki, H; Shimazaki, C; Takahashi, M; Takeyama, K; Tamura, J; Tanimoto, M; Tsubaki, K; Yamada, O | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Karasawa, M; Kim, K; Kobayashi, S; Koiso, H; Naruse, T; Sakai, H; Tamura, J; Tomiazwa, T; Ueki, K; Yano, S | 1 |
| Dias Wickramanayake, P; Diehl, V; Franklin, J; Glasmacher, A; Neufang, A; Scheid, C; Schulz, A; Staib, P; Steinmetz, HT; Tesch, H | 1 |
| Hokland, P; Kristensen, JS; Nørgaard, JM; Olesen, G; Pedersen, B | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Andreeff, M; Champlin, RC; Dong, J; Estey, EH; Estrov, Z; Jiang, S; Konopleva, M; Kornblau, SM; Okcu, MF; Reed, JC; Sanchez-Williams, G; Snell, VE; Xie, Z; Zhang, X; Zhao, S | 1 |
| Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP | 1 |
| Braess, J; Hiddemann, W; Kern, W; Pförtner, J; Schleyer, E | 1 |
| Fujisawa, S; Harano, H; Ishigatsubo, Y; Kanamori, H; Mohri, H; Motomura, S; Tanabe, J | 1 |
| Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G | 1 |
| Abgrall, JF; Audhuy, B; Casassus, P; Deconinck, E; Delain, M; Desablens, B; Guilhot, F; Guyotat, D; Harousseau, JL; Hunault-Berger, M; Le Prise, PY; Lioure, B; Solary, E; Tournilhac, O; Vilque, JP; Witz, B | 1 |
| Balduzzi, A; Galli, MA; Longoni, D; Nicolini, B; Tagliabue, A; Uderzo, C | 1 |
| Bauduer, F; Capdupuy, C; Dastugue, N; Ducout, L; Renoux, M | 1 |
| Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K | 1 |
| Chan, FS; IP, NY; Leung, MF; Xie, P | 1 |
| Gangadharan, VP; Jayasree, K; Nayak, N; Prakash, NP | 1 |
| Ahmed, T; Baskind, P; Darzynkiewicz, Z; Feldman, EJ; Goff, H; Pozzuoli, M; Santos, S; Seiter, K; Traganos, F | 1 |
| Gribble, GW; Honda, T; Ito, Y; Kharbanda, S; Kufe, D; Pandey, P; Place, A; Sporn, MB | 1 |
| Andreeff, M; Estrov, Z; Harris, D; Konopleva, M; López-Berestein, G; Tari, AM; Xie, Z; Zhao, S | 1 |
| Braess, J; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Unterhalt, M; Wegendt, C | 1 |
| Chithrathara, K; Elizabath, KA; Gangadharan, VP; Preetha, S; Sreejith, G | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Januszewicz, EH; Juneja, S; Prince, HM; Seymour, C; Strickland, AH; Wolf, M | 1 |
| Briscoe, CV; Chisi, JE; Ezan, E; Genet, R; Riches, AC; Wdzieczak-Bakala, J | 1 |
| Arber, D; Dagis, A; Forman, SJ; Margolin, KA; Nademanee, A; Niland, J; O'Donnell, MR; Parker, PM; Schmidt, GM; Slovak, ML; Smith, EP; Snyder, DS; Somlo, G; Stein, AS | 1 |
| Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H | 1 |
| Akiyama, H; Asou, N; Kitamura, K; Kiyoi, H; Kuriyama, K; Kusumoto, S; Minami, S; Miyawaki, S; Motoji, T; Nakano, Y; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K | 1 |
| Braess, J; Haferlach, T; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Schoch, C; Voss, S | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 2 |
| Bennett, JM; Cassileth, PA; Kim, KM; Letendre, L; O'Connell, MJ; Oken, MM; Robles, C; Wiernik, PH | 1 |
| Akasya, E; Büyükbabani, N; Diz-Küçükkaya, R; Oncü, S; Ozkaya-Bayazit, E; Pekçelen, Y | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Katagiri, T; Kawanishi, Y; Miyazawa, K; Nishimaki, J; Ohyashiki, K; Yaguchi, M | 1 |
| Barge, RM; Honders, MW; Landegent, JE; Veuger, MJ; Willemze, R | 1 |
| Dent, P; Fisher, PB; Grant, S; Wang, S; Wang, Z | 1 |
| Lange, B | 1 |
| Arima, N; Fukushima, T; Kanamaru, A; Kishimoto, Y; Kusumoto, GS; Motoji, T; Ohno, R; Okamoto, T; Shimazaki, C; Takahashi, M; Takemoto, Y; Takeshita, A; Tsukuda, K; Uike, N; Yorimitsu, S | 1 |
| Gáliková, J; Haas, T; Lemez, P | 1 |
| Barbier, M; Boutonnat, J; Ronot, X; Seigneurin, D | 1 |
| Fukushima, T; Jinnai, I; Kuriyama, K; Matsuo, T; Miyazaki, Y; Moriuchi, Y; Taguchi, J; Tomonaga, M; Yoshida, S | 1 |
| Denault, A; Larouche, G; Prénovault, J | 1 |
| Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S | 1 |
| Appelbaum, FR; Cassileth, PA; Forman, SJ; Harrington, DH; Head, DR; Kopecky, KJ; Mohamed, A; Paietta, E; Rowe, JM; Slovak, ML; Theil, KS; Willman, CL | 1 |
| Cantón, I; García-Torremocha, S; Iglesias, M; Sastre, JL; Ulibarrena, C; Vázquez, MO | 1 |
| Appelbaum, FR; Banker, DE; Cooper, JJ; Garrido, SM; Kopecky, K; Willman, CL | 1 |
| Amenomori, T; Atogami, S; Fukushima, T; Hayashibara, T; Honda, M; Ikeda, S; Jinnai, I; Kuriyama, K; Kusano, M; Matsuo, T; Miyazaki, Y; Momita, S; Nagai, K; Nonaka, H; Soda, H; Taguchi, J; Tomonaga, M; Toriya, K; Yoshida, S; Yoshida, Y | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Brookes, J; Carey, P; Chu, P; Deane, M; Duncombe, A; Ganly, PS; Hutchinson, M; Jackson, G; Johnson, SA; Littlewood, TJ; MacKie, MJ; Marcus, R; Mehta, AB; Schey, S; Smith, A; Smith, GM; Taylor, P; Tollerfield, SM; Turner, GE; Wilson, MP | 1 |
| Büchner, T; Fonatsch, C; Haase, D; Haferlach, T; Heinecke, A; Hiddemann, W; Löffler, H; Sauerland, MC; Schlegelberger, B; Schoch, C; Staib, P | 1 |
| Ehninger, G; Illmer, T; Lisske, P; Mohr, B; Neubauer, A; Ritter, M; Schaich, M; Schäkel, U; Thiede, C | 1 |
| Ahn, JH; Bahng, H; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH | 1 |
| al-Ramadi, B; Ellis, M; Gorka, W; Shamoon, A; Zwaan, F | 1 |
| Cheng, G; Chik, KW; Chui, CH; Lau, FY; Li, CK; Tsang, KS; Wong, R | 1 |
| Dalton, W; Dorr, R; Greer, J; Grogan, T; Karanes, C; List, AF; Litchman, M; Moore, J; Pearce, T; Roe, D; Schiller, G; Spier, C; Weinberger, B | 1 |
| Collins, M; Dunussi-Joannopoulos, K; Lee, K; Leonard, JP; Runyon, K; Zuberek, K | 1 |
| Buckley, DA; du Vivier, AW; Hopster, D; Keane, FM; Mufti, GJ; Munn, SE | 1 |
| Bousquet, B; Deschamps, F; Dombret, H; Gourmel, B; Houzé, P | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Büchner, T; Haferlach, T; Heinecke, A; Hiddemann, W; Sauerland, MC; Schoch, C | 1 |
| Burnett, AK; Liu Yin, JA; Rees, JK; Wheatley, K | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, RG; Dodds, AJ; Enno, A; Garson, OM; Gillett, EA; Hermann, RP; Joshua, DE; Juneja, SK; Lowenthal, RM; Ma, DD; Matthews, JP; Szer, J; Taylor, KM; Wolf, M; Young, GA | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA | 1 |
| Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Aoudjhane, M; Chéron, N; Deloux, J; Douay, L; Elloumi, M; Fouillard, L; Gorin, NC; Guiguet, M; Isnard, F; Laporte, JP; Lesage, S; Lopez, M; Najman, A; Van Den Akker, J; Zunic, P | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Braess, J; Fiegl, M; Haase, D; Haferlach, T; Hiddemann, W; Jahns-Streubel, G; Kern, W; Schleyer, E; Schoch, C; Voss, S | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Castagnola, C; Colombo, A; Corso, A; Della Porta, M; Lazzarino, M; Lunghi, M; Mangiacavalli, S; Pagnucco, G | 1 |
| Baer, MR; Berg, DT; Bloomfield, CD; Dodge, RK; George, SL; Lee, EJ; Moore, JO; Paciucci, PA; Powell, BL; Schiffer, CA; Schulman, PP; Stone, RM | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Behm, FG; Pritchard, M; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Srivastava, DK; Tong, X | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, K; Brighton, T; Cannell, P; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Gottlieb, D; Januszewicz, H; Joshua, D; Leahy, M; Lowenthal, R; Matthews, J; Schwarer, A; Taylor, K; Young, G | 1 |
| Burnett, AK; Clark, RE; Goldstone, AH; Hutchinson, RM; Smith, AG; Wheatley, K | 1 |
| Burnett, AK; Chatters, S; Goldstone, AH; Grimwade, D; Harrison, CJ; Harrison, G; Oliver, F; Walker, H; Wheatley, K | 1 |
| Calvo, F; Cros, E; Dumontet, C; El Jafaari, A; Galmarini, CM; Graham, K; Mackey, JR; Rousselot, P; Thomas, X | 1 |
| Ardi, VC; Avramis, VI; Danenberg, PV; Fu, CH; Martin-Aragon, S; Weinberg, KI | 1 |
| Asano, S; Iseki, T; Ito, K; Nagayama, H; Ooi, J; Shirafuji, N; Tani, K; Tojo, A; Tomonari, A | 1 |
| Fukushima, T; Goto, N; Imamura, S; Iwasaki, H; Kawai, Y; Kishi, S; Masada, M; Tsutani, H; Ueda, T; Urasaki, Y; Yamauchi, T; Yoshida, A | 1 |
| Andreesen, R; Aul, C; Balleisen, L; Berdel, W; Büchner, T; Eimermacher, H; Gassmann, W; Grüneisen, A; Haase, D; Haferlach, T; Hartlapp, J; Heinecke, A; Hiddemann, W; Hirschmann, WD; Löffler, H; Ludwig, WD; Maschmeyer, G; Pielken, HJ; Rasche, H; Reis, HE; Sauerland, MC; Schoch, C; Staib, P; Uhlig, J; Weh, HJ; Wörmann, B | 1 |
| Fujimaki, K; Fujisawa, S; Ishigatsubo, Y; Kanamori, H; Tanaka, M; Tomita, N; Yamaji, S | 1 |
| Faber, E; Hlusí, A; Hubácek, J; Indrák, K; Jarosová, M; Jebavý, L; Kmonícek, M; Knotková, R; Krahulová, M; Malý, J; Mayer, J; Penka, M; Szotkowski, T; Voglová, J; Zapletalová, J | 1 |
| Motta, M; Pelizzari, A; Puoti, M; Rossi, G | 1 |
| Appelbaum, FR; Banker, DE; Cooper, JJ; Cotter, FE; Fennell, DA; Willman, CL | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Leen, R; van Gennip, AH; van Kuilenburg, AB; Verschuur, AC; Voûte, PA | 1 |
| Barge, RM; Heemskerk, MH; Honders, MW; Veuger, MJ; Willemze, R | 1 |
| Appelbaum, FR | 1 |
| Akiyama, H; Asou, N; Kiyoi, H; Kodera, Y; Kuriyama, K; Kusumoto, S; Miyawaki, S; Motoji, T; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K; Tagawa, Y; Ueda, R | 1 |
| Iwakiri, R; Kumakawa, T; Mikoshiba, M; Mori, M; Ohta, M; Tsutsumi, H | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Becker, PS; O'Donnell, J; Quesenberry, PJ; Rossi, HA; Sarcinelli, F; Stewart, FM | 1 |
| Autrup, H; Autrup, JL; Hokland, P; Pedersen, L | 1 |
| Gallagher, M; Garban, F; Jacob, MC; Jouvin-Marche, E; Marche, PN; Moine, A; Sotto, JJ | 1 |
| Ben-Am, M; Burnett, A; Capdeville, R; Dekker, A; Ferrant, C; Gratwohl, A; Kovacsovics, T; Löwenberg, B; Ossenkoppele, G; Pfister, C; Rosenkranz, G; Sonneveld, P; Vellenga, E; Verhoef, G; Vossebeld, P; Yin, L | 1 |
| Anglaret, B; Archimbaud, E; Belhabri, A; Chelghoum, Y; Dhedin, N; Dombret, H; Fière, D; Michallet, M; Reman, O; Thomas, X; Vekhoff, A; Wattel, E | 1 |
| Dölken, G; Fiedler, F; Hasenclever, D; Helbig, W; Herold, M; Kämpfe, D; Krahl, R; Kubel, M; Mantovani, L; Niederwieser, D; Pasold, R; Pönisch, W; Schmoll, HJ; Súbert, R | 1 |
| Annunziata, M; Annunziata, S; Copia, C; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Schiavone, EM; Sebastio, L; Viola, A | 1 |
| Calvo, F; Cros, E; Dumontet, C; El Jafaari, A; Galmarini, CM; Rousselot, P; Thomas, X | 1 |
| Andresen, S; Elson, P; He, XY; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B | 1 |
| Beksac, M; Dalva, K; Hayran, M; Ilhan, O; Koc, H; Konuk, N; Ozcan, M; Sertkaya, D; Topcuoglu, P; Ustün, C | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Calvo, F; Cros, E; Dumontet, C; El Jaffari, A; Galmarini, CM; Rabilloud, M; Rousselot, P; Thomas, X | 1 |
| Annunziata, S; Ferrara, F; Gianfaldoni, G; Leoni, F; Mele, G; Palmieri, S; Pocali, B; Pollio, F; Schiavone, EM; Sebastio, L; Viola, A | 1 |
| Brighton, T; Kwan, YL; Manoharan, A; Trickett, A | 1 |
| Bottomley, RH; Grozea, PN; Nordquist, RE; Shaw, MT | 1 |
| Chabner, BA; Coleman, CN; Drake, JC; Stoller, RG | 1 |
| Wiernik, PH | 2 |
| Preisler, HD; Renick, J; Rustum, YM; Walczak, I | 1 |
| Barabash, G; Benjamin, D; Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A | 1 |
| Horiuchi, M; Ichikawa, Y; Maeda, M | 1 |
| Chabner, BA; Coleman, CN; Johns, DG | 1 |
| Chabner, BA; Hande, KR | 1 |
| Anner, RM; Drewinko, B; Lennon, JM | 1 |
| Black, JA; Harrison, JF; Lilleyman, JS | 1 |
| Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A | 1 |
| Braine, HG; Burke, PJ; Karp, JE; Vaughan, WP | 1 |
| Anderson, BC; Crow, SE; Henness, AM | 1 |
| Huguley, CM; Miller, D; Smalley, RV; Vogel, J | 1 |
| Buskard, NA; Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Spiers, AS | 1 |
| Crow, SE; Henness, AM | 1 |
| Canellos, GP; Gralnick, HR; Rosenthal, S; Whang-Peng, J | 1 |
| Ide, T; Misawa, S; Sawai, K; Sonoda, Y; Takemura, S | 1 |
| Hauptmann, E; Heinz, R; Jaksic, B; Stacher, A | 1 |
| Bagby, GC | 1 |
| Asherov, J; Pinkhas, J; Shoenfeld, Y | 1 |
| Kawashima, K; Ogata, K; Watanabe, E; Yamada, K | 1 |
| Robins, AB | 1 |
| Baccarani, M; Guolo, ML; Tura, S | 1 |
| Bailey, R; Bowden, L; Chaganti, R; Clarkson, B; Cunningham, I; Dowling, M; Gee, T; Hopfan, S; Knapper, W; Turnbull, A | 1 |
| Chiyoda, S; Kubota, K; Miura, Y; Mizoguchi, H; Muto, Y; Takaku, F | 1 |
| Boleda Relats, M; Buxó Costa, J; Rodríguez Ferrera, JC; Sans-Sabrafen, J | 1 |
| Berliner, GB; Mendeleev, IM; Miasnikov, AA | 1 |
| Fleischer, J | 1 |
| Schmähl, D; Zeller, WJ | 1 |
| Koelmel, HW; Weizsaecker, M | 1 |
| Burke, PJ; Jung, J; Vaughn, WP | 1 |
| Slater, AJ; Whittaker, JA | 1 |
| Anderton, KJ; Hill, AS; Lilleyman, JS | 1 |
| Arlin, Z; Chou, TC; Clarkson, BD; Phillips, FS | 1 |
| Kuntz, HD | 1 |
| Ichida, F; Inoue, K; Kohama, T; Nishi, M; Sasaki, H | 1 |
| Ellison, RR | 1 |
| Bekesi, JG; Corey, RW; Cuttner, J; Ellison, RR; Glidewell, O; Hoagland, HC; Holland, JF; Rai, K; Schwartz, J; Wallace, HJ; Wiernik, P | 1 |
| Brodsky, I; Conroy, JF; Fuscaldo, KE; Kahn, SB; Lamping, CG | 1 |
| Baguley, BC; Falkenhaug, EM | 1 |
| Bergsagel, DE; Cowan, DH; Curtis, JE; Hasselback, R; McCulloch, EA | 1 |
| Baccarani, M; Tura, S; Zaccaria, A | 1 |
| Omine, M; Perry, S; Sarna, G | 1 |
| Gil, JL; Giralt, M; Raichs, A | 1 |
| Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Whang-Peng, J; Young, RC | 1 |
| Henderson, ES; Humphrey, GB; Mutz, ID | 1 |
| Gailani, S; Nussbaum, A | 1 |
| Beard, M; Fairley, GH; Gauci, C; Kirk, B; Sikora, E; Wrigley, P | 1 |
| Baccarani, M; Killmann, SA; Santucci, AM; Tura, S | 1 |
| Bodey, GP; Burgess, MA; Frei, E; Freireich, EJ; McCredie, KB; Rodriguez, V | 1 |
| Elbadawi, A; Griner, PF; Packman, CH | 1 |
| Greenberg, PL; Mosny, S; VanKersen, I | 1 |
| Gemon-Auclerc, MF; Jacquillat, C; Weil, M | 1 |
| Höcker, P; Lutz, D; Pittermann, E; Stacher, A | 1 |
| Baccarani, M; Bagnara, GP; Brunelli, MA; Gobbi, M; Ricci, P; Ruggero, D; Santucci, AM; Tura, S; Zaccaria, A | 1 |
| Garwood, FA; Groth, D; Vogler, WR | 1 |
| Chan, YK; Kremer, WB; Vogler, WR | 1 |
| Arimori, S; Nagao, T; Yonekura, S | 1 |
| Huang, HS; Jimenez, JJ | 1 |
| Brach, MA; Herrmann, F; Kufe, DW | 1 |
| Aiso, M; Horie, T; Iizuka, Y; Ohshima, T; Sawada, S | 1 |
| Bennett, JM; Kashyap, A; Seshi, B | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| McCulloch, EA; Yang, GS | 1 |
| Furusawa, S; Nagashima, S; Saito, K; Shishido, H; Waga, K | 1 |
| Desforges, JF; Fogaren, T; Miller, KB; Slapak, CA | 1 |
| Huguet, F; Hurteloup, P; Michallet, M; Reiffers, J; Stoppa, AM | 1 |
| Azarnia, N; Bennett, JM; Browman, G; Day, RS; Goldberg, J; Gottlieb, A; Grunwald, H; Larson, RA; Miller, K; Raza, A | 1 |
| Anderson, J; Bennett, J; Browman, G; Gezer, S; Goldberg, J; Larson, R; Lykins, J; Preisler, HD; Raza, A; Vogler, R | 1 |
| Curtis, JE; Lipton, JH; Lockwood, GA; McCulloch, EA; Messner, HA; Minden, MD; Tritchler, DL | 1 |
| Isaev, VG; Kulikov, SM; Parovichnikova, EN; Sarycheva, TG; Savchenko, VG; Tikhonova, LIu | 1 |
| Gau, JP; Hu, HT; Hwang, WL; Tsai, YT; Young, JH | 1 |
| Bhalla, K; Grant, S; Holladay, C; Huang, Y; Hughes, M; Ibrado, AM; Mahoney, ME; Tang, C; Tourkina, E | 1 |
| Büchner, T; Hiddemann, W; Kewer, U; Reuter, C; Rolf, C; Schleyer, E; Uhrmeister, C; Unterhalt, M; Wörmann, B; Zühlsdorf, M | 1 |
| Cohen, N; Cuddy, DP; Hensley, DR; Ross, DD | 1 |
| Anglaret, B; Archimbaud, E; Fiere, D; Guyotat, D; Jaubert, J; Sebban, C; Thomas, X | 1 |
| Cronin, S; Dan, ME; de Planque, MM; Karanes, C; Leisz, MC; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J | 1 |
| Büchner, T; Busemann, C; Hiddemann, W; Kiehl, M; Schleyer, E; Wörmann, B; Zühlsdorf, M | 1 |
| Tanaka, M | 1 |
| Bergmann, OJ; Dahl, M; Ellegaard, B; Ellegaard, J | 1 |
| Bennett, JM; Cassileth, PA; Edelstein, M; Harrington, DP; Hines, JD; Lynch, E; Mazza, JJ; McGlave, PB; O'Connell, MJ; Oken, MM | 1 |
| Andersen, JW; Bennett, JM; Cassileth, PA; Harrington, DP; Hines, JD; Lazarus, HM; Mazza, JJ; McGlave, PP; O'Connell, MJ; Paietta, E | 1 |
| Abgrall, JF; Desablens, B; Dufour, P; Guyotat, D; Harousseau, JL; Herve, P; Ifrah, N; Milpied, N; Pignon, B; Solary, E | 1 |
| Attal, M; Blaise, D; Cony-Makhoul, P; Corront, B; Gastaut, JA; Marit, G; Michallet, M; Reiffers, J; Rigal-Huguet, F; Stoppa, AM | 1 |
| Civin, C; Gresik, M; Krischer, J; Ravindranath, Y; Steuber, P; Vietti, T; Weinstein, H | 1 |
| Amadori, S; Giona, F; Giuliano, M; Mandelli, F; Moleti, ML; Pession, A; Rolla, M; Rondelli, R; Testi, AM | 1 |
| Gray, R; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Berg, DT; Davis, RB; Frei, E; Mayer, RJ; Sarno, E; Schiffer, CA | 1 |
| Aul, C; Büchner, T; Hiddemann, W; Hossfeld, D; Löffler, H; Ludwig, WD; Maschmeyer, G; Nowrousian, M; Schaefer, UW; Wörmann, B | 1 |
| Caronia, F; de Witte, T; Gattringer, C; Leoni, P; Liso, V; Mandelli, F; Petti, MC; Resegotti, L; Rotoli, B; Zittoun, R | 1 |
| Asoh, N; Hiraoka, A; Imai, K; Kobayashi, T; Kodera, K; Morishima, Y; Ohno, R; Takahashi, I; Tomonaga, M; Tsubaki, K | 1 |
| Hutchinson, RM; Winfield, DA | 1 |
| Kawano, F; Nishimura, Y; Sanada, I; Satoh, M; Shido, T; Tsukamoto, A | 1 |
| Hassan, HT; Maurer, HR; Spandidos, DA; Tsiriyotis, C | 1 |
| Andersen, JW; Berg, DT; Mayer, RJ; Rubin, EH; Schiffer, CA; Stone, RM | 1 |
| Benedetti-Panici, P; De Vincenzo, R; Iovino, MS; Leone, G; Macrì, E; Menichella, G; Piantelli, M; Pierelli, L; Scambia, G; Teofili, L | 1 |
| Jäger, U; Köller, U; Koller-Weber, E; Marosi, C; Nowotny, H; Pirc-Danoewinata, H; Schneider, B; Schwarzinger, I; Steger, G; Vahls, P | 1 |
| Caballero, MD; Cañizo, MC; González, M; Nieto, MJ; Orfao, A; San Miguel, JF | 1 |
| Arentsen-Honders, MW; Colly, LP; Kester, MG; Richel, DJ; ter Riet, PM; Willemze, R | 1 |
| Burke, PJ; Hood, AF; Horn, TD; Karp, JE; Kerker, BJ | 1 |
| Brach, M; Herrmann, F; Klein, H; Mertelsmann, R; Platzer, E | 1 |
| Chou, TC; Kong, XB; Tong, WP | 1 |
| Brach, MA; Herrmann, F; Kharbanda, SM; Kufe, DW | 1 |
| Datta, R; Kharbanda, S; Kufe, DW | 1 |
| Davies, JM; Flanagan, NG; Gorst, DW; Johnson, PR; Lewis, MJ; Liu Yin, JA | 1 |
| Bernabei, PA; D'Ippolito, G; Dal Pozzo, O; Fenigli, S; Lombardini, L; Rossi Ferrini, P | 1 |
| Hassan, HT; Maurer, HR | 1 |
| Ballestrero, A; Bogliolo, F; Rebora, A; Rongioletti, F | 1 |
| Büchner, T; Gassmann, W; Heit, W; Hiddemann, W; Hossfeld, D; Löffler, G; Ludwig, WD; Maschmeyer, G; Thiel, E; Weh, H | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, B; Harousseau, JL; Ifrah, N; Leprise, PY; Milpied, N | 2 |
| Ito, T; Ito, Y; Kitaori, K; Nagai, T; Ohno, R; Okumura, M; Sugiura, I; Takeo, T; Yano, K; Yokomaku, S | 1 |
| Boeckmann, A; Freire, EA; Frisch, J; Hiddemann, W; Innig, G; Reuter, C; Rottmann, R; Schulz, G; Wörmann, B; Zühlsdorf, M | 1 |
| Hassan, HT; Ragab, MH; Rees, JK; Zyada, LE | 1 |
| Benítez, J; Calabuig, T; Outeiriño, J; Pérez Sáenz, MA; Prieto, E; Rodríguez, C; Sánchez Fayos, J | 1 |
| Grassi, D; Tartas, N | 1 |
| Caplan, S; Davis, RB; Dillman, RO; Gottlieb, AJ; Green, MR; Kopel, S; McIntyre, OR; Preisler, H; Schiffer, C; Weiss, RB | 1 |
| Arlin, Z; Bhalla, K; Grant, S; Holladay, C; Ibrado, AM; Jasiok, M | 1 |
| Berg, D; Cannistra, SA; DiCarlo, J; Griffin, JD; Groshek, P; Kanakura, Y; Mayer, RJ | 1 |
| Huijgens, PC; Langenhuijsen, MM; Nauta, JJ; Ossenkoppele, GJ; Wijermans, PW | 1 |
| Boise, L; Grant, S; Howe, C; McCrady, C; Pettit, GR; Turner, A; Westin, E | 1 |
| Boeckmann, A; Büchner, T; Freire, EA; Hiddemann, W; Innig, G; Koenigsmann, M; Ludwig, WD; Maschmeyer, G; Wörmann, B; Zühlsdorf, M | 1 |
| Baars, A; Freund, M; Giller, S; Hinrichs, F; Körfer, A; Link, H; Meran, J; Poliwoda, H | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Järventie, G; Jouppila, J; Kätkä, K; Koivunen, E; Lahtinen, R; Oivanen, T; Palva, IP | 1 |
| Hedenus, M; Hörnsten, P; Malm, C; Wahlin, A | 1 |
| Bhalla, K; Grant, S; Swerdlow, P | 1 |
| Anderson, H; Chang, J; Deakin, DP; Heron, D; Morgenstern, GR; Oppenheim, B; Ranson, MR; Ryder, D; Scarffe, JH | 1 |
| Bouffard, DY; Momparler, LF; Momparler, RL | 1 |
| Gunji, H; Kharbanda, S; Kufe, D | 1 |
| Fishbein, G; Iseri, O; Knodell, RG; Rosen, AA | 1 |
| Brennscheidt, U; Henschler, R; Herrmann, F; Mertelsmann, R | 1 |
| Farhi, DC; Rosenthal, NS | 1 |
| David, JC; Marquet, J; Zittoun, J | 1 |
| Daly, KM; Gore, S; Larson, RA; Le Beau, MM; Lukin, CL; Mick, R | 1 |
| Mejer, JN | 1 |
| Conard, P; Gaynon, P; Johnson, FL; Kowal-Vern, A; Nachman, J; Radhakrishnan, J; Trujillo, Y | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Ben-Ishay, Z; Prindull, G; Sharon, S | 1 |
| De Witte, T; Haanen, C; Muus, P; Preijers, F; Raymakers, R; Van Der Lely, N | 1 |
| Datta, R; Kharbanda, S; Kufe, D | 1 |
| Amagasaki, T; Green, R; Jacobsen, DW | 1 |
| Arentsen-Honders, MW; Arkesteijn, GJ; Colly, LP; Kerster, MG; Richel, DJ; ter Riet, PM; Willemze, R | 1 |
| Bouffard, DY; Momparler, LF; Momparler, RL; Onetto-Pothier, N | 1 |
| Arlin, Z; Bhalla, K; Grant, S; Howe, CW | 1 |
| Mivechi, NF; Miyachi, H; Scanlon, KJ | 1 |
| Andreeff, M; Hegewisch-Becker, S; Tafuri, A | 1 |
| Bianchi-Scarră, G; Capra, V; Fiorentini, P; Garrĕ, C; Ravazzolo, R | 1 |
| Boyett, J; Kitchens, CS; Kramer, BS; Noyes, WD; Oblon, DJ; Ross, W; Weiner, RS | 1 |
| Codacci-Pisanelli, G; Franchi, F; Seminara, P | 1 |
| Degos, L | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Freireich, EJ; Gutterman, J; Kantarjian, HM; Keating, MJ; Kurzrock, R; McCredie, KB; Talpaz, M | 1 |
| Bahakim, HM | 1 |
| Arlin, ZA; Feldman, EJ; Puccio, CA | 1 |
| Colly, LP; Lurvink, E; Richel, DJ; Willemze, R | 1 |
| Blau, W; Elstner, E; Goldschmidt, H; Ihle, R; Wächter, M | 1 |
| Higashigawa, M; Kamiya, H; Kawasaki, H; Ohkubo, T; Sakurai, M | 1 |
| Ayscue, LH; Dent, GA; High, KA; Leglise, MC; Ross, DW | 1 |
| Lotem, J; Sachs, L; Shabo, Y | 1 |
| Berdel, WE; Danhauser-Riedl, S; Hong, CI; Okamoto, S; Rastetter, J; Vogler, WR; West, CR; Winton, EF | 1 |
| Hino, K; Nakamaki, T; Sakashita, A; Sano, M; Suzuki, K; Tomoyasu, S; Tsuruoka, N | 1 |
| Cooper, B; Fay, JW; Flexner, JM; Greer, JP; Herzig, GP; Herzig, RH; Lazarus, HM; Phillips, GL; Stein, RS; Wolff, SN | 1 |
| Hisano, S; Ishibashi, M; Kawara, T; Kimura, N; Kyoushouin, K; Morioka, E; Okumura, M | 1 |
| Miyazaki, T; Morioka, M; Sakurada, K | 1 |
| Daus, H; Pees, HW; Radtke, H; Schwamborn, J; Thumser, B | 1 |
| Fu, Z; Hou, CH; Li, JL; You, XY; Zhang, ZY; Zhu, YF | 1 |
| Andersson, B; Beran, M; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Talpaz, M; Walters, RS | 1 |
| Bigner, SH; Gockerman, JP; Sokal, JE | 1 |
| Fernandez, LA; Zayed, E | 1 |
| Heinemann, V; Meyn, RE; Murray, D; Plunkett, W; Walters, R | 1 |
| Appelbaum, FR; Buckner, CD; Clift, R; Riddell, S; Sanders, J; Stewart, P; Storb, R; Sullivan, K; Thomas, ED | 1 |
| Bolwell, BJ; Cassileth, PA; Gale, RP | 1 |
| Hayashi, M; Honma, Y; Hozumi, M; Okabe-Kado, J | 1 |
| Fisher, RI; Fisher, SG; Messmore, HL; Nand, S; Patel, R | 1 |
| Iacoboni, S; Keating, MJ; Plunkett, W | 1 |
| Hammerstrøm, J; Hoff, JE; Langtind, J; Lødemel, B; Waage, A | 1 |
| Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y | 1 |
| Lihou, MG; Smith, PJ | 1 |
| Estey, E; Freireich, EJ; Iacoboni, SJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, W | 1 |
| Jacobs, P | 1 |
| Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG | 1 |
| Chyosa, M; Kawano, F; Lee, SY; Maeda, Y; Mizokuni, T; Nakai, R; Sawada, T; Shiozaki, A; Tajima, H; Tejima, Y | 1 |
| Bourguignat, A; Eydoux, P; Floiras, JL; Le Doussal, V; Trassard, M; Turpin, F | 1 |
| Ballesta, F; Cervantes, F; Milá, M; Rozman, C | 1 |
| Aoki, I; Naganuma, Y; Sai, M; Toyama, K | 1 |
| Lazarus, AA; McMillan, M; Miramadi, A | 1 |
| Dent, G; Prenant, M; Pryzwansky, KB; Ross, DW | 1 |
| Gomez, GA; Leong, SS; Sokal, JE | 1 |
| Fujimoto, T; Hamazaki, H; Horiuchi, A; Horiuchi, F; Irimajiri, K; Maeda, Y; Shimotsuma, N; Tsubaki, K | 1 |
| Kamiya, H; Nobori, T | 1 |
| Brewer, G; Kobs, G; Peltz, SW; Ross, J | 1 |
| Dua, H; Kochipillai, V; Kumar, L | 1 |
| Delacrétaz, F; Mermillod, B; Piguet, D; Schmidt, PM | 1 |
| Ishii, E; Kato, Y; Matsuzaki, A; Miyazaki, S; Ueda, K | 1 |
| Fisher, AJ; Lobell, M; Sylvester, RK | 1 |
| Adams, TM; Estey, E; Kantarjian, H; Keating, MJ; Liliemark, JO; Nowak, B; Plunkett, W | 1 |
| Barnett, MJ; Ganesan, TS; Lister, TA; Miller, A; Richards, MA; Rohatiner, AZ | 1 |
| Bauters, F; Fenaux, P; Jouet, JP | 1 |
| Merino Moreno, J; Núñez Olarte, JM; Ortega Núñez, A; Pastor Gómez-Cornejo, L; Picó Sambucety, JM | 1 |
| Benetton, G; Blasi, E; Clayton, M; Gronberg, A; Radzioch, D; Tonini, GP; Varesio, L | 1 |
| Fujita, N; Gotoh, T; Haruyama, H; Ijichi, H; Itoh, K; Nakagawa, M; Nakanishi, S; Nishio, A; Shimazaki, C; Takeda, N | 1 |
| Roda, PI | 1 |
| Kitani, T; Machii, T; Nakamura, Y; Nishimoto, M; Shibano, M; Taniguchi, N; Ueda, E; Waki, K | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Háber, J; Klener, P; Kolesková, E | 1 |
| Andreeff, M; Chou, TC; Fanucchi, MP; Fox, JJ; Kong, XB; Vidal, P; Watanabe, KA | 1 |
| Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ | 1 |
| Kariyone, S; Kimura, H; Kokubun, K; Matsuda, S; Sakai, K; Shineha, H; Uchida, T; Yoshida, M; Yui, T | 1 |
| Balaian, LN; Kravtsova, VM; Patterson, D; Petrova, EM; Zabelina, TS | 1 |
| David, R; Douay, L; Gorin, NC; Kantor, G; Laporte, JP; Lemonnier, MP; Lopez, M; Pene, F; Stachowiak, J; van den Akker, J | 1 |
| Kufe, DW; Spriggs, DR; Stone, RM | 1 |
| Barlogie, B; Freireich, EJ; Hester, J; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Trujillo, J; Vellekoop, L | 1 |
| Ardeman, S; Greene, ML; Ruddell, K; Schey, SA | 1 |
| Arlin, ZA; Berman, E; Chaganti, RS; Clarkson, BD; Gee, T; Jhanwar, SC; Kurland, E; Mertelsmann, R; Moore, MA | 1 |
| Háber, J; Klener, P | 1 |
| Griffin, J; Kufe, D; Mitchell, T; Sabbath, K; Sariban, E; Watanabe, T | 1 |
| Gaynor, ER; Larson, RA; Miller, KB; Variakojis, D; Winter, JN | 1 |
| Haanen, C; Marie, JP; Marquet, J; Zittoun, J; Zittoun, R | 1 |
| Asano, S; Miura, Y; Miwa, S; Mizoguchi, H; Sakamoto, S; Takaku, F; Urabe, A; Wakabayashi, Y; Yamada, O; Yoshida, M | 1 |
| Abita, JP; Balitrand, N; Chomienne, C; Degos, L | 1 |
| Andersson, B; Beran, M; Estey, E; Freireich, EJ; Iacoboni, S; Kantarjian, H; Keating, MJ; McCredie, KB; Plunkett, W; Walters, R | 1 |
| Cowan, DH; London, B; Pinkerton, PH | 1 |
| Cacciola, E; di Raimondo, F; Giustolisi, R; Guglielmo, P; Milone, G | 1 |
| Clark, M; Dale, NL; Garvin, DF; Hummer, W; Schumacher, HR; Stark, EW; Surana, RB | 1 |
| Goldberg, J; Paolozzi, FP | 1 |
| Birgens, HS; Geisler, C; Hansen, NE; Hasselbalch, H | 1 |
| Gallo, JH; Grace, CS; McKinley, R; Rozenberg, MC | 1 |
| Hammerstrøm, J; Lamvik, J; Waage, A | 1 |
| Bligham, G; Freireich, EJ; Gehan, E; Hester, JP; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Talpaz, M; Walters, RS | 1 |
| Akashi, M; Furukawa, Y; Ikeda, K; Komatsu, N; Muroi, K; Ohsaka, A; Ohta, M; Suda, K; Takeda, K; Yoshida, M | 1 |
| Kuliczkowski, K; Preisler, HD; Raza, A; Raza, AS; Zhao, SC | 1 |
| Burgaleta, C; Dancausa, JP; Moreno, MT; Serrano, LG | 1 |
| Seeber, S | 1 |
| Breithaupt, H; Pralle, H | 1 |
| Gassmann, W; Löffler, H; Schmitz, N | 1 |
| Billing, R; Bozdech, MJ; Exten, R; Finlay, JL; Hong, R; Horowitz, SD; Longo, W; Moen, R; Sondel, PM; Trigg, ME | 1 |
| Cheung, NK; Coccia, PF; Gordon, EM; Graham-Pole, J; Gross, S; Herzig, RH; Lazarus, HM; Spitzer, TR; Strandjord, SE; Warkentin, PI | 1 |
| Curtis, JE; Messner, HA; Minden, MM | 1 |
| Coccia, PF; Herzig, GP; Herzig, RH; Lazarus, HM; Wolff, SN | 1 |
| Mayers, G; Preisler, HD; Raza, A; Ucar, K | 1 |
| Prentice, HG; Robbins, G; Wimperis, JZ | 1 |
| Barnett, MJ; Butler, MG; Ganesan, TS; Lister, TA; Richards, MA; Rohatiner, AZ; Slevin, ML; Smith, BF; Waxman, JH | 1 |
| Berney, JJ; Francis, GE; Guimaraes, JE; Wing, MA | 1 |
| Jánossa, M; Kelemen, E; Magyar, T; Sellyei, M; Szalay, F; Triska, E; Váradi, A | 1 |
| Mann, JR | 1 |
| Bailey, CC; Brown, MJ; Geary, CG; Israëls, MC; Weatherall, DJ; Whittaker, JA | 1 |
| Burchenal, JH; Carter, SK | 1 |
| Chabner, BA; Drake, JC; Johns, DG | 1 |
| Clarkson, BD; Yataganas, X | 1 |
| Jaenicke, L; Sauer, H; Wilmanns, W; Wilms, K | 1 |
| Bohunicky, L; Cerny, V; Halko, J; Koza, I; Krizan, Z; Petrek, C; Poliakova, L | 1 |
| Band, PR; Bernard, J; Holland, JF; Rall, D; Walker, M; Weil, M | 1 |
| Alimena, G; Amadori, S; Esposito, A; Mandelli, F; Monarca, B; Papa, G | 1 |
| Bolognesi, DP; Green, RW; Metzgar, RS; Miller, DS; Mohanakumar, T | 1 |
| Mellett, LB | 1 |
| Cejka, J; Khalifa, AS; Take, H; Zuelzer, WW | 1 |
| Alberti, A; Amadori, S; Baccarani, M; Basetta, E; Buonanno, G; Cacciola, E; Cajozzo, A; Carnevali, C; di Marco, P; Fioritoni, G; Leoni, F; Lucarelli, G; Magro, S; Mandelli, F; Monfardini, S; Musso, R; Panzacchi, G; Porcellini, A; Rizzoli, V; Rossi Ferrini, P; Salti, F; Torlontano, G; Tura, S | 1 |
| Calabresi, P; Creasey, WA; Markiw, ME; Papac, RJ; Welch, AD | 1 |
| Gralnick, HR; Halterman, R; McGinniss, M | 1 |
| Bazley, W; Bhoopathi, B; Ostapowicz, F | 1 |
| Green, GI; Levin, RL; Pierce, LE; Witorsch, P | 1 |
| Ruffner, BW | 1 |
| Bourdarias, H; Caruel, N; Najman, A; Singer, B | 1 |
| Powles, RL; Russell, JA | 1 |
| Dedrick, RL; Forrester, DD; Ho, DH | 1 |
| Gunz, FW; Levi, JA; Vincent, PC | 1 |
| Chanana, AD; Cronkite, EP; Giacomelli, G; Greenberg, ML; Schiffer, LM; Stryctmans, PA; Vincent, PC | 1 |
| Colebatch, JH; Matthews, RN | 1 |
| Advincula, EG; Galbraith, PR | 1 |
| Bornstein, RS; Kennedy, BJ; Nesbit, M | 1 |
| Fennelly, JJ; Gorman, A; O'Connell, LG | 1 |
| George, RP; Johnson, PK; Poth, JL; Schrier, SL | 1 |
| Garg, SK; Silber, R | 1 |
| Ishizaki, M; Kinoshita, H; Kitajima, K; Nagao, T; Takahashi, I | 1 |
| Coltman, CA; Jenkins, DW; Rivera, HP | 1 |
| Bernard, J; Blom, J; Boiron, M; Brunner, K; Cooper, MR; Cuttner, J; Ellison, RR; Gailani, S; Glidewell, OJ; Haurani, F; Holland, JF; Hoogstraten, B; Jacquillat, C; Levy, R; Lowenstein, L; Nissen, NI; Rege, VB; Serpick, AA; Silver, RT; Wasserman, L; Weil, M; Wiernik, PH | 1 |
| Domańska, B; Lawkowicz, W; Polubiec, A | 1 |
| Infelise, V; Paolino, W; Resegotti, L; Rossi, M | 1 |
| Boggs, DR; Chervenick, PA; Hyde, EF; Pan, SF; Srodes, CH | 1 |
| Abbrederis, K; Braunsteiner, H; Huber, H; Michlmayr, G; Schmalzl, F | 1 |
| Ho, DH | 1 |
| Bloomfield, CD; Theologides, A | 1 |
| Damasio, EE; Marmont, AM | 1 |
| Azarnoff, DL; Hoogstraten, B; Huffman, DH; Larsen, WE; Wan, SH | 1 |
| Moe, PJ; Thunold, S | 1 |
| Benöhr, HC; Frommhold, W; Oehmichen, M; Peiffer, J; Rückle, H; Waller, HD; Wilmans, W; Wilms, K | 1 |
| Bickers, JN; Coltman, CA; Freireich, EJ; Gehan, EA; Hewlett, JS; Stuckey, WJ; Van Slyck, EJ; Wilson, HE | 1 |
| Parker, AC | 1 |
| Friend, JH; Giles, C; Richardson, SG | 1 |
| Gee, TS; Grabstald, H; Schreibman, SM | 1 |
| Andorka, DW; Arosemena, A; Harris, JL | 1 |
| Canellos, GP; O'Connell, M; Rosenoff, SH; Wiernik, PH | 1 |
| Böhnel, J; Gingold, N; Hermansky, F; Pawlowski, M; Stacher, A | 1 |
| Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Spiers, AD | 1 |
| Aye, MT; McCulloch, EA; Niho, Y; Till, JE | 1 |
| Clarkson, BD; Perez, A; Strife, A; Yataganas, X | 1 |
| Crowther, D | 1 |
| De Carvalho, S | 1 |
| Habel, A | 1 |
| Davey, FR; Nelson, DA; Stuart, MJ; Wolk, JA | 1 |
| Falda, M; Infelise, VE; Resegotti, L; Rossi, M | 1 |
| Bodey, GP; Freireich, EJ; Rodriguez, V | 1 |
| Carter, SK | 1 |
| Bernard, J; Jacquillat, C; Weil, M | 1 |
| Hunstein, W | 1 |
| Hansen, NE; Karle, H | 1 |
| Wilmanns, W | 1 |
| Bernard, J; Blom, J; Boiron, M; Cuttner, J; Ellison, RR; Forcier, RJ; Gussoff, B; Haurani, F; Hayes, DM; Holland, JF; Hutchison, JL; Jacquillat, C; Karanas, A; Kyle, R; Leone, LA; Moon, JH; Rosner, F; Sawitsky, A; Silver, RT; Spurr, CL; Weil, M | 1 |
| Nakamura, T; Sawada, H; Shirakawa, S; Todo, A; Yoshida, Y | 1 |
| Perry, S; Skipper, HE | 1 |
| Vogler, WR | 1 |
| Bodey, GP; Freireich, EJ; Hart, J; Rodriguez, V | 1 |
| Bell, WR; Block, JB; Brecher, G; Carbone, PP; Whang, JJ | 1 |
| Creasey, WA; DeConti, RC; Kaplan, SR | 1 |
| Lee, SL; Rosner, F | 1 |
| Hall, TC; Kessel, D; Rosenthal, D | 1 |
| Hall, TC; Roberts, D; Rosenthal, D | 1 |
| Serpick, AA; Wiernik, PH | 1 |
| Aoki, Y; Moore, GE | 1 |
| Bodey, GP; Selawry, OS; Vietti, TJ; Wang, JJ | 1 |
| Brodie, GN; Penny, R | 1 |
| Finklestein, JZ; Freedman, MH; Gilchrist, GS; Hammond, GD; Higgins, GR; Hyman, CB; Karon, MR; Shore, NA; Williams, KO | 1 |
| White, LP | 1 |
| Bruder, M; Prager, D; Sawitsky, A | 1 |
| Holland, JF | 1 |
| Canova, R; Casalino, C; Fischioni, P; Maroncelli, P | 1 |
| Guganig, ME; Nakai, GS | 1 |
| Barry, A; Delage, JM | 1 |
| Hartje, J; Wilmanns, W | 1 |
| Burke, PJ; Owens, AH | 1 |
| Burke, PS; Coltman, CA | 1 |
| Braunsteiner, H; Schmalzl, F | 1 |
| Rachmilewitz, B; Rachmilewitz, M | 1 |
| Maurice, PA | 1 |
70 review(s) available for cytarabine and Leukemia, Myeloid
| Article | Year |
|---|---|
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Analysis; Transplantation, Homologous | 2021 |
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Topics: Acute Disease; Anthracyclines; Antineoplastic Agents; Apoptosis; Cell Cycle; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid; Piperidines | 2009 |
Optimal induction and post-remission therapy for AML in first remission.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Living Donors; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Young Adult | 2009 |
Understanding and treating opioid addiction in a patient with cancer pain.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents; Brain; Cytarabine; Daunorubicin; Heroin Dependence; Hormones; Humans; Hydromorphone; Leukemia, Myeloid; Male; Pain | 2011 |
Older adults with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aging; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Tolerance; Growth Substances; Humans; Leukemia, Myeloid; Recurrence; Remission Induction | 2002 |
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Child; Chromosome Aberrations; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Mitoxantrone; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2003 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyadenosines; Double-Blind Method; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hypotension; Immunocompromised Host; Leukemia, Myeloid; Male; Mycoses; Neutropenia; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Retrospective Studies; Sepsis; Streptococcal Infections; Viridans Streptococci | 2003 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Problems related to resistance to cytarabine in acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Myeloid; Ribonucleotide Reductases | 2004 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aminoglycosides; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Gemtuzumab; Humans; Leukemia, Myeloid; Middle Aged; Probability; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2003 |
Non-transplant therapy for older adults with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aminoglycosides; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytarabine; Cytogenetic Analysis; Gemtuzumab; Humans; Leukemia, Myeloid; Quinolones | 2006 |
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Humans; Leukemia, Myeloid; Male; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
Treatment of acute myeloid leukemia in older patients.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease Management; Drug Design; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Prognosis; Randomized Controlled Trials as Topic; Receptor, Macrophage Colony-Stimulating Factor; Risk Assessment; Signal Transduction | 2007 |
Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cell Cycle; Child; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Flavonoids; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Piperidines; Premedication; Prognosis; Rats; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2007 |
Chronic granulocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Busulfan; Chromosomes, Human, 21-22 and Y; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Palliative Care; Prednisolone; Prednisone; Thioguanine; Vincristine | 1984 |
[Chromosome analysis and TdT determination: important prognostic parameters of blastic crises in chronic myelocytic leukemia].
Topics: Busulfan; Chromosome Aberrations; Cytarabine; DNA Nucleotidylexotransferase; DNA Nucleotidyltransferases; Humans; Hydroxyurea; Karyotyping; Leukemia, Myeloid; Prednisone; Prognosis; Thioguanine; Vincristine | 1982 |
Adult acute nonlymphocytic leukemias.
Topics: Acute Disease; Aged; Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Resistance; Female; Hemorrhage; Humans; Immunotherapy; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Spinal Cord; Syndrome | 1980 |
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; DNA Polymerase II; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Neutropenia; Randomized Controlled Trials as Topic; Survival Analysis | 1994 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
Acute myeloid leukaemia in the elderly: biology and treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid; Palliative Care; Prognosis | 1993 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia.
Topics: Acute Disease; Cytarabine; Cytokines; DNA-Directed DNA Polymerase; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Lymphocyte Activation; Recombinant Proteins; S Phase | 1994 |
Long term remission of acute myeloid leukaemia with trilineage myelodysplasia treated solely with low dose cytarabine.
Topics: Acute Disease; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Time Factors | 1994 |
Two additional cases of acute myeloid leukemia with t(7;11)(p15;p15) having low neutrophil alkaline phosphatase scores.
Topics: Acute Disease; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Neutrophils; Prednisolone; Primary Myelofibrosis; Remission Induction; Translocation, Genetic | 1993 |
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Transplantation, Autologous | 1993 |
Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Cell Differentiation; Cell Division; Colony-Stimulating Factors; Cytarabine; Drug Combinations; Growth Inhibitors; Hematopoietic Cell Growth Factors; Humans; Interleukin-6; Leukemia Inhibitory Factor; Leukemia, Myeloid; Lymphokines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Is intensive treatment beneficial to elderly patients with ANLL?
Topics: Acute Disease; Aged; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction | 1993 |
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid; Middle Aged; Morbidity; Myelodysplastic Syndromes; Survival Rate | 1996 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Does it matter how remission is achieved in acute leukemia?
Topics: Acute Disease; Adult; Antineoplastic Agents; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Time Factors | 1996 |
Multidrug resistance in acute myeloid leukaemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Phenotype | 1996 |
High-dose chemotherapy in adult acute myeloid leukemia: rationale and results.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1996 |
Diabetes insipidus, acute myelogenous leukemia, and monosomy 7.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Cytarabine; Diabetes Insipidus; Diagnosis, Differential; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Male; Middle Aged; Monosomy | 1996 |
Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leukemia L1210; Leukemia, Myeloid; Mice; Randomized Controlled Trials as Topic | 1996 |
[Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 1996 |
High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid | 1997 |
Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Myeloid | 1997 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis | 1998 |
Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Cost-Benefit Analysis; Cytarabine; Drug Therapy, Combination; Drug Tolerance; Economics, Pharmaceutical; Formularies as Topic; Health Care Costs; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 1993 |
Isolated recurrence of granulocytic sarcoma of the brain: successful treatment with surgical resection, intrathecal injection, irradiation and prophylactic systemic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Injections, Spinal; Leukemia, Myeloid; Male; Prednisolone; Recurrence; Remission Induction | 1999 |
Tailoring the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid | 1999 |
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Genetic Predisposition to Disease; Humans; Infant; Infant, Newborn; Leukemia; Leukemia, Myeloid; Male; Maternal Age; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Vincristine | 2000 |
Acute myeloid leukaemia (AML): treatment of the older patient.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 2001 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
Acute myeloid leukemia in adults: where do we go from here?
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Randomized Controlled Trials as Topic | 2001 |
Consequences of acute myelogenous leukemia in early pregnancy.
Topics: Abortion, Therapeutic; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant Mortality; Infant, Newborn; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Risk; Teratogens; Thioguanine; Vincristine | 1977 |
Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.
Topics: Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; RNA, Neoplasm; Tetrahydrouridine; Thymidine | 1977 |
Management of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Transfusion; Cytarabine; Daunorubicin; Drug Therapy, Combination; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Middle Aged; Prognosis; Remission, Spontaneous; Thioguanine; Thrombocytopenia; Time Factors | 1975 |
Hematopoietins in combination with 1-beta-D-arabinofuranosylcytosine: a possible strategy for improved treatment of myeloid disorders.
Topics: Acute Disease; Antineoplastic Agents; Cytarabine; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid; Leukemia, Myeloid, Acute; S Phase | 1992 |
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Remission Induction; Thioguanine | 1991 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Features of the initial metabolism of 1-beta-D-arabinofuranosylcytosine in human myeloid leukemic cells.
Topics: Cytarabine; Humans; Leukemia, Myeloid | 1991 |
Granulocytic sarcoma of the ileum treated by bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Graft vs Host Disease; Humans; Ileal Neoplasms; Leukemia, Myeloid; Male; Methotrexate; Remission Induction; Whole-Body Irradiation | 1991 |
High dose cytarabine: a review.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pancytopenia | 1988 |
The treatment of myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Prognosis | 1986 |
New cancer chemotherapeutic agents.
Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bleomycin; Carmustine; Chlorides; Cyclization; Cyclohexanes; Cytarabine; Cytidine; Doxorubicin; Glycosides; Humans; Hydroxyurea; Imidazoles; Leukemia, Lymphoid; Leukemia, Myeloid; Mice; Nitrosourea Compounds; Picolinic Acids; Platinum; Podophyllotoxin; Streptozocin; Thiosemicarbazones; Triazenes | 1972 |
Combination chemotherapy for lymphomas and leukemias.
Topics: Adult; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Hodgkin Disease; Humans; Immunotherapy; Infections; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Mercaptopurine; Methotrexate; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous; Vincristine | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Hodgkin Disease; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Melanoma; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Vincristine | 1973 |
Treatment of acute granulocytic leukemias.
Topics: Adult; Age Factors; Antineoplastic Agents; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Heart; Hemorrhage; Humans; Hydrazones; Injections, Intravenous; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count | 1974 |
[Therapeutic considerations in chronic myeloid leukemia].
Topics: Busulfan; Chronic Disease; Cytarabine; Humans; Hydrocarbons, Brominated; Leukemia, Myeloid; Mannitol | 1974 |
[Lysozyme and leukemia. Diagnostic, prognostic and pathogenic significance of lysozyme measurements].
Topics: Cytarabine; Evaluation Studies as Topic; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methods; Muramidase; Neutrophils; Thioguanine | 1974 |
[Current status of cytostatic therapy].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Mitosis; Neoplasm Metastasis; Thymine Nucleotides | 1974 |
[Nucleic acid metabolism of leukemia cell].
Topics: Busulfan; Cytarabine; Dexamethasone; DNA; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocytes; Mercaptopurine; Nucleic Acids; Prednisolone; Pyrimidines; RNA; RNA, Neoplasm | 1970 |
Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Cytarabine; Hematopoietic System; Humans; Kinetics; Leukemia; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Mice; Neoplasm Transplantation; Thymidine; Time Factors; Tritium | 1970 |
281 trial(s) available for cytarabine and Leukemia, Myeloid
| Article | Year |
|---|---|
Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Cytoreduction Surgical Procedures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Transplantation Conditioning | 2022 |
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Topics: Antimetabolites, Antineoplastic; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Treatment Outcome | 2021 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Physical Fitness; Survival Analysis; Treatment Outcome | 2018 |
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Topics: Cytarabine; Disease Progression; Down Syndrome; Historically Controlled Study; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukemoid Reaction; Neoplasm, Residual; Survival Analysis | 2018 |
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Remission Induction; Thalidomide | 2018 |
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid; Liver; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Prospective Studies | 2016 |
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Fatigue; Feasibility Studies; Female; Fever; Follow-Up Studies; Humans; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Analysis; T-Lymphocytes; Thrombocytopenia; Time Factors; Treatment Outcome | 2008 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotides; Peripheral Nervous System Diseases; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2009 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carbohydrates; Cell Death; Child; Child, Preschool; Citrulline; Cytarabine; Daunorubicin; DNA; Enterocytes; Etoposide; Feces; Female; Humans; Infant; Interleukin-8; Intestinal Absorption; Leukemia, Myeloid; Leukocyte L1 Antigen Complex; Male; Mitoxantrone; Models, Biological; Mucositis; Stomatitis | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Transplantation Chimera; Treatment Outcome | 2011 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Down Syndrome; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Prognosis; Prospective Studies; Time Factors; Treatment Outcome | 2011 |
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2012 |
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bryostatins; Cytarabine; Female; Humans; Infusions, Intravenous; Lactones; Leukemia, Myeloid; Macrolides; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase C; Tumor Cells, Cultured | 2002 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Fever; Humans; Hypotension; Infections; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Treatment Outcome | 2002 |
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemical and Drug Induced Liver Injury; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neutropenia; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infections; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Humans; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Trisomy | 2002 |
Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Infection Control; Length of Stay; Leukemia, Myeloid; Male; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Thrombocytosis; Treatment Outcome | 2002 |
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Topotecan; Treatment Outcome | 2002 |
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cause of Death; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Poland; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2002 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome | 2003 |
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Genetic Markers; Genetic Predisposition to Disease; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Treatment Outcome | 2003 |
Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Clinical Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Leukemia, Myeloid; Male; Patient Selection; Prognosis; Remission Induction; Stem Cell Transplantation; Survival Rate; Translocation, Genetic | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Topics: Acute Disease; Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2003 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort Studies; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Thioguanine; Vidarabine | 2003 |
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Rate; Thioguanine | 2003 |
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chronic Disease; Cytarabine; Cytogenetics; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Time Factors | 2004 |
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous | 2003 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Prognosis; Recurrence; Risk Factors; Transplantation Conditioning | 2004 |
Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Topics: Acute Disease; Adolescent; Adult; Analysis of Variance; Antimetabolites, Antineoplastic; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Recurrence; Survival Analysis; Translocation, Genetic; United States | 2004 |
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Male; Recurrence; Treatment Outcome | 2004 |
Maintenance therapy in childhood acute myeloid leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Mercaptopurine; Mitoxantrone; Prognosis; Survival Analysis; Time Factors | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation, Homologous | 2004 |
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Treatment Outcome | 2005 |
[Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male | 2004 |
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Hemorrhage; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2004 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Remission Induction; Transplantation, Autologous | 2004 |
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis | 2005 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2005 |
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2005 |
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cytarabine; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Irinotecan; Leukemia, Myeloid; Male; Middle Aged; Recurrence | 2006 |
Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Transplantation; Cause of Death; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Poland; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Down Syndrome; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Interleukin-11; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Mitoxantrone; Thioguanine; Treatment Outcome; United Kingdom | 2006 |
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pyridines; Recurrence; Risk Factors; Thiosemicarbazones; Treatment Outcome | 2006 |
Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Caspases; Cell Count; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Common Antigens; Leukocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; Remission Induction | 2006 |
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; DNA Fragmentation; Female; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Mitoxantrone; Nucleosomes; Predictive Value of Tests; Prognosis; Thioguanine; Thymidine Kinase; Treatment Outcome | 2006 |
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2006 |
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Infant; Infections; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Vincristine | 2007 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pancytopenia; Patient Compliance; Risk Factors | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis | 2007 |
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Premedication; Proportional Hazards Models; Recombinant Proteins; Risk; Salvage Therapy; Stimulation, Chemical; Transplantation, Homologous; Treatment Outcome | 2007 |
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival; Treatment Outcome; Tretinoin | 2007 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Palliative Care; Remission Induction; Salvage Therapy; Survival Analysis | 2007 |
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Oncogene Proteins, Fusion; Prognosis; Remission Induction; Risk Factors; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Thioguanine | 2007 |
Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Treatment Outcome | 2007 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cytarabine; Daunorubicin; Humans; In Vitro Techniques; Leukemia, Myeloid; Models, Biological; Nonlinear Dynamics; Prognosis; Retrospective Studies; Spectrometry, Fluorescence; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemtuzumab; Humans; Infant; Leukemia, Myeloid; Male; Mitoxantrone; Survival Rate | 2008 |
Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Random Allocation; Splenectomy; Thioguanine; Time Factors | 1984 |
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisone; Vincristine | 1984 |
Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Hydroxyurea; Immunotherapy; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Sex Factors; Splenectomy; Vincristine | 1984 |
Chemotherapy of the myeloid leukaemias.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Remission, Spontaneous; Thioguanine | 1980 |
[Results of a clinical study of the preparation Lenvis in leukemias in children and adults].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Drug Therapy, Combination; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine | 1981 |
[The results of 2 and 1/2 years of work of the Russian Multicenter Trial on the Treatment of Acute Myeloid Leukemias in Adults].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Remission Induction; Russia; Survival Analysis; Time Factors | 1995 |
Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Pilot Projects; Recombinant Proteins; Recurrence; Tumor Cells, Cultured; Whole-Body Irradiation | 1994 |
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 1994 |
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; DNA Polymerase II; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Neutropenia; Randomized Controlled Trials as Topic; Survival Analysis | 1994 |
Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Opportunistic Infections; Patient Acceptance of Health Care; Preleukemia; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1994 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Humans; Infant; Karyotyping; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 1995 |
Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Topics: Acute Disease; Adolescent; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Immunophenotyping; Infant; Leukemia, Myeloid; Neoplastic Stem Cells; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Sensitivity and Specificity; Treatment Outcome | 1995 |
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 1995 |
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Treatment Outcome | 1995 |
No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Japan Adult Leukemia Study Grou
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Mercaptopurine; Prednisolone; Recombinant Proteins; Recurrence; Remission Induction; Survival Analysis; Time Factors; Vincristine | 1993 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Wider benefits of leukodepletion of blood products.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Transplantation; Cell Separation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Filtration; Humans; Immunization; Leukemia, Myeloid; Leukocytes; Life Tables; Prospective Studies; Remission Induction; Treatment Outcome | 1995 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate | 1995 |
MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Remission Induction; RNA, Neoplasm; Survival Rate; Treatment Outcome | 1993 |
Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Sex Factors; Survival Rate; Thioguanine | 1994 |
[The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Russia | 1994 |
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 1994 |
High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 1994 |
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Prospective Studies; Survival Analysis | 1994 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Survival Analysis | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Treatment Outcome | 1993 |
Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Probability; Retrospective Studies; Survival Analysis | 1993 |
Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor.
Topics: Aclarubicin; Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypothyroidism; Iodide Peroxidase; Leukemia, Myeloid; Male; Recombinant Proteins; Thyroid Function Tests; Thyrotropin; Thyroxine; Triiodothyronine | 1993 |
Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vincristine | 1993 |
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Heart; Heart Function Tests; Humans; Infant; Leukemia, Myeloid; Male; Mitoxantrone; Prognosis; Thioguanine; Vincristine | 1996 |
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leucine; Leukemia, Myeloid; Logistic Models; Male; Mercaptopurine; Middle Aged; Multivariate Analysis; Prednisolone; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 1996 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy | 1995 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Survival Analysis; Thioguanine; Transplantation, Autologous | 1996 |
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Eye Diseases; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Infant; Leukemia, Myeloid; Life Tables; Male; Mitoxantrone; Nuclear Family; Prognosis; Prospective Studies; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 1996 |
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Intestinal Mucosa; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Quality of Life; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Life Tables; Male; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate; Thioguanine; Treatment Outcome | 1996 |
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Influence of rhGM-CSF on Ara-C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cell Cycle; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Recombinant Proteins; S Phase | 1996 |
Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Myelodysplastic Syndromes; Platelet Count; Remission Induction; Thioguanine; Treatment Outcome | 1996 |
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Life Tables; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 1996 |
Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Infant; Length of Stay; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Thioguanine | 1996 |
Peripheral blood stem cells mobilized from patients with acute myeloid leukaemia have different platelet repopulating abilities compared with those mobilized from patients with other diseases.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Cell Differentiation; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Megakaryocytes; Multiple Myeloma; Ovarian Neoplasms; Platelet Count; Thioguanine; Time Factors | 1996 |
High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Filgrastim; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
[Low-dose chemotherapy].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction | 1996 |
Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction | 1996 |
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1996 |
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Remission Induction | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
Topics: Acute Disease; Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Child, Preschool; Contraindications; Cytarabine; Etoposide; Female; Humans; Infant; Infections; Leukemia, Myeloid; Male; Salvage Therapy; Treatment Outcome | 1997 |
High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Treatment Outcome | 1997 |
A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1997 |
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1997 |
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Acute Disease; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Rate | 1997 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Probability; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1997 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation fo
Topics: Acute Disease; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction | 1997 |
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prognosis; Remission Induction | 1997 |
Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Cell Cycle; Cell Division; Cytarabine; Disease-Free Survival; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Middle Aged; Risk Assessment; Tumor Stem Cell Assay; Vidarabine | 1995 |
A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Pilot Projects; Recombinant Proteins; S Phase | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Survival Analysis | 1998 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Drug Costs; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hospital Costs; Humans; Karnofsky Performance Status; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Survival Analysis; Treatment Outcome | 1998 |
Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia.
Topics: Acute Disease; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Remission Induction; Terminal Care; Treatment Outcome | 1998 |
Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Quality of Life; Thioguanine | 1998 |
Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.
Topics: Adult; Aged; Cholecalciferol; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Tetradecanoylphorbol Acetate | 1998 |
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Double-Blind Method; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Infection Control; Leukemia, Myeloid; Life Tables; Middle Aged; Neutropenia; Recombinant Proteins; Remission Induction; Safety; Survival Analysis; Treatment Outcome | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Infections; Leukemia, Myeloid; Male; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 1998 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine | 1998 |
Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Danazol; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Life Tables; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Quinine; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vault Ribonucleoprotein Particles | 1998 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence | 1998 |
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prospective Studies; Risk Factors | 1998 |
Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Pilot Projects; Prednisolone; Recombinant Proteins; Time Factors; Vincristine | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Topics: Acute Disease; Adolescent; Adult; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studies; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Remission Induction; Treatment Outcome | 1998 |
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Topics: Acute Disease; Administration, Oral; Adult; Antineoplastic Agents; Arabinonucleotides; Biological Availability; Cytarabine; Cytidine Monophosphate; Diarrhea; Dose-Response Relationship, Drug; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Prodrugs; Regression Analysis | 1998 |
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Critical Care; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Recurrence; Salvage Therapy; Time Factors | 1998 |
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction | 1995 |
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 1998 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality Therapy; Cytarabine; Diarrhea; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Neutropenia; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Genes, ras; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogenes; Receptor Protein-Tyrosine Kinases; Remission Induction; Survival Rate | 1999 |
A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carubicin; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Failure; Vincristine | 1999 |
Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cytarabine; Daunorubicin; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Prognosis; Receptors, Estrogen; Regression Analysis | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Double-Blind Method; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pilot Projects; Transplantation, Autologous | 1999 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence | 1999 |
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Treatment Outcome | 1999 |
[Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Time Factors; Treatment Outcome | 1999 |
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1999 |
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Remission Induction; Treatment Outcome | 1999 |
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 1999 |
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Recurrence; Vidarabine | 1999 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2000 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Recombinant Proteins; Remission Induction; Treatment Outcome | 2000 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 2000 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Conjunctivitis; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Risk; Stomatitis; Stroke Volume; Survival Analysis; Survival Rate; Treatment Outcome; Tretinoin; Ventricular Dysfunction, Left | 2000 |
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA Mutational Analysis; Etoposide; Female; Gene Deletion; Genes, p53; Humans; Japan; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Mutation; Mutation, Missense; Neoplasm Proteins; Prednisolone; Prognosis; Regulatory Sequences, Nucleic Acid; Single-Blind Method; Survival Analysis; Tumor Suppressor Protein p53; Vincristine | 2000 |
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction | 2000 |
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Risk; Survival Analysis; Translocation, Genetic; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Vidarabine | 2001 |
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Thioguanine | 2001 |
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Risk Factors; Treatment Outcome | 2001 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 2001 |
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
Topics: Actuarial Analysis; Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Cost-Benefit Analysis; Cytarabine; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Survival Rate | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Karyotyping; Lenograstim; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Predictive Value of Tests; Prednisone; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Topics: Acute Disease; Aged; Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Survival Rate | 2001 |
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Follow-Up Studies; Gene Deletion; Genotype; Glutathione Transferase; Humans; Isoenzymes; Leukemia, Myeloid; Mercaptopurine; Multivariate Analysis; NAD(P)H Dehydrogenase (Quinone); Neoplasm Proteins; Peroxidase; Polymorphism, Genetic; Prednisolone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alleles; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Doxorubicin; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Leukemia, Myeloid; Male; Middle Aged; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cohort Studies; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Hypokalemia; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Proteins; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Tretinoin | 2002 |
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Topics: Acute Disease; Adolescent; Adult; Algorithms; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2002 |
Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutrophils; Platelet Count; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis; Transplantation, Homologous; Vidarabine | 2002 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2002 |
Effect of early splenectomy and cyclic acute leukemia-like chemotherapy on the course of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Splenectomy; Thioguanine; Vincristine | 1978 |
The immunotherapy of acute myelogenous leukaemia using intravenous BCG.
Topics: Acute Disease; Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Injections, Intravenous; Leukemia, Myeloid; Middle Aged; Remission, Spontaneous; Skin Tests | 1977 |
Acute myelocytic leukemia.
Topics: Animals; BCG Vaccine; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Leukemia L1210; Leukemia, Myeloid; Mercaptopurine; Mice; Mycobacterium bovis; Neuraminidase; Thioguanine | 1976 |
A clinical trial of early splenectomy, hydroxyurea, and cyclic arabinosyl cytosine, vincristine, and prednisone in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Liver; Male; Middle Aged; Organ Size; Prednisone; Spleen; Splenectomy; Time Factors; Vincristine | 1975 |
Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Splenectomy; Thioguanine | 1975 |
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Chromosomes, Human, 21-22 and Y; Cytarabine; Diploidy; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1976 |
Cell kinetics in leukemia. Correlation with clinical features and response to chemotherapy.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Kinetics; Leucovorin; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Mitotic Index; Thioguanine | 1975 |
An attempt at synchronization of marrow cells in acute leukemia: relationship to therapeutic response.
Topics: Adult; Age Factors; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cytarabine; Female; Humans; Leucovorin; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Sex Factors; Vincristine | 1976 |
Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol.
Topics: Acute Disease; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Bone Marrow; Calcitriol; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxyurea; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged | 1992 |
Intensive induction chemotherapy in elderly patients. The BGMT Group.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged | 1992 |
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
Topics: Acute Disease; Bone Marrow; Bromodeoxyuridine; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; S Phase; Tritium; Tumor Cells, Cultured | 1992 |
High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged; Prednisone; Survival Analysis; Tretinoin | 1992 |
[The therapeutic results in acute myeloid leukemias in elderly patients].
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Remission Induction; Time Factors | 1992 |
Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission.
Topics: Acute Disease; Aged; Aged, 80 and over; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction | 1992 |
Varying intensity of postremission therapy in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Follow-Up Studies; Heparin; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Thioguanine | 1992 |
Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis; Thioguanine; Transplantation, Autologous | 1992 |
Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; France; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous | 1992 |
The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Infant; Leukemia, Myeloid; Prognosis; Remission Induction; Survival Rate; Thioguanine | 1992 |
Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Italy; Leukemia, Myeloid; Male; Pilot Projects; Random Allocation; Recurrence; Remission Induction | 1992 |
Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid; Recurrence; Remission Induction; Thioguanine; United Kingdom | 1992 |
Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1992 |
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Thioguanine | 1992 |
Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Italy; Leukemia, Myeloid; Middle Aged; Remission Induction; Thioguanine | 1992 |
Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Japan; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction; Vincristine | 1992 |
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Creatinine; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Nervous System Diseases; Risk Factors | 1992 |
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Remission Induction; Thioguanine | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis | 1991 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Infusions, Intravenous; Leukemia, Myeloid; Mitoxantrone; Recombinant Proteins; Thioguanine; Tumor Stem Cell Assay | 1991 |
A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Remission Induction; Thioguanine; Time Factors; Vincristine | 1991 |
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Recombinant Proteins; S Phase | 1991 |
Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1991 |
Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Interferon-alpha; Leukemia, Myeloid; Male; Prospective Studies; Remission Induction; Thioguanine | 1991 |
Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; New Zealand; Remission Induction; Survival Rate | 1991 |
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Remission Induction | 1991 |
High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Humans; Immunosuppression Therapy; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid | 1988 |
Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects | 1986 |
Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Cytarabine; Evaluation Studies as Topic; Female; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunologic Deficiency Syndromes; Infant; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Prednisone; Rosette Formation; T-Lymphocytes | 1985 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Female; Heart; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Nausea; Stroke Volume; Vomiting | 1985 |
Central nervous system toxicity of high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Central Nervous System Diseases; Cerebellar Diseases; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Nystagmus, Pathologic; Syndrome; Tremor | 1985 |
Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.
Topics: Acute Disease; Adult; Blood Cell Count; Blood Platelets; Cytarabine; Female; Hemoglobinometry; Humans; Infusions, Parenteral; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Regression, Spontaneous; Remission, Spontaneous; Sex Factors; Time Factors | 1974 |
Clinical trials of 1-beta-D-arabinofuranosyl cytosine and 1,3-bis-(2-chloroethyl)-1-nitrosourea combination in metastatic cancer and acute leukemia.
Topics: Age Factors; Blood Cell Count; Blood Platelets; Blood Urea Nitrogen; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Hemoglobins; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Nitrogen Mustard Compounds; Nitroso Compounds; Nitrosourea Compounds; Remission, Spontaneous; Reticulocytes; Sex Factors; Urea; Uric Acid | 1971 |
Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271).
Topics: Acute Disease; Adolescent; Adult; Aged; Alanine Transaminase; Alopecia; Aspartate Aminotransferases; Bone Marrow Diseases; Child; Clinical Trials as Topic; Cyclophosphamide; Cystitis; Cytarabine; Drug Combinations; Evaluation Studies as Topic; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nausea; Remission, Spontaneous; Vomiting | 1970 |
740 other study(ies) available for cytarabine and Leukemia, Myeloid
| Article | Year |
|---|---|
A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
Topics: Amino Acids; Animals; Antineoplastic Agents; Body Weight; Carbolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytarabine; Differential Thermal Analysis; DNA; Drug Screening Assays, Antitumor; Esters; Humans; Inhibitory Concentration 50; Intercalating Agents; Leukemia, Myeloid; Liver Neoplasms; Male; Melanoma; Mice; Mice, Inbred ICR; Models, Molecular; Neoplasm Transplantation; Organ Size; Quantitative Structure-Activity Relationship | 2011 |
Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Physiological Phenomena; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Oxindoles | 2021 |
SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
Topics: Acute Disease; Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Proliferation; Cytarabine; Doxorubicin; Gene Expression Regulation, Leukemic; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Inbred C57BL; Mice, Knockout; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Sequence Homology, Amino Acid; Sirtuin 2; Tumor Cells, Cultured | 2022 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoxantrone; Respiratory Tract Infections; Sepsis | 2023 |
Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine Kinase; Dexamethasone; Drug Interactions; Leukemia, Myeloid; Rats | 2020 |
Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Vancomycin; Vancomycin-Resistant Enterococci; Young Adult | 2017 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Core Binding Factors; Cytarabine; Gene Expression Regulation, Leukemic; Humans; Interleukin-13; Janus Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Mutation, Missense; Phosphorylation; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT Transcription Factors; Transfection | 2017 |
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2018 |
Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2018 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.
Topics: Adolescent; Adult; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Whole-Body Irradiation; Young Adult | 2019 |
A Case of Granulocytic Sarcoma of the Lung in Acute Myeloid Leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid | 2019 |
Acute myeloid leukemia in first remission: to choose transplantation or not?
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decision Making; Female; Humans; Leukemia, Myeloid; Nucleophosmin; Patient Preference; Remission Induction; Review Literature as Topic; Stem Cell Transplantation; Transplantation, Homologous | 2013 |
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Nucleophosmin; Peripheral Blood Stem Cell Transplantation; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis; Trans-Activators; Transplantation, Autologous; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine; Young Adult | 2013 |
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
BMP4 is involved in the chemoresistance of myeloid leukemia cells through regulating autophagy-apoptosis balance.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Bone Morphogenetic Protein 4; Caspase 2; Caspase 3; Caspase 9; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cytarabine; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Leukemia, Myeloid; Membrane Proteins; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; RNA Interference; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Comparative Genomic Hybridization; Cytarabine; DNA Copy Number Variations; Drug Administration Schedule; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Remission Induction | 2014 |
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 2014 |
Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cell Count; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid; Middle Aged; Neoplastic Stem Cells; Remission Induction; Retreatment; Time Factors | 2015 |
Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cytarabine; Fatty Acid-Binding Proteins; Female; Humans; In Situ Hybridization, Fluorescence; Infant; Karyotype; Leukemia, Myeloid; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Remission Induction; Treatment Outcome | 2015 |
An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Cytarabine; Dendritic Cells; Galactosylceramides; Green Fluorescent Proteins; Killer Cells, Natural; Leukemia, Myeloid; Mice, Inbred C57BL; Mice, Transgenic; Prognosis; Secondary Prevention; Transplantation, Autologous | 2014 |
[Progress of study on drug therapy in adults patients with acute myeloid leukemia (non APL) after remission].
Topics: Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2014 |
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2015 |
Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Endothelial Cells; Flow Cytometry; Humans; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Reactive Oxygen Species; Stilbenes; Time Factors; Xenograft Model Antitumor Assays | 2016 |
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.
Topics: Anilides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Nucleotidyltransferases; Tumor Cells, Cultured | 2016 |
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32(4):507-523.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; History, 20th Century; Humans; Leukemia; Leukemia, Myeloid | 2016 |
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Cell Line, Tumor; Cell Proliferation; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Homeodomain Proteins; Humans; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transcription Factors; Vindesine | 2016 |
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Exanthema; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Mucositis; Neutropenia; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Imatinib-induced pseudoporphyria.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytarabine; Drug Eruptions; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Porphyrias; Pyrimidines | 2009 |
JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
Topics: Azo Compounds; Comet Assay; Cytarabine; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid; Nitric Oxide Donors; Piperazines | 2009 |
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; G1 Phase; Humans; Hydroxamic Acids; Leukemia, Myeloid; S Phase; Tumor Cells, Cultured; Vorinostat | 2009 |
Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Communication; Cluster Analysis; Cytarabine; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Inactivation, Metabolic; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Suppressor Protein p53 | 2009 |
Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2009 |
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |
Last exit clofarabine?
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Humans; Leukemia; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2009 |
Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003.
Topics: Antineoplastic Agents; Child, Preschool; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Down Syndrome; Female; France; Humans; Infant; Leukemia, Myeloid; Male; Registries; Treatment Outcome | 2010 |
CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; HL-60 Cells; Humans; Leukemia, Myeloid; Membrane Proteins; RNA, Messenger; Smad5 Protein | 2010 |
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line, Tumor; Cell Survival; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Muscle Proteins; Mutation; Oligonucleotides, Antisense; Prognosis; Survival Analysis; Young Adult | 2011 |
Simultaneous acute myeloid leukaemia and de novo acute hepatitis B: a novel management strategy.
Topics: Acute Disease; Antineoplastic Agents; Antiviral Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Humans; Leukemia, Myeloid; Treatment Outcome; Young Adult | 2011 |
Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Immunophenotyping; Infant; Killer Cells, Natural; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Treatment Outcome | 2011 |
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2011 |
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Topics: Acute Disease; Bone Marrow Cells; Cell Proliferation; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Liposomes; Stem Cells; Tumor Cells, Cultured | 2011 |
Therapy-related leukemia cutis with histopathologic changes resembling xanthogranuloma.
Topics: Adult; Biopsy, Needle; Cytarabine; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Granuloma; Humans; Immunohistochemistry; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemic Infiltration; Lymphoma, T-Cell; Risk Assessment; Xanthomatosis | 2011 |
MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Differentiation; Cytarabine; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Myeloid; Membrane Proteins; MicroRNAs; Monocytes; Oligoribonucleotides, Antisense; Proto-Oncogene Proteins; U937 Cells; Up-Regulation; Vitamin D | 2011 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Feasibility Studies; Female; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Outpatients; Patient Readmission | 2012 |
RNAi screening of the kinome with cytarabine in leukemias.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cytarabine; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Leukemia, Myeloid; Nuclear Proteins; Phosphotransferases; Protein-Tyrosine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering | 2012 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Chromosome Aberrations; Cohort Studies; Comorbidity; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Palliative Care; Remission Induction; Retrospective Studies; Serbia; Treatment Outcome | 2012 |
Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neutropenia; Obesity; Outcome Assessment, Health Care; Prognosis; Remission Induction; Young Adult | 2013 |
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Remission Induction; Translocation, Genetic; Young Adult | 2012 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
SAB--a promising new treatment to improve remission rates in AML in the elderly?
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid; Remission Induction; Thioguanine | 2002 |
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; beta 2-Microglobulin; Bone Marrow Cells; Cell Division; Cytarabine; Down-Regulation; fas Receptor; Flow Cytometry; Genes, bcl-2; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Tretinoin | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Anti-angiogenic activity of the purine analog 6-thioguanine.
Topics: 2-Aminopurine; Acute Disease; Aged; Allantois; Anemia; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cattle; Cell Line, Transformed; Chick Embryo; Chorion; Cytarabine; Daunorubicin; Drug Evaluation; Endothelial Growth Factors; Endothelium, Vascular; Etoposide; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Leukemia, Myeloid; Lymphokines; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neovascularization, Pathologic; Neovascularization, Physiologic; Remission Induction; Stress, Mechanical; Thioguanine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Headache; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Patient Compliance; Pilot Projects; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Failure; Tretinoin | 2002 |
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Cells; Cell Adhesion; Cell Division; Culture Media, Serum-Free; Cytarabine; DNA Primers; Female; Fluorescent Dyes; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Mice; Middle Aged; Organic Chemicals; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Stromal Cells; Tumor Cells, Cultured; Up-Regulation | 2002 |
Erythematous eruption in a man with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Cytarabine; Drug Eruptions; Humans; Leukemia, Myeloid; Male | 2002 |
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cladribine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplastic Stem Cells; Recurrence; Remission Induction; Tetrazolium Salts; Thiazoles; Translocation, Genetic; Trisomy | 2002 |
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Topics: Acute Disease; Adolescent; Adult; Alleles; Amino Acid Substitution; Antimetabolites, Antineoplastic; Codon; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Deletion; Gene Duplication; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome | 2002 |
Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia, Myeloid; Recurrence | 2002 |
Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression; Genes, bcl-2; Genes, MDR; Genes, p53; Heat-Shock Proteins; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bryostatins; Carrier Proteins; Caspases; Cytarabine; Cytochrome c Group; Drug Synergism; Enzyme Activation; Gene Deletion; HL-60 Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lactones; Leukemia, Myeloid; Macrolides; Maleimides; Mitochondrial Proteins; Mutation; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; U937 Cells | 2003 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow Cells; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Cytarabine; Daunorubicin; Drug Synergism; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Myeloid; Lipoproteins, LDL; Lovastatin; Membrane Lipids; Protein Prenylation; Protein Processing, Post-Translational; Radiation-Sensitizing Agents; Tricarboxylic Acids; Tumor Cells, Cultured | 2003 |
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Diphtheria Toxin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunocompromised Host; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Interleukin-2; Interleukin-3; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplastic Stem Cells; Recombinant Fusion Proteins | 2003 |
Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Drug Evaluation; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome | 2003 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Stem Cell Transplantation | 2003 |
Maternal and fetal outcomes in pregnancy complicated with acute leukemia: a single institutional experience with 10 pregnancies at 16 years.
Topics: Abortion, Spontaneous; Abortion, Therapeutic; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fatal Outcome; Female; Fetal Death; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Turkey | 2003 |
HLA-DR antigen-negative acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; HLA-DR Antigens; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prospective Studies; Recurrence; Treatment Outcome | 2003 |
In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cytarabine; Drug Antagonism; Drug Synergism; Humans; Intracellular Membranes; Leukemia, Myeloid; Membrane Potentials; Mitochondria; Purines; Tumor Cells, Cultured | 2003 |
Survival of acute myeloid leukemia cells requires PI3 kinase activation.
Topics: Acute Disease; Animals; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Everolimus; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous | 2003 |
Mucormycosis in acute myeloid leukaemia.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Combined Modality Therapy; Cytarabine; Frozen Sections; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Mucormycosis; Thoracic Wall | 2003 |
Immunophenotyping is an independent factor for risk stratification in AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis | 2003 |
Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Models, Biological; Peripheral Blood Stem Cell Transplantation; Remission Induction; Risk; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2003 |
Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Palliative Care; Remission Induction; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Topics: 5'-Nucleotidase; Acute Disease; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cytarabine; Deoxycytidine Kinase; Disease-Free Survival; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Treatment Outcome | 2003 |
Cytarabine-induced corneal toxicity.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Corneal Diseases; Cytarabine; Humans; Leukemia, Myeloid; Male; Vision Disorders | 2003 |
Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Cytarabine; Heparin, Low-Molecular-Weight; Homozygote; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Male; Myeloid Cells; Neoplastic Stem Cells; Pedigree; Protein C Deficiency | 2003 |
Cytarabine syndrome revisited.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Fever; Humans; Leukemia, Myeloid; Syndrome | 2003 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Enterocolitis, Necrotizing; Female; Humans; Infusions, Parenteral; Injections, Subcutaneous; Intestinal Diseases; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Remission Induction; Retrospective Studies; Thrombocytopenia | 2003 |
Chemotherapy increases transgene expression in leukemic cells.
Topics: Acute Disease; Animals; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Gene Expression; Genetic Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lac Operon; Leukemia, Myeloid; Mice; Neoplasm Transplantation; Transfection; Transgenes; Tumor Cells, Cultured | 2003 |
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Down Syndrome; Etoposide; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Prospective Studies; Retrospective Studies; Thioguanine | 2004 |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Transformed; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Genistein; Humans; Indoles; Leukemia, Myeloid; MAP Kinase Signaling System; Milk Proteins; Mutagenesis; Phenotype; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Tyrphostins | 2004 |
Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Cells; CD13 Antigens; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukemic Infiltration; Lipopolysaccharide Receptors; Male; Methylprednisolone; Mitoxantrone; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome | 2004 |
Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Cytogenetics; Daunorubicin; DNA Nucleotidylexotransferase; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate | 2004 |
Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Chromosome Aberrations; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; L-Selectin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin | 2003 |
Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Cell Cycle; Cytarabine; HL-60 Cells; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Up-Regulation | 2004 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glucosyltransferases; Glycosylation; HL-60 Cells; Humans; Leukemia, Myeloid; Morpholines; Protective Agents; U937 Cells | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Middle Aged; Recurrence | 2004 |
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.
Topics: Acute Disease; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Division; Cell Line, Tumor; Cytarabine; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured; Valproic Acid | 2004 |
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 2004 |
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Prognosis; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thioguanine | 2004 |
5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid; Molecular Sequence Data; Nucleotidases; Prognosis; RNA, Messenger | 2004 |
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cytarabine; Disease Progression; Female; Humans; Isotretinoin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine | 2004 |
A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Topics: Acute Disease; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Daunorubicin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Oxazoles; Telomerase; Telomere; U937 Cells | 2004 |
Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells.
Topics: Acute Disease; Animals; Antigens, CD; B7-1 Antigen; B7-2 Antigen; B7-H1 Antigen; Blood Proteins; Cell Line, Tumor; Cytarabine; Cytotoxicity, Immunologic; Humans; Leukemia, Myeloid; Membrane Glycoproteins; Mice; Mice, Inbred C3H; Peptides; T-Lymphocytes, Cytotoxic; Up-Regulation | 2004 |
In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
Topics: Acute Disease; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Caspofungin; Cytarabine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Interactions; Echinocandins; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid; Lipopeptides; Mycoses; Peptides; Peptides, Cyclic; Substrate Specificity | 2004 |
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Apoptosis; Caspase 3; Caspases; Cytarabine; Enzyme Activation; Etoposide; Fas Ligand Protein; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Nucleic Acid Synthesis Inhibitors; Treatment Outcome | 2004 |
Fatal peripheral neuropathy following FLA chemotherapy.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrimidines; Triazoles; Vidarabine; Voriconazole | 2004 |
Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Stem Cell Factor; Tyrphostins | 2004 |
Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Malaysia; Male; Treatment Outcome | 2004 |
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
Topics: Acute Disease; Adult; Aged; Apoptosis; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Translocation, Genetic; Tumor Cells, Cultured | 2004 |
A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia.
Topics: Acute Disease; Animals; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Mice; Mice, SCID; Oncogene Proteins; Oncogene Proteins, Fusion; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2004 |
The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
Topics: Animals; Cytarabine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Recombinant Fusion Proteins | 2004 |
Pressure-induced bullae and sweat gland necrosis following chemotherapy induction.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blister; Cytarabine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Idarubicin; Leukemia, Myeloid; Male; Necrosis; Remission Induction; Sweat Gland Diseases; Sweat Glands | 2004 |
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Tumor Cells, Cultured; Vidarabine | 2004 |
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Proliferation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2004 |
Cytarabine-induced fever complicating the clinical course of leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Retrospective Studies | 2005 |
PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways.
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Animals; Antigens, CD; Antigens, CD34; Antimetabolites, Antineoplastic; Cell Survival; Chromones; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Membrane Glycoproteins; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Cell Lineage; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cytarabine; Cytotoxicity Tests, Immunologic; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorometry; Gene Rearrangement; Glucocorticoids; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Proto-Oncogenes; Statistics, Nonparametric; Transcription Factors; Translocation, Genetic | 2005 |
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Diseases; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells | 2005 |
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Differentiation; Cell Membrane; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; GPI-Linked Proteins; Granulocytes; HL-60 Cells; Humans; Hydroxyurea; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monocytes; Oncogene Proteins, Fusion; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Fusion Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Stem Cell Assay; U937 Cells | 2005 |
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Tretinoin | 2005 |
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosome Aberrations; Cytarabine; Female; Hemoglobins; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Neoplasm Staging; Platelet Count; Prognosis; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2005 |
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3 | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Topics: Acute Disease; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Oligospermia; Sperm Motility; Spermatozoa | 2005 |
Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Palliative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Creatine Kinase, MB Form; Cytarabine; Echocardiography; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Troponin T | 2005 |
"3+7" therapy for the treatment of acute myeloid leukemia. PRO.
Topics: Acute Disease; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Remission Induction; Treatment Outcome | 2005 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder.
Topics: Acute Disease; Cytarabine; Down Syndrome; Female; Follow-Up Studies; GATA1 Transcription Factor; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Infant, Newborn; Leukemia, Myeloid; Longitudinal Studies; Male; Mutation; Myeloproliferative Disorders; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
Topics: Acute Disease; Adult; Algorithms; Antimetabolites, Antineoplastic; Area Under Curve; Bone Marrow Cells; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Meta-Analysis as Topic; Models, Biological; Randomized Controlled Trials as Topic | 2005 |
Genetics in the management of adult de novo AML.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Chromosome Aberrations; Chromosome Banding; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid; Middle Aged; Multicenter Studies as Topic; Prognosis; Prospective Studies; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2003 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
Topics: Acute Disease; Adult; Antigens, CD; B-Lymphocytes; Blast Crisis; Bone Marrow Cells; CD79 Antigens; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Flow Cytometry; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Male; T-Lymphocytes; Translocation, Genetic | 2005 |
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Vidarabine | 2006 |
Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways.
Topics: Acute Disease; Animals; Cell Death; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Mice; Mitogen-Activated Protein Kinases; Neurofibromin 1; Protein Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
[What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Cytarabine; Fever; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Neck Pain; Paresis; Prognosis; Recurrence; Remission Induction | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.
Topics: 5'-Nucleotidase; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proportional Hazards Models; Pyrimidine Nucleotides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Treatment Outcome | 2005 |
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cell Membrane; Child; Cytarabine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gene Expression Profiling; Humans; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2005 |
Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Incidence; Infant; Infant, Newborn; Infection Control; Leukemia, Myeloid; Male; Retrospective Studies; Sepsis; Streptococcal Infections; Survival Rate; Treatment Outcome; Viridans Streptococci | 2006 |
Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Drug Administration Schedule; Female; Granulocytes; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Neutrophils; Time Factors | 2006 |
JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells.
Topics: Blotting, Western; Bone Marrow Cells; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Cytarabine; Gene Silencing; Granulocytes; Heat-Shock Proteins; Hemin; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myeloid; Macrophages; Membrane Transport Proteins; Monocytes; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tetradecanoylphorbol Acetate; Time Factors; Tretinoin; U937 Cells | 2006 |
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Cytarabine; DNA; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; G1 Phase; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Central Nervous System; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gingiva; Humans; Hydrocortisone; Idarubicin; Infant; Infant, Newborn; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Leukemic Infiltration; Male; Methotrexate; Orbit; Prognosis; Remission Induction; Sarcoma, Myeloid; Skin; Testis | 2007 |
Conversion disorder with convulsion and motor deficit mimicking the adverse effects of high-dose Ara-C treatment in a posttransplant acute myeloid leukemia patient: a case report and review of the literature.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Conversion Disorder; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Neurotoxicity Syndromes; Psychomotor Performance; Seizures | 2004 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Effects of interferon gamma on native human acute myelogenous leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Proliferation; Chemokine CXCL9; Chemokines, CXC; Cytarabine; Endothelium, Vascular; Female; Fibroblasts; Flow Cytometry; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon gamma Receptor; Interferon-gamma; Interleukin-1beta; Interleukin-3; Interleukin-8; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphocyte Activation; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteoblasts; Phosphorylation; Receptors, Interferon; Signal Transduction; STAT1 Transcription Factor; Stromal Cells; T-Lymphocytes; Tumor Cells, Cultured | 2007 |
Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cytarabine; DNA Primers; Down-Regulation; Drug Resistance, Neoplasm; Exons; Humans; Leukemia, Myeloid; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA Splicing; RNA, Messenger; Tumor Suppressor Protein p53 | 2006 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
Core binding factor acute myeloid leukemia.
Topics: Acute Disease; Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Neoplasm, Residual; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Treatment Outcome | 2006 |
Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia.
Topics: Acute Disease; Adult; Aged; Apoptosis; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; K562 Cells; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Oncogene Protein v-akt; Receptor, IGF Type 1; Suramin; Up-Regulation | 2006 |
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 2006 |
Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
Topics: Acute Disease; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged; Peripheral Nervous System Diseases | 2006 |
Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine.
Topics: Acute Disease; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Myeloid; Selection, Genetic; Tumor Cells, Cultured; Vincristine | 2006 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Infant; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Translocation, Genetic; WT1 Proteins | 2007 |
Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults.
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cord Blood Stem Cell Transplantation; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow Cells; Caspase 3; Cell Proliferation; Cytarabine; Diphosphonates; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid; Male; Middle Aged; Zoledronic Acid | 2007 |
De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center.
Topics: Academic Medical Centers; Acute Disease; Brazil; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Middle Aged; Patient Selection; Remission Induction; Retrospective Studies; Socioeconomic Factors; Survival Rate | 2006 |
Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells.
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Etoposide; Gemtuzumab; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 2006 |
[Bulky lymphadenopathy in acute myeloid leukemia with inv (16) (p13q22): a case report].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Lymphatic Diseases; Male; Neoplasm, Residual; Prognosis | 2006 |
Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
Topics: Acute Disease; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cytarabine; Humans; Indoles; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2006 |
t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mexico; Middle Aged; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Prevalence; Prospective Studies; Remission Induction; RUNX1 Translocation Partner 1 Protein; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2006 |
Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Erythropoietin; Etoposide; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Primary Myelofibrosis; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Epidemiologic Methods; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Severity of Illness Index; Treatment Outcome | 2007 |
Improved outcome after relapse in children with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine | 2007 |
Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Treatment Outcome | 2007 |
Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Survival; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infant; Inhibitory Concentration 50; Leukemia; Leukemia, Myeloid; Male; Methylphenazonium Methosulfate; Middle Aged; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Staining and Labeling; Tetrazolium Salts; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2007 |
An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aortic Valve Stenosis; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Liver Diseases; Male; Middle Aged; Mycoses; Pleural Effusion; Treatment Outcome; Vidarabine | 2007 |
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Alleles; Amino Acid Substitution; Antimetabolites, Antineoplastic; Cytarabine; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prognosis; Survival Rate; Tandem Repeat Sequences; Treatment Outcome | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
Topics: Acute Disease; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Autocrine Communication; Cell Division; Cell Line, Tumor; Cytarabine; Down-Regulation; Etoposide; Humans; Insulin-Like Growth Factor I; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction | 2007 |
Pseudomembranous necrotizing tracheobronchitis caused by Aspergillus spp--contribution of one case with acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Bronchitis; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Necrosis; Opportunistic Infections; Radiography, Thoracic; Tracheitis | 2006 |
The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Image Processing, Computer-Assisted; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Recovery of Function; Remission Induction; Time Factors | 2007 |
Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Blood Gas Analysis; Bone Marrow Transplantation; Cytarabine; Dyspnea; Female; Fever; Humans; Hypoxia; Leukemia, Myeloid; Lung Diseases; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cytarabine; Down-Regulation; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Indazoles; Leukemia, Myeloid; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-mos; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2008 |
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Topics: Acute Disease; Cell Differentiation; Child; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Down Syndrome; Drug Resistance, Neoplasm; Erythroid Precursor Cells; Erythropoiesis; GATA1 Transcription Factor; Gene Dosage; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; K562 Cells; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Neoplasm Proteins; Proto-Oncogene Mas; Proto-Oncogene Protein c-ets-2; Thrombopoiesis | 2008 |
[Acute non-lymphatic leukemia after treatment of Hodgkin's lymphoma with chemotherapy and radiotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Mechlorethamine; Prednisone; Procarbazine; Radiotherapy; Thioguanine; Vinblastine; Vincristine | 1984 |
Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Cell Line; Cell Survival; Cytarabine; Cytidine Triphosphate; DNA; Humans; Hydroxyurea; Kinetics; Leukemia L1210; Leukemia, Myeloid; Mice; RNA | 1983 |
Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Retrospective Studies | 1983 |
Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
Topics: Bone Marrow; Cells, Cultured; Cytarabine; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Phosphotransferases; Tetrahydrouridine; Uridine | 1980 |
Histomorphologic study of bone marrow in acute leukemia following chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thioguanine; Time Factors; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1983 |
[The Münster study of intensive induction and consolidation therapy without maintenance therapy of acute myeloid leukemia. Results of 93 patients--cellular determinants for response and length of remission].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Platelets; Cytarabine; Daunorubicin; Germany, West; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid; Middle Aged; Thioguanine; Time Factors | 1983 |
[Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Thioguanine | 1983 |
[Results of treatment of acute myeloid leukemia in adults].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1983 |
Autologous marrow transplantation for patients with chronic myelogenous leukemia (CML) in blast crisis.
Topics: Adult; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Freezing; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Teniposide; Thioguanine; Tissue Preservation; Transplantation, Autologous | 1984 |
Marrow transplantation for stable-phase chronic granulocytic leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Male; Middle Aged; Transplantation, Homologous | 1984 |
Treatment of myeloid blastic crisis of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid; Prednisone; Transplantation, Autologous; Vincristine | 1984 |
Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Topics: Animals; Cell Cycle; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Leukemia, Experimental; Leukemia, Myeloid; Rats | 1983 |
Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion.
Topics: Cytarabine; Drug Administration Schedule; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia, Myeloid; Thrombophlebitis; Time Factors | 1983 |
Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow Cells; Cytarabine; Female; Granulocytes; Hematopoietic Stem Cells; Humans; Hydroxyurea; Interphase; Leukemia, Myeloid; Macrophages; Male; Middle Aged; Thymidine | 1983 |
Treatment of the blastic crisis of chronic myelogenous leukemia with the combination of vindesine and prednisolone, and cytosine arabinoside.
Topics: Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Prednisolone; Vinblastine; Vindesine | 1983 |
Latent period of 9 years in the presentation of a myeloproliferative disorder.
Topics: Adult; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Mercaptopurine; Skin Manifestations; Time Factors | 1983 |
Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia.
Topics: Adult; Aminoisobutyric Acids; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Pseudouridine; Uridine | 1983 |
[Clinical studies of BH-AC-DMP in adult acute nonlymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1983 |
Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.
Topics: Aged; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Muramidase; Prognosis | 1984 |
Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long-term maintenance chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Recurrence; Splenectomy; Time Factors; Vincristine | 1984 |
[Chemotherapy of chronic myelogenous leukemia in blastic crisis--vindesine, cytosine arabinoside prednisolone combination therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone; Vinblastine; Vindesine | 1984 |
Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes.
Topics: Adult; Aged; Anemia, Aplastic; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1984 |
Serous effusions in monocytic leukaemias.
Topics: Aged; Ascitic Fluid; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Razoxane | 1984 |
Hepatic dysfunction and jaundice following high-dose cytosine arabinoside.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Liver; Male; Middle Aged; Prednisone; Vincristine | 1984 |
[A case report of chronic myelomonocytic leukemia--therapeutic effect of VP 16-213 and cytosine arabinoside].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Male | 1984 |
Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.
Topics: Adult; Arteries; Axons; Brain; Child; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukoencephalopathy, Progressive Multifocal; Male; Meningeal Neoplasms; Methotrexate; Necrosis; Veins | 1984 |
Diffusion chamber cultures of bone marrow cells in refractory anemia with excess oil blasts (RAEB).
Topics: Anemia, Aplastic; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Methylprednisolone; Thioguanine | 1981 |
Tumour lysis syndrome with hypocälcaemia in accelerated chronic granulocytic leukaemia.
Topics: Adult; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Hypocalcemia; Leukemia, Myeloid; Prednisone; Syndrome; Time Factors; Vincristine | 1982 |
Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Line; Cell Transformation, Neoplastic; Complement C3; Cytarabine; Dactinomycin; Doxorubicin; Humans; Hydroxyurea; Immunoglobulin Fc Fragments; Leukemia, Myeloid; Leukocytes; Mitomycins; Muramidase; Rosette Formation | 1980 |
[DNA breaks in the leukocytes and tumor cells as an indicator of therapeutic activity of cytostatics].
Topics: Cytarabine; DNA; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocytes; Methotrexate; Nucleic Acid Denaturation | 1980 |
Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia (CML) following a chemotherapy-induced loss of the Ph1 chromosome.
Topics: Adult; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Clone Cells; Cytarabine; Daunorubicin; Female; Glucosephosphate Dehydrogenase; Heterozygote; Humans; Karyotyping; Leukemia, Myeloid; Thioguanine | 1980 |
Congenital monocytic leukaemia.
Topics: Clinical Enzyme Tests; Cytarabine; Humans; Infant, Newborn; Leukemia, Myeloid; Male; Mercaptopurine; Monocytes; Muramidase; Naphthol AS D Esterase | 1980 |
Leukemia cutis in blastic transformation of chronic myelocytic leukemia: TdT positive blasts and response to vincristine and prednisone.
Topics: Aged; Blastomeres; Cell Transformation, Neoplastic; Cytarabine; DNA Nucleotidyltransferases; Humans; Leukemia, Myeloid; Male; Microscopy, Electron; Prednisone; Skin Neoplasms; Vincristine | 1980 |
Cytokinetic changes in the peripheral blood of leukemic patients during cytostatic therapy. VI. Effect of arabinosylcytosine.
Topics: Adult; Aged; Blood Cells; Cytarabine; DNA; Female; Humans; Interphase; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Primary Myelofibrosis | 1980 |
Corneal toxicity with systemic cytarabine.
Topics: Corneal Diseases; Corneal Opacity; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1981 |
Re-induction of complete remissions in adults with acute non-lymphocytic leukemia.
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Thioguanine | 1981 |
Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.
Topics: Antineoplastic Agents; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Regression Analysis | 1981 |
Enzymatic studies on possible improvement of cytosine arabinoside treatment.
Topics: Adult; Cell Extracts; Cytarabine; Cytidine Deaminase; Deamination; Deoxycytidine; Deoxycytidine Kinase; Female; Humans; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Phosphorylation | 1981 |
In vitro culture and ultrastructure analysis of peripheral blood cells separated by discontinuous albumin density gradient during blast crisis of chronic granulocyte leukemia.
Topics: Blood Cells; Cells, Cultured; Centrifugation, Density Gradient; Colony-Forming Units Assay; Cytarabine; Granulocytes; Humans; Leukemia, Myeloid; Monocytes; Thioguanine | 1981 |
[Case of full remission of a blast crisis in myelocytic leukemia].
Topics: Blood Transfusion; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Remission, Spontaneous | 1981 |
[Acute myelocytic leukemia in childhood: results of treatment from 1964 to 1979].
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Male | 1980 |
Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Binding Sites; Bone Marrow Cells; Carrier Proteins; Cell Transformation, Neoplastic; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Nucleosides; Thioinosine; Time Factors | 1982 |
Prevention of blastic crisis in Ph1-positive chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow; Cytarabine; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Platelet Count; Thioguanine; Vincristine | 1982 |
Busulfan, antimetabolites, radiotherapy, and cost of treatment in chronic myelocytic leukemia. A non-controlled, non-randomized monocenter study with historical controls.
Topics: Busulfan; Costs and Cost Analysis; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Radiography; Spleen; Thioguanine | 1981 |
Vincristine and prednisolone therapy in blast crisis of chronic myelogenous leukaemia in childhood.
Topics: Adolescent; Child; Cyclophosphamide; Cytarabine; DNA Nucleotidylexotransferase; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Prednisolone; Prognosis; Vincristine | 1981 |
Functional compartmentation of DNA precursors in human leukaemoblastoid cell lines.
Topics: Cell Line; Cytarabine; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Nucleic Acid Precursors; Thymidine; Thymine Nucleotides | 1982 |
Modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids.
Topics: Cell Line; Cytarabine; DNA; Humans; Hydroxamic Acids; Leukemia, Myeloid; Time Factors | 1982 |
Enzymatic studies on possible improvement of cytosine arabinoside treatment.
Topics: Adult; Aged; Cytarabine; Cytidine Deaminase; Deamination; Deoxycytidine Kinase; Female; Humans; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Phosphorylation | 1982 |
Treatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
Topics: Adult; Aged; Animals; Bone Marrow; Bone Marrow Transplantation; Cell Division; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Rats | 1981 |
High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1993 |
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine | 1993 |
Upregulation of cell surface expression of T-lymphoid antigens and adhesion molecules on acute myeloid leukaemia cells after in vivo administration of granulocyte colony-stimulating factor.
Topics: Aclarubicin; Acute Disease; Aged; Antigens, CD; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Adhesion Molecules; Cell Separation; Cytarabine; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; T-Lymphocytes; Up-Regulation | 1994 |
Cell kinetic effects of granulocyte colony-stimulating factor on the sensitivity of nonlymphocytic leukemia cells to cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Division; Cell Survival; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured | 1993 |
1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells.
Topics: Amino Acid Sequence; CDC2 Protein Kinase; Cytarabine; Humans; In Vitro Techniques; Leukemia, Myeloid; Macromolecular Substances; Molecular Sequence Data; Phosphotyrosine; Precipitin Tests; Protein Binding; Protein-Tyrosine Kinases; src-Family Kinases; Tumor Cells, Cultured; Tyrosine | 1995 |
Secondary tumours following etoposide containing therapy for germ cell cancer.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Cytarabine; Dactinomycin; Dose-Response Relationship, Drug; Etoposide; Germinoma; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Neoplasms, Second Primary; Testicular Neoplasms; Vincristine | 1995 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
CD7 expression does not predict for poor outcome in acute myeloblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Survival Analysis; T-Lymphocyte Subsets | 1995 |
Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Analysis of Variance; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Bone Marrow; Cell Division; Cells, Cultured; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Predictive Value of Tests; Remission Induction; Survival Rate | 1995 |
The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro.
Topics: Acute Disease; Bone Marrow; Cell Cycle; Cells, Cultured; Cytarabine; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukemia, Myeloid | 1995 |
Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.
Topics: Acute Disease; Antineoplastic Agents; Cell Survival; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydrogen Peroxide; Leukemia, Myeloid; Oncogenes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Recombinant Proteins; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 1995 |
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Cytarabine; Cytogenetics; Humans; Karyotyping; Leukemia, Myeloid; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Sequence Deletion; Survival Rate; Treatment Outcome | 1995 |
Growth modulation and differentiation of acute myeloid leukemia cells by jaspamide.
Topics: Antigens, CD; Cell Differentiation; Cell Division; Cytarabine; Depsipeptides; Humans; Leukemia, Myeloid; Peptides, Cyclic; Tumor Cells, Cultured | 1995 |
Hypoplastic acute myeloid leukaemia with 7 years of complete remission by low-dose cytosine arabinoside therapy alone.
Topics: Acute Disease; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid; Remission Induction | 1995 |
Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA Damage; Gene Expression; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogenes; Recombinant Fusion Proteins; Tumor Cells, Cultured | 1993 |
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
Topics: Acute Disease; Aged; Cell Survival; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Methylcellulose; Middle Aged; Tretinoin; Tumor Cells, Cultured | 1993 |
Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs.
Topics: Aclarubicin; Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Survival; Coloring Agents; Cytarabine; Daunorubicin; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Remission Induction | 1993 |
Activation of the early growth response 1 gene and nuclear pp90rsk in human myeloid leukemia cells by 1-(beta-D-arabinofuranosyl)cytosine.
Topics: Base Sequence; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cytarabine; DNA Mutational Analysis; DNA-Binding Proteins; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Leukemia, Myeloid; Molecular Sequence Data; Nuclear Proteins; Protein Serine-Threonine Kinases; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Ribosomal Protein S6; Ribosomal Protein S6 Kinases; Ribosomal Proteins; RNA; RNA, Messenger; Sequence Deletion; Serum Response Factor; Subcellular Fractions; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
[Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1995 |
1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells.
Topics: Amino Acid Sequence; CDC2 Protein Kinase; Cytarabine; Humans; Leukemia, Myeloid; Molecular Sequence Data; Phosphorylation; Tyrosine | 1995 |
Aspartate-based inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 1; Cell Cycle; Cell Line; Cysteine Endopeptidases; Cytarabine; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Kinetics; Leukemia, Myeloid; Time Factors; Tumor Cells, Cultured | 1995 |
Transverse nail ridgings (Beau's lines) induced by chemotherapy--a dose-dependent phenomenon.
Topics: Acute Disease; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Nail Diseases; Nails | 1994 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Treatment Outcome | 1995 |
[Hemostasis in patients with acute leukemia treated with high doses of cytosine-arabinoside: the effect of chemotherapy and infectious complications on hemostasis].
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Female; Hemostasis; Humans; Leukemia, Myeloid; Male; Middle Aged; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Post-remission chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adult; Cytarabine; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction | 1995 |
Salivary glands enlargement in association with cytosine arabinoside application in patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Humans; Leukemia, Myeloid; Male; Sialadenitis | 1994 |
Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Preleukemia; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1994 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Rhodamine 123; Rhodamines; Survival Analysis | 1995 |
Combined antileukemic activity of pIXY 321 and Ara-C against human acute myeloid leukemia cells.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Northern; Blotting, Western; Cytarabine; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Nucleosomes; Recombinant Fusion Proteins; Tumor Cells, Cultured | 1994 |
Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Ethyl Methanesulfonate; Etoposide; Humans; Leukemia, Myeloid; Mutagenesis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1994 |
Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol.
Topics: Abortion, Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infertility, Female; Leukemia, Myeloid; Menstruation; Middle Aged; Pregnancy; Pregnancy Outcome; Primary Ovarian Insufficiency; Remission Induction; Reoperation; Survivors; Thioguanine; Transplantation, Autologous | 1994 |
Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Cell Division; Clone Cells; Cytarabine; Drug Resistance; Female; Flow Cytometry; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis | 1994 |
Capacity of individual chronic lymphatic leukemia lymphocytes and leukemic blast cells for repair of O6-ethylguanine in DNA: relation to chemosensitivity in vitro and treatment outcome.
Topics: Acute Disease; Carmustine; Cyclophosphamide; Cytarabine; DNA Repair; Doxorubicin; Drug Resistance; Ethylnitrosourea; Glutathione; Guanine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphocytes; Treatment Outcome | 1994 |
Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Stimulation, Chemical; Treatment Failure; Verapamil | 1994 |
1-beta-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells.
Topics: Cytarabine; Drug Resistance; Enzyme Activation; Gene Expression Regulation; Genes, jun; Humans; Leukemia, Myeloid; Protein Serine-Threonine Kinases; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1994 |
Intensified therapy for acute myeloid leukemia.
Topics: Acute Disease; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Remission Induction | 1994 |
Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia.
Topics: Acute Disease; Cause of Death; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Pulmonary Edema; Respiratory Insufficiency; Salvage Therapy | 1994 |
Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Bryostatins; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lactones; Leukemia, Myeloid; Macrolides; Protein Kinase C; Tumor Cells, Cultured | 1994 |
Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to 1-beta-D-arabinofuranosylcytosine.
Topics: Cell Differentiation; Cell Nucleus; Cytarabine; Cytoplasm; DNA, Neoplasm; Drug Resistance; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-jun; Sp1 Transcription Factor; Tumor Cells, Cultured | 1994 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1994 |
Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells.
Topics: Acute Disease; Adolescent; Adult; Blood Cells; Cell Movement; Cells, Cultured; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.
Topics: Apoptosis; Cytarabine; DNA; Dose-Response Relationship, Drug; Genes, jun; Genes, myc; Humans; Leukemia, Myeloid; Mitoxantrone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.
Topics: Cell Differentiation; Cell Division; Cytarabine; Down-Regulation; Erythrocytes; Gene Expression Regulation, Leukemic; Genes, myc; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Macrophages; Megakaryocytes; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Effect of Bcl-2 on ionizing radiation and 1-beta-D-arabinofuranosylcytosine-induced internucleosomal DNA fragmentation and cell survival in human myeloid leukemia cells.
Topics: Cell Survival; Cytarabine; DNA; DNA Damage; Gene Expression; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1993 |
Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1993 |
Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Cryopreservation; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Macrophages; Male; Middle Aged; Remission Induction | 1993 |
Acute myeloid leukemia presenting as granulocytic sarcoma of the lung.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Humans; Leukemia, Myeloid; Lung Neoplasms; Male | 1993 |
Differential modulation of the expression of the intermediate filament proteins vimentin and nuclear lamins A and C by differentiation inducers in human myeloid leukemia (U-937, HL-60) cells.
Topics: Bucladesine; Butyrates; Butyric Acid; Cell Differentiation; Cytarabine; Gene Expression; Humans; In Vitro Techniques; Lamins; Leukemia, Myeloid; Nuclear Proteins; RNA, Messenger; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured; Vimentin | 1993 |
Treatment of childhood acute myeloid leukaemia using the BFM-83 protocol.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Survival Analysis; Treatment Outcome | 1993 |
Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells.
Topics: Adenosine; Binding Sites; Carrier Proteins; Cell Line; Cytarabine; Fluoresceins; Humans; Leukemia, Myeloid; Ligands; Membrane Proteins; Nucleoside Transport Proteins; Purine Nucleosides; Thioinosine; Thionucleosides | 1993 |
Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Biopsy, Needle; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cell Differentiation; Cell Division; Cytarabine; Daunorubicin; Drug Therapy, Combination; Granulocytes; Humans; Leukemia, Myeloid; Prognosis; Remission Induction; Risk Factors | 1993 |
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Tetrahydrouridine; Treatment Outcome | 1993 |
Neutrophilic eccrine hidradenitis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Facial Dermatoses; Female; Hidradenitis; Humans; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Female; Humans; Incidence; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Translocation, Genetic | 1993 |
Activation of the jun-D gene during treatment of human myeloid leukemia cells with 1-beta-D-arabinofuranosylcytosine.
Topics: Activating Transcription Factor 2; Base Sequence; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cytarabine; Dactinomycin; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Genes, jun; Humans; Kinetics; Leucine Zippers; Leukemia, Myeloid; Molecular Sequence Data; Protein Binding; Protein Processing, Post-Translational; Repressor Proteins; RNA, Messenger; Stimulation, Chemical; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
[Clinical and immunologic characteristics of CD 34 positive acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1995 |
Low-dose cytosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy.
Topics: Acute Disease; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Survival Analysis | 1995 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Catheterization, Central Venous; Cross Infection; Cytarabine; Daunorubicin; Disease Susceptibility; Etoposide; Female; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Patient Discharge; Safety; Treatment Outcome | 1996 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Epidural Space; Fatal Outcome; Frontal Bone; Humans; Leukemia, Myeloid; Leukemic Infiltration; Male; Methylprednisolone; Spinal Canal; Thrombocythemia, Essential | 1996 |
Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cell Line, Transformed; Cells, Cultured; Child; Child, Preschool; Chromosomes, Human, Pair 21; Cystathionine beta-Synthase; Cytarabine; Deoxycytosine Nucleotides; Disease-Free Survival; Down Syndrome; Female; Herpesvirus 4, Human; Homocysteine; Humans; Infant; Infant, Newborn; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Methotrexate; Myelodysplastic Syndromes; Neoplastic Stem Cells; Remission, Spontaneous; Survival Rate | 1996 |
Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Cytarabine; DNA Damage; Endopeptidases; Enzyme Activation; Genes, jun; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Membrane Proteins; Mitomycin; Molecular Sequence Data; Myelin Basic Protein; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Proteins; Neoplastic Stem Cells; Nucleosomes; Phosphorylation; Protein Kinase C; Protein Kinase C-delta; Protein Processing, Post-Translational; Proteins; Signal Transduction; Substrate Specificity; Tumor Cells, Cultured | 1996 |
Renal venous thrombosis complicating acute myeloid leukemia with hyperleukocytosis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Cytarabine; Daunorubicin; Humans; Infant; Kidney; Leukapheresis; Leukemia, Myeloid; Leukocyte Count; Leukocytosis; Male; Renal Veins; Thioguanine; Thrombosis; Tomography, X-Ray Computed; Ultrasonography, Doppler | 1996 |
High-dose cytarabine induction for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 1996 |
Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents; Cell Differentiation; Cell Survival; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Treatment Outcome; Tumor Cells, Cultured | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; fas Receptor; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Thioguanine; Treatment Outcome | 1996 |
Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Topics: Acute Disease; Base Sequence; Burkitt Lymphoma; Cytarabine; Dose-Response Relationship, Immunologic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Molecular Sequence Data; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Transcription, Genetic | 1995 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; DNA Fragmentation; DNA, Complementary; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 1996 |
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Male | 1996 |
Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Diseases; Cytarabine; Daunorubicin; Female; Humans; Kidney; Kidney Failure, Chronic; Leukemia, Myeloid; Lupus Nephritis; Mitoxantrone | 1996 |
Regulation of the synthesis of bcl-2 protein by growth factors.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Tumor Cells, Cultured | 1996 |
Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Northern; Blotting, Western; Cell Differentiation; Cytarabine; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid; Neomycin; Plasmids; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection | 1996 |
Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Facial Paralysis; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mastoid; Middle Aged; Mitoxantrone; Mucormycosis; Myringoplasty; Neutropenia; Otitis Media, Suppurative; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 1996 |
Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Disease Progression; Flow Cytometry; Gene Expression Regulation, Leukemic; Genes, p53; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Sensitivity and Specificity; Tumor Cells, Cultured | 1997 |
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1997 |
Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cytarabine; Daunorubicin; Female; Heart; Humans; Leukemia, Myeloid; Male; Middle Aged; Razoxane; Recurrence | 1996 |
FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vidarabine; Vomiting | 1996 |
Involvement of stress-activated protein kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents.
Topics: Adaptor Proteins, Signal Transducing; Androstadienes; Antimetabolites, Antineoplastic; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Cytarabine; DNA Damage; Enzyme Activation; Enzyme Inhibitors; Glutathione Transferase; GRB2 Adaptor Protein; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Protein Kinases; Proteins; Proto-Oncogene Proteins c-jun; Recombinant Proteins; src Homology Domains; Stress, Physiological; Tumor Cells, Cultured; Wortmannin | 1995 |
Hemin-induced erythroid differentiation of human myeloleukemia K562 cell line and its modification by bioresponse modifiers.
Topics: Animals; Cattle; Cytarabine; Erythropoiesis; Hemin; Humans; Leukemia, Myeloid; Ligands; Molecular Structure; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myb; Proto-Oncogene Proteins c-myc; Protoporphyrins; Receptors, GABA-A; Retinoids; RNA, Messenger; Trans-Activators; Tubulin; Tumor Cells, Cultured | 1997 |
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; Cytarabine; Deoxycytidine Kinase; DNA-Directed DNA Polymerase; DNA, Neoplasm; Drug Interactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Thymidine Kinase; Tumor Cells, Cultured | 1997 |
CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; B7-1 Antigen; CD8-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; Cytarabine; Evaluation Studies as Topic; Female; Immunization Schedule; Immunotherapy, Active; Immunotherapy, Adoptive; Leukemia, Myeloid; Leukemia, Radiation-Induced; Lymphocyte Activation; Lymphokines; Mice; Mice, Inbred Strains; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Th1 Cells; Tumor Cells, Cultured; Vaccines | 1997 |
Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Platelet Transfusion; Thioguanine; Thrombocytopenia | 1997 |
5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line.
Topics: 5-Aminolevulinate Synthetase; Cell Line; Cytarabine; Fibroblast Growth Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hemin; Hemoglobins; Humans; Leukemia, Myeloid; RNA, Messenger | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based primi
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytidine Deaminase; Daunorubicin; DNA Polymerase II; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Lymphocytes; Male; Middle Aged; Nucleoside Deaminases; Thioguanine; Thymidine Kinase | 1997 |
Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine.
Topics: Antibiotics, Antineoplastic; Cell Differentiation; Cytarabine; Deoxyadenosines; Drug Combinations; Growth Inhibitors; HL-60 Cells; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Pentostatin; Tretinoin; Tumor Cells, Cultured | 1997 |
Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.
Topics: Acute Disease; Bone Marrow; Cell Survival; Child; Cytarabine; Daunorubicin; Down Syndrome; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1997 |
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Multivariate Analysis | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Time Factors | 1997 |
The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Prognosis; Remission Induction; Retrospective Studies; Sialic Acid Binding Ig-like Lectin 3 | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-kappa B activation.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzoquinones; Cytarabine; DNA Fragmentation; Etoposide; Humans; Kinetics; Lactams, Macrocyclic; Leukemia, Myeloid; NF-kappa B; Phosphorylation; Phosphotyrosine; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinones; Rifabutin; Tumor Cells, Cultured | 1998 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Humans; Lethal Dose 50; Leukemia, Myeloid; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia.
Topics: Adult; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm, Residual; Recombinant Proteins | 1998 |
Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Tumor Cells, Cultured | 1998 |
High-dose therapy in acute leukemia.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 1997 |
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Risk Factors; Time Factors; Vidarabine | 1998 |
[Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Myelodysplastic Syndromes; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Thioguanine; Treatment Outcome; Vincristine; Waldenstrom Macroglobulinemia | 1998 |
Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cytarabine; DNA Primers; Dose-Response Relationship, Drug; Doxorubicin; Humans; Leukemia, Myeloid; Mice; Mutation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Transfection; Tretinoin; Tumor Cells, Cultured | 1998 |
Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 8; Cohort Studies; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Trisomy | 1998 |
Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate | 1998 |
Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Cycle; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Flow Cytometry; Genes, p53; Humans; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Mutation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Sensitivity and Specificity | 1998 |
Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.
Topics: Acute Disease; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Bryostatins; Cell Death; Cytarabine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia, Myeloid; Leukocytes, Mononuclear; Macrolides; Tetrazolium Salts; Thiazoles | 1998 |
Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Clone Cells; Cytarabine; Cytokines; Daunorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-10; Interleukin-2; Leukemia, Myeloid; Leukopenia; Lymphopenia; Male; Middle Aged; Phytohemagglutinins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stimulation, Chemical | 1998 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis | 1998 |
A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological re
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Hematopoiesis, Extramedullary; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prednisolone; Preleukemia; Remission Induction | 1998 |
Proportion of blasts with a clear halo around nucleoli at the end of induction therapy of acute myeloid leukemia correlates with achievement of complete remission, remission duration and relapse.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Nucleolus; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Leukemia, Myeloid; Mercaptopurine; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Remission Induction; Retrospective Studies; Vincristine | 1998 |
Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cytarabine; Drug Interactions; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Proteins; Proto-Oncogene Proteins; Receptors, Cytokine; Receptors, Thrombopoietin; RNA, Messenger; Stem Cell Factor; Thrombopoietin; Thymidine; Trans-Activators | 1998 |
Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Humans; Leukemia, Myeloid; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Recombinant Fusion Proteins; Remission Induction; RNA-Directed DNA Polymerase; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic | 1998 |
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
Topics: Acute Disease; Antidotes; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cytarabine; Deferoxamine; Drug Interactions; Drug Synergism; HL-60 Cells; Humans; Iron; Leukemia, Myeloid; Receptors, Transferrin; Tumor Cells, Cultured | 1998 |
Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid; Micrococcaceae; Mouth; Neutropenia; Opportunistic Infections; Pneumonia, Bacterial; Sepsis | 1998 |
Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction | 1998 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; KB Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Phenotype; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 1995 |
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Genes, MDR; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction | 1998 |
Transplantation in first remission of acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Southern; Cytarabine; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mutation; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Blood Coagulation Disorders; Cytarabine; Female; Hemorrhage; Humans; Leukemia, Myeloid; Leukocytosis; Leukostasis; Male; Middle Aged; Radiography; Thrombocytopenia | 1999 |
Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells.
Topics: Blotting, Northern; Blotting, Western; Burkitt Lymphoma; CCCTC-Binding Factor; Cell Differentiation; Cytarabine; Dimethyl Sulfoxide; DNA-Binding Proteins; Down-Regulation; Erythrocytes; Gene Expression Regulation; Humans; Isoelectric Focusing; Leukemia, Myeloid; Leukocytes; Megakaryocytes; Phosphorylation; Proto-Oncogene Proteins c-myc; Repressor Proteins; RNA Processing, Post-Transcriptional; Staurosporine; Tetradecanoylphorbol Acetate; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 1999 |
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins | 1999 |
High-dose cytarabine produces high cure rate in some AML patients.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
A case report of neutrophilic eccrine hidradenitis in a patient receiving chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Drug Eruptions; Hidradenitis; Humans; Leukemia, Myeloid; Male | 1998 |
Fatal mycobacteremia caused by Mycobacterium tuberculosis in a patient with acute leukemia.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Bacteremia; Cytarabine; Diagnosis, Differential; Fatal Outcome; Humans; Immunocompromised Host; Incidence; Klebsiella Infections; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Neutropenia; Pneumonia, Bacterial; Tuberculosis; Tuberculosis, Pulmonary | 1999 |
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
Topics: Acute Disease; Antigens, CD34; Bone Marrow Cells; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Monocytes | 1999 |
Treatment of acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Remission Induction; Transplantation Conditioning | 1999 |
Treatment of acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid; Patient Compliance; Prognosis; Remission Induction; Research Design | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Cutaneous granulocytic sarcoma mimicking immunoblastic large cell lymphoma.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Doxorubicin; Etoposide; Flow Cytometry; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Myeloid; Lymph Nodes; Lymphoma, Large-Cell, Immunoblastic; Male; Methotrexate; Microscopy, Electron; Prednisone; Skin Neoplasms; Treatment Outcome; Vincristine | 1999 |
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
Topics: Acute Disease; Antineoplastic Agents; Cell Cycle; Cell Division; Cytarabine; Diphtheria Toxin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Myeloid; Membrane Potentials; Mitochondria; Protein Synthesis Inhibitors; Recombinant Fusion Proteins | 1999 |
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Chromosome Banding; Cytarabine; Daunorubicin; DNA, Complementary; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; K562 Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Oligonucleotide Probes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Tumor Cells, Cultured | 1999 |
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Child; Child, Preschool; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Down Syndrome; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukocytes; Tumor Cells, Cultured | 1999 |
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured; Vidarabine | 1999 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Survival Rate; Transplantation, Autologous; Vidarabine | 1999 |
Isolated granulocytic sarcoma of the humerus.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Cytarabine; Diagnosis, Differential; Fatal Outcome; Humans; Humerus; Idarubicin; Leukemia, Myeloid; Magnetic Resonance Imaging; Male; Pain; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Evaluation Studies as Topic; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Primary Myelofibrosis | 1999 |
Leukaemia cell drug resistance and prognostic factors in AML.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Blast Crisis; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Prognosis; Tetrazolium Salts | 1999 |
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cytarabine; Down-Regulation; Flow Cytometry; Gene Expression; Genes, bcl-2; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplasm, Residual; Phosphorylation; Phosphoserine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survival Rate; Tretinoin; Tumor Cells, Cultured | 1999 |
Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
Topics: Acute Disease; Blast Crisis; Bone Marrow Cells; Cell Count; Cytarabine; Cytidine Deaminase; Deamination; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1999 |
Acute minimally differentiated myeloid leukemia (M0) with inv(3)(q21q26).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytarabine; Daunorubicin; Fatal Outcome; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone | 1999 |
Mild pre-transplant cardiomyopathy may not impair long-term quality of life after bone marrow transplantation.
Topics: Acute Disease; Anthracyclines; Bone Marrow Transplantation; Cardiomyopathies; Child; Cytarabine; Daunorubicin; Electroencephalography; Graft vs Host Disease; Humans; Immunosuppressive Agents; Karnofsky Performance Status; Leukemia, Myeloid; Male; Quality of Life; Transplantation, Homologous | 2000 |
De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Female; Hospitals, General; Humans; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Survival Analysis | 1999 |
Induction of TrkA expression by differentiation inducers in human myeloid leukemia KG-1 cells.
Topics: Butyrates; Calcitriol; Cell Differentiation; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Receptor, trkA; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2000 |
Granulocyte macrophage--colony stimulating factor (GM-CSF) as adjunct in induction therapy of acute myeloid leukemia.
Topics: Acute Disease; Adjuvants, Immunologic; Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction | 1999 |
The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Differentiation; Cell Division; Cytarabine; DNA Fragmentation; HL-60 Cells; Humans; Leukemia, Myeloid; Oleanolic Acid; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; U937 Cells | 2000 |
Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Cell Division; Cells, Cultured; Cytarabine; Female; Genes, bcl-2; HL-60 Cells; Humans; Leukemia, Myeloid; Liposomes; Male; Middle Aged; Oligodeoxyribonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Ribonucleotide Reductases; Vidarabine | 2000 |
Primary granulocytic sarcoma of the ovary.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Ovarian Neoplasms; Remission Induction | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Vidarabine | 1999 |
Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antimetabolites, Antineoplastic; Captopril; Cell Division; Cell Line; Cells, Cultured; Cytarabine; Hematopoietic Stem Cells; Interleukin-3; Leukemia, Myeloid; Macrophage Colony-Stimulating Factor; Mice; Mice, Inbred Strains; Oligopeptides; Peptidyl-Dipeptidase A; Recombinant Proteins; S Phase | 2000 |
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Diseases; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Sepsis; Translocation, Genetic; Treatment Outcome | 2000 |
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States | 2000 |
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
Topics: Acute Disease; Adult; Aged; Cell Division; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; DNA; Female; Half-Life; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Linear Models; Lymphocytes; Male; Middle Aged; Statistics, Nonparametric; Time Factors | 2000 |
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Recombinant Proteins; Solubility | 2000 |
Expression of CD11b/CD18 on neutrophils after consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; CD18 Antigens; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Macrophage-1 Antigen; Male; Melphalan; Middle Aged; Neoplasm Proteins; Neutropenia; Recombinant Proteins; Remission Induction | 2000 |
Bullous acral erythema and concomitant pigmentation on the face and occluded skin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Drug Eruptions; Erythema; Female; Hand Dermatoses; Humans; Hyperpigmentation; Leukemia, Myeloid; Skin Diseases, Vesiculobullous | 2000 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro.
Topics: Adult; Aged; Cell Differentiation; Cell Division; Clone Cells; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Tumor Cells, Cultured | 2000 |
A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Phytohemagglutinins; Protein Biosynthesis; Rats; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
Topics: Apoptosis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Cytarabine; Gene Expression Regulation, Neoplastic; Histocytochemistry; Humans; Leukemia, Myeloid; Macrophage-1 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Oligonucleotides, Antisense; Phosphorylation; Proto-Oncogene Proteins c-myc; Retinoblastoma Protein; U937 Cells | 2000 |
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Japan; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate | 2000 |
[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Erythroblasts; Humans; Leukemia, Myeloid; Megakaryocytes; Middle Aged | 1999 |
Nucleus labeling or membrane labeling for studying the proliferation of drug treated cells?
Topics: Acute Disease; Antineoplastic Agents; Cell Cycle; Cell Division; Cell Membrane; Cell Membrane Permeability; Cell Nucleus; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; K562 Cells; Leukemia, Myeloid; Propidium | 2000 |
Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD).
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Japan; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2000 |
Corticosteroids and serious cytarabine-induced pulmonary edema.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Fatal Outcome; Female; Glucocorticoids; Humans; Leukemia, Myeloid; Methylprednisolone; Radiography; Respiratory Distress Syndrome | 2000 |
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate | 2000 |
Low dose cytarabine and Granulocyte / Macrophage-Colony Stimulating Factor induced long-term remission in a patient with acute myeloid leukemia in early relapse after intensive chemotherapy.
Topics: Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction | 2000 |
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
Topics: Acute Disease; Adult; Aged; Aging; Antibiotics, Antineoplastic; Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Cells; Cell Cycle; Cytarabine; Daunorubicin; G2 Phase; Humans; Leukemia, Myeloid; Middle Aged; Mitosis; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured | 2001 |
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prognosis; Treatment Outcome; Tretinoin | 2001 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Case-Control Studies; Cytarabine; Daunorubicin; Female; Gene Expression; Genes, MDR; Genes, ras; Humans; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation; Prospective Studies; Protein Tyrosine Phosphatases; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction | 2001 |
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2001 |
Severe hepatic injury associated with lipid formulations of amphotericin B.
Topics: Adolescent; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Liver; Liver Diseases | 2001 |
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
Topics: Acute Disease; Adult; Blood Transfusion; Cytarabine; Fatal Outcome; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; HLA Antigens; Homozygote; Humans; Idarubicin; Leukemia, Myeloid; Male | 2001 |
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
Topics: Acute Disease; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; B7-2 Antigen; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Immunoglobulin G; Immunologic Memory; Immunotherapy; Leukemia, Myeloid; Leukemia, Radiation-Induced; Lymphoma, Non-Hodgkin; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Recombinant Fusion Proteins; T-Lymphocytes; Thymus Neoplasms | 2001 |
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hidradenitis; Humans; Leukemia, Myeloid; Mitoxantrone | 2001 |
Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Chromatography, Micellar Electrokinetic Capillary; Cytarabine; Humans; Leukemia, Myeloid; Osmolar Concentration; Reproducibility of Results; Sensitivity and Specificity; Temperature | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Incidence; Leukemia, Myeloid; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Rate; Time Factors; Treatment Failure | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine | 2001 |
Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2001 |
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Division; Chromosome Inversion; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Karyotyping; Leukemia, Myeloid; Middle Aged; Prognosis; Translocation, Genetic | 2001 |
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Transplantation, Autologous | 2001 |
Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Cladribine; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Treatment Outcome | 2001 |
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
Topics: 5'-Nucleotidase; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Survival Rate; Transcription, Genetic; Treatment Outcome | 2001 |
Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Asparaginase; Cytarabine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; HL-60 Cells; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, T-Cell; Polyethylene Glycols; Proto-Oncogene Proteins c-bcl-2; Thioguanine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells | 2001 |
Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Fetal Blood; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Area Under Curve; Biotransformation; Cytarabine; Female; Humans; Infusions, Intravenous; Intracellular Fluid; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prodrugs; Remission Induction; Sensitivity and Specificity; Treatment Outcome | 2001 |
Remission induction therapy: the more intensive the better?
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Thioguanine | 2001 |
Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia.
Topics: Antigens, CD7; Biomarkers, Tumor; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Mercaptopurine; Middle Aged; Neoplasms, Second Primary; Prednisolone; Trisomy | 2001 |
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hodgkin Disease; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Vidarabine; Vincristine; Virus Activation | 2001 |
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Resistance, Multiple; Flow Cytometry; Humans; Isoquinolines; Leukemia, Myeloid; Ligands; Receptors, GABA-A; Tumor Cells, Cultured | 2002 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
Cyclopentenyl cytosine increases the phosphorylation and incorporation into dna of arabinofu-ranosyl cytosine in a myeloid leukemic cell-line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Nitrogen Ligases; Cytarabine; Cytidine; Cytidine Diphosphate; Cytidine Monophosphate; Deoxycytosine Nucleotides; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Phosphorylation | 2000 |
Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.
Topics: Acute Disease; Alternative Splicing; Animals; Bone Marrow Cells; Cell Survival; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia, Myeloid; Protein Isoforms; Rats; Transduction, Genetic; Tumor Cells, Cultured | 2002 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Topics: Acute Disease; Age Factors; Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholinesterases; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Japan; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Survival Rate | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Immunotherapy by non-myeloablative stem cell transplantation: study of the immune reconstitution. Arguments for distinct cell subsets in skin and blood.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blood; Blood Cells; Carmustine; CD8-Positive T-Lymphocytes; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Female; Graft Survival; Graft vs Host Reaction; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Immunotherapy; Leukemia, Myeloid; Male; Middle Aged; Minisatellite Repeats; Multiple Myeloma; Prednisone; Receptors, Antigen, T-Cell, alpha-beta; Skin; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 2000 |
High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).
Topics: Acute Disease; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2002 |
Potential mechanisms of resistance to cytarabine in AML patients.
Topics: 5'-Nucleotidase; Acute Disease; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; France; Humans; Leukemia, Myeloid; Life Tables; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis | 2002 |
In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Fluorescent Dyes; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rhodamine 123; Treatment Outcome; Tretinoin | 2002 |
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
Topics: 5'-Nucleotidase; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Cytarabine; Cytidine Deaminase; Disease-Free Survival; DNA Polymerase I; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Lymphocytes; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Heterogeneity of morphological, cytochemical, and cytogenetic features in the blastic phase of chronic granulocytic leukemia.
Topics: Acute Disease; Adult; Alkaline Phosphatase; Aneuploidy; Biopsy; Bone Marrow; Bone Marrow Cells; Cell Nucleus; Child; Chromosome Aberrations; Cytarabine; Cytoplasm; Female; Histocytochemistry; Humans; Leukemia, Myeloid; Male; Microscopy, Electron; Middle Aged; Mitochondria; Organoids; Peroxidases; Prednisone; Remission, Spontaneous; Staining and Labeling; Thioguanine; Vincristine | 1975 |
Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes.
Topics: Azacitidine; Blood Proteins; Cell Separation; Cell-Free System; Cytarabine; Cytidine Deaminase; Deoxycytidine; Granulocytes; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Phosphates; Phosphotransferases; Tissue Extracts; Uridine Kinase | 1975 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation.
Topics: Azacitidine; Bone Marrow; Cell Division; Cell Separation; Centrifugation; Cytarabine; Humans; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1977 |
A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
Topics: Adult; Busulfan; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
Induction of differentiated functions which are reversibly suppressed by cytochalasin B.
Topics: Animals; Bromodeoxyuridine; Cell Division; Cell Line; Cell Movement; Culture Media; Cytarabine; Cytochalasin B; Depression, Chemical; Floxuridine; Latex; Leukemia, Myeloid; Mice; Mice, Inbred Strains; Microspheres; Mitosis; Phagocytosis; Polystyrenes; Radiation Effects; Trypsin; X-Rays | 1975 |
Control of normal differentiation of myeloid leukemic cells. VI. Inhibition of cell multiplication and the formation of macrophages.
Topics: Animals; Blood; Bromodeoxyuridine; Cell Adhesion; Cell Differentiation; Cell Division; Cell Movement; Clone Cells; Cycloheximide; Cytarabine; Dactinomycin; Endotoxins; Floxuridine; Hydroxyurea; Idoxuridine; Leukemia, Myeloid; Macrophages; Mice; Mitomycins; Thymidine; Vinblastine | 1975 |
Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Cytidine Deaminase; Deoxycytidine; Drug Resistance; Erythrocytes; Granulocytes; Humans; Kinetics; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nucleoside Deaminases; Phosphotransferases; Tetrahydrouridine | 1975 |
Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells.
Topics: Animals; Cell Line; Cytarabine; Deoxycytidine Monophosphate; Humans; In Vitro Techniques; Kinetics; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Nucleoside-Phosphate Kinase; Phosphotransferases; Pyrimidine Nucleotides; Sulfhydryl Reagents | 1978 |
Prognostic significance of morphologic and cytochemical markers in adult acute leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Inclusion Bodies; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocytes; Middle Aged; Nucleoproteins; Prednisone; Prognosis; Vincristine | 1978 |
Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine.
Topics: Administration, Oral; Cytarabine; Female; Humans; Infant; Injections, Subcutaneous; Leukemia, Myeloid; Life Expectancy; Mercaptopurine; Quality of Life | 1977 |
Sucessful treatment of severe bone pain and acute arthritis in chronic myelomonocytic leukaemia by cytosine arabinoside.
Topics: Arthritis; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged; Pain | 1977 |
Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Growth Substances; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission, Spontaneous; Thymidine | 1977 |
Monocytic leukemia in three cats.
Topics: Animals; Brain; Cat Diseases; Cats; Cytarabine; Female; Leukemia, Myeloid; Lung; Male | 1977 |
Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy.
Topics: Blood Cell Count; Blood Platelets; Bone Marrow; Bone Marrow Cells; Chromosomes, Human, 21-22 and Y; Cytarabine; Granulocytes; Humans; Leukemia, Myeloid; Leukocyte Count; Thioguanine; Time Factors | 1977 |
Multiple-drug chemotherapy for acute leukemia The TRAMPCOL regimen: results in 86 patients.
Topics: Adolescent; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Methotrexate; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Treatment of feline myelogenous leukemia: four case reports.
Topics: Animals; Blood Transfusion; Cat Diseases; Cats; Cyclophosphamide; Cytarabine; Female; Infusions, Parenteral; Leukemia, Myeloid; Male; Prednisone | 1977 |
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications.
Topics: Adult; Bone Marrow; Carmustine; Cytarabine; Diploidy; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Male; Maryland; Middle Aged; Prednisone; Retrospective Studies; Splenectomy; Vincristine | 1977 |
[Incidence of the Philadelphia chromosome before and after DCMP-therapy during the chronic phase of chronic myelocytic leukemia (author's transl)].
Topics: Adult; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Mitobronitol; Prednisone | 1977 |
Treatment of acute non-lymphoid leukemias: comparison of two protocols.
Topics: Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Prognosis; Thioguanine; Vincristine | 1977 |
Stem cell (CFU-C) proliferation and emergence in a case of chronic granulocytic leukaemia: the role of the spleen.
Topics: Adult; Bone Marrow Cells; Cell Division; Cell Survival; Cells, Cultured; Clone Cells; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Male; Spleen; Splenectomy | 1978 |
Bone pains in chronic myelomonocytic leukaemia, treated by cytosine arabinoside.
Topics: Bone Diseases; Chronic Disease; Cytarabine; Humans; Leukemia, Myeloid; Pain | 1978 |
[Intensive treatment aiming at eradication of chronic myelogeneous leukemia (author's transl)].
Topics: Adolescent; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Splenectomy | 1978 |
Interaction of 6-thioguanine and cytosine arabinoside in cultured cells from patients with acute myeloid leukaemia.
Topics: Cells, Cultured; Cytarabine; Cytidine Deaminase; Drug Synergism; Humans; Leukemia, Myeloid; Thioguanine | 1978 |
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
Topics: Adolescent; Adult; Asparaginase; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 and Y; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Radiography; Spleen; Splenectomy; Thioguanine | 1979 |
Serial studies on in vitro colony formation in patients with acute leukemia in relation to the maintenance of remission.
Topics: Acute Disease; Adult; Child; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous | 1978 |
[Complete clinical remission over 50 months of a patient with acute monocytic leukaemia (author's transl)].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Gingival Hypertrophy; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Male; Remission, Spontaneous | 1979 |
[Program O9 OML 71 and splenectomy in the treatment of myelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Middle Aged; Prednisolone; Splenectomy | 1979 |
[Splenectomy and polychemotherapy in chronic myelosis].
Topics: Busulfan; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Mitobronitol; Prognosis; Splenectomy; Vincristine | 1979 |
Leukemias induced by ethylnitrosourea in Wistar rats: incidence and chemotherapy.
Topics: Acute Disease; Animals; Cytarabine; Doxorubicin; Drug Therapy, Combination; Ethylnitrosourea; Leukemia, Experimental; Leukemia, Myeloid; Leukocyte Count; Male; Nitrosourea Compounds; Rats; Vincristine | 1979 |
Meningeal involvement in leukemias and malignant lymphomas of adults: incidence, course of disease, and treatment for prevention.
Topics: Adult; Cytarabine; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Meningeal Neoplasms; Methotrexate; Prognosis; Retrospective Studies; Time Factors | 1979 |
BN rat myeloid leukemia transferred to the (LEW x BN)F1 rat.
Topics: Animals; Cytarabine; Female; Leukemia, Experimental; Leukemia, Myeloid; Neoplasm Transplantation; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous | 1978 |
[Monocytic leukemia. Analysis of clinical and hematological data in 21 patients (author's transl)].
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow Examination; Chronic Disease; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Histocytochemistry; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Monocytes; Sternum; Vincristine | 1977 |
[A case of acute promyelocytic leukemia treated with quadruple combination therapy and bone marrow transfusion (author's transl)].
Topics: Adult; Bone Marrow Cells; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Prednisolone; Transplantation, Homologous | 1975 |
Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine.
Topics: Administration, Oral; Aminohydrolases; Animals; Cell Count; Cytarabine; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Half-Life; Humans; Leukemia L1210; Leukemia, Myeloid; Leukocytes; Mice; Uridine | 1975 |
Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Clone Cells; Culture Media; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocytes; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine | 1975 |
[Evolution and therapy of blastic crises].
Topics: Bone Marrow; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Spleen | 1975 |
Cytokinetics of human acute leukemia before and after chemotherapy.
Topics: Adolescent; Adult; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Child; Cytarabine; DNA, Neoplasm; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Male; Thioguanine; Thymidine | 1975 |
[Análisis de los resultados en veintitrés casos. (COAP therapy for acute grAnulocytic leukaemia. An assay of the results in 25 cases.) (author's transl)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Vincristine | 1975 |
"Chronic myelogenous" leukemia of juvenile type. Report of two cases and review of therapy.
Topics: Age Factors; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Splenectomy | 1976 |
Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
Topics: Cytarabine; Cytosine Nucleotides; Deamination; Female; Hemangiopericytoma; Humans; Leukemia; Leukemia, Myeloid; Melanoma; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Oxidative Phosphorylation; Splenic Neoplasms | 1976 |
Blast crisis of chronic myeloid leukaemia: the effect of intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Allopurinol; Antineoplastic Agents; Asparaginase; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1976 |
Arabinosyl cytosine in chronic myeloid leukaemia: evidence for high cytokinetic sensitivity of myeloblasts.
Topics: Adult; Bone Marrow; Bone Marrow Cells; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Mitosis; Time Factors | 1976 |
Combinations of arabinosyl cytosine and 6-thioguanine for treatment of adults with acute leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cytarabine; DNA; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1975 |
Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.
Topics: Acute Disease; Adolescent; Aged; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Cytarabine; Hepatic Veins; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver; Male; Thioguanine | 1976 |
Cytotoxic effects of 1-beta-D-arabinofuranosylcytosine and 6-thioguanine in vitro on granulocytic progenitor cells.
Topics: Animals; Cell Division; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Endotoxins; Granulocytes; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia, Myeloid; Leukocytes; Male; Mice; Mice, Inbred C57BL; Thioguanine | 1976 |
[Current treatment and prognosis of chronic myeloid leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Prognosis; Vincristine | 1976 |
Aids in the management of leukemia (cellremoval by continuous flow leukapheresis and impulsecytophotometry).
Topics: Blood Cell Count; Blood Cells; Blood Platelets; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Separation; Cytarabine; DNA; Doxorubicin; Erythrocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Thioguanine | 1976 |
A simultaneous study of bone marrow, spleen, and liver in chronic myeloid leukemia: evidence for differences in cell composition and karyotypes.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Cells; Cell Count; Cytarabine; Erythroblasts; Erythrocyte Count; Female; Granulocytes; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Liver; Male; Middle Aged; Mitotic Index; Spleen; Splenectomy | 1975 |
Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia.
Topics: Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid; Male; Mercaptopurine; Prednisolone; Thrombocythemia, Essential | 1992 |
IL-1 synergizes with ARA-C in aborting the development of chloroleukemia while protecting from ARA-C-induced alopecia in the rat model.
Topics: Alopecia; Animals; Cell Differentiation; Cytarabine; Disease Models, Animal; Drug Synergism; In Vitro Techniques; Interleukin-1; Leukemia, Myeloid; Neoplasm Transplantation; Rats | 1992 |
Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells.
Topics: Base Sequence; Cytarabine; Enhancer Elements, Genetic; Gene Expression Regulation; Humans; Leukemia, Myeloid; Microbial Collagenase; Molecular Sequence Data; Oligonucleotides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Regulatory Sequences, Nucleic Acid; Transcription, Genetic; Tumor Cells, Cultured | 1992 |
Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; CD4 Antigens; CD8 Antigens; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Female; Humans; Immunophenotyping; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction | 1992 |
Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Topics: Acid Phosphatase; Acute Disease; Alkaline Phosphatase; Antigens, CD; Antigens, Differentiation, Myelomonocytic; CD13 Antigens; Cytarabine; Drug Therapy, Combination; Flow Cytometry; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Myeloid; Lipopolysaccharide Receptors; Mitoxantrone; Peroxidase; Phenotype; Sialic Acid Binding Ig-like Lectin 3 | 1992 |
Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azides; Cell Survival; Cycloheximide; Cytarabine; Cytokines; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Interferon Type I; Interleukin-1; Interleukin-3; Interleukin-6; Leukemia, Experimental; Leukemia, Myeloid; Mice; Recombinant Proteins; Sodium Azide; Stem Cell Factor; Transforming Growth Factor beta; Tumor Cells, Cultured; Vincristine | 1992 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
Topics: Acute Disease; Cell Survival; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Reference Values; Stem Cells; Tumor Cells, Cultured | 1992 |
DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1992 |
Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells.
Topics: Actins; Apoptosis; Blotting, Northern; Cell Death; Cytarabine; Drug Synergism; Genes, jun; Genes, myc; Granulocyte-Macrophage Colony-Stimulating Factor; GTP-Binding Proteins; Humans; Interleukin-3; Kinetics; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogenes; Recombinant Fusion Proteins; RNA, Neoplasm; Tumor Cells, Cultured | 1992 |
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine | 1992 |
Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.
Topics: Carbon Radioisotopes; Cell Nucleus; Chromatography, High Pressure Liquid; Cytarabine; DNA Damage; DNA Replication; DNA, Neoplasm; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid; Nucleosides; Tritium; Tumor Cells, Cultured | 1992 |
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous | 1992 |
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; DNA, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; S Phase; Tumor Stem Cell Assay | 1992 |
Enhancement of the cytotoxicity of cytosine arabinoside by interleukin-3.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; Drug Synergism; Feasibility Studies; Humans; Interleukin-1; Interleukin-3; Leukemia, Myeloid; Tumor Stem Cell Assay | 1992 |
Gingival status during chemical plaque control with or without prior mechanical plaque removal in patients with acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Chlorhexidine; Cytarabine; Dental Calculus; Dental Plaque; Dental Scaling; Female; Gingival Hemorrhage; Gingivitis; Humans; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Mouthwashes; Netilmicin; Piperacillin; Premedication; Thrombocytopenia | 1992 |
Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Transplantation, Homologous | 1992 |
Mitozantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukaemia. Trent Working Party on Adult Leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid; Mitoxantrone | 1992 |
Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
Topics: Acute Disease; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1992 |
Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Humans; Interferon Type I; Interferon-gamma; Leukemia, Myeloid; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured | 1992 |
The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth.
Topics: Acute Disease; Cell Division; Cytarabine; Drug Synergism; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quercetin; Receptors, Estrogen; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis | 1992 |
Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, B-Cell; Leukemia, Myeloid; Middle Aged; Neoplasms, Multiple Primary; Remission Induction | 1992 |
Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.
Topics: Cell Division; Cytarabine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA; Drug Resistance; Humans; Hydroxyurea; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
Endothelial expression of intercellular adhesion molecule (ICAM-1) is unaffected by marrow aplasia-inducing chemotherapy.
Topics: Amsacrine; Antigens, CD; Antineoplastic Agents; Bone Marrow; Cell Adhesion Molecules; Cytarabine; Daunorubicin; Endothelium; Humans; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Lymphocyte Function-Associated Antigen-1; Skin | 1991 |
Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts.
Topics: Antigens, CD; Antigens, CD34; Antigens, Differentiation; Blotting, Northern; Cell Differentiation; Cell Survival; Cytarabine; Drug Synergism; Humans; In Vitro Techniques; Interleukin-3; Interphase; Leukemia, Myeloid; Peroxidase; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-myc; Receptor, Macrophage Colony-Stimulating Factor; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1990 |
Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Topics: Azacitidine; Base Sequence; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Neoplasm; Drug Resistance; Enzyme Induction; Humans; Kinetics; Leukemia, Experimental; Leukemia, Myeloid; Methylation; Molecular Sequence Data; Time Factors; Tritium; Tumor Cells, Cultured | 1991 |
Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine.
Topics: Base Sequence; Cytarabine; DNA; Electrophoresis; Gene Expression Regulation, Leukemic; Humans; Leukemia, Experimental; Leukemia, Myeloid; Molecular Sequence Data; NF-kappa B; Nuclear Proteins; Signal Transduction; Transcription, Genetic; Translocation, Genetic; Tumor Cells, Cultured | 1992 |
Transcriptional and posttranscriptional regulation of H1 histone gene expression by 1-beta-D-arabinofuranosylcytosine.
Topics: Cycloheximide; Cytarabine; Dactinomycin; Down-Regulation; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Experimental; Leukemia, Myeloid; Protein Processing, Post-Translational; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1992 |
Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Remission Induction | 1991 |
Daunorubicin impairs 1-beta-D-arabinofuranosylcytosine uptake.
Topics: Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid; Tumor Cells, Cultured | 1991 |
Effects of recombinant human cytokines on cytarabine activity in K562 human myeloid leukaemia cells.
Topics: Cytarabine; Cytokines; Drug Interactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon Type I; Interferon-gamma; Interleukin-3; Leukemia, Myeloid; Recombinant Proteins; Tumor Cells, Cultured | 1991 |
Necrotizing eccrine squamous syringometaplasia presenting as acral erythema.
Topics: Adult; Cytarabine; Diagnosis, Differential; Eccrine Glands; Erythema; Hand Dermatoses; Humans; Leukemia, Myeloid; Male; Metaplasia; Necrosis; Skin; Skin Diseases | 1991 |
Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leuke
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Vinca Alkaloids | 1991 |
New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Drug Synergism; Humans; Leukemia, Myeloid; Tretinoin; Tumor Cells, Cultured | 1991 |
[Subleukemic acute monophagocytic leukemia. A biological phenotype close to malignant histiocytosis].
Topics: Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Doxorubicin; Etoposide; Female; Giant Cells; Histiocytic Sarcoma; Humans; Leukemia; Leukemia, Myeloid; Phagocytosis; Thioguanine | 1991 |
[Controversies in the treatment of acute myeloid leukemia of the adult. Chemotherapy vs bone marrow transplantation].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged | 1991 |
Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Kinetics; Leukemia, Myeloid; Monocytes; Recombinant Proteins; Reference Values; Stem Cells; Tumor Cells, Cultured | 1991 |
Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity.
Topics: Acute Disease; Aged; Aged, 80 and over; Cell Division; Cell Survival; Cytarabine; Female; Granulocytes; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Bryostatins; Cell Count; Cytarabine; Diterpenes; DNA, Neoplasm; Humans; Kinetics; Lactones; Leukemia, Experimental; Leukemia, Myeloid; Macrolides; Phorbol 12,13-Dibutyrate; Phosphorylation; Terpenes; Time Factors; Tumor Cells, Cultured | 1991 |
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neutropenia; Recombinant Proteins; Remission Induction; Thioguanine | 1991 |
Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cell Cycle; Cell Survival; Cytarabine; DNA; Drug Resistance; Humans; Hydroxyurea; In Vitro Techniques; Leukemia, Myeloid; Thymidine; Tumor Cells, Cultured | 1991 |
Post consolidation therapy for adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1991 |
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Cytarabine; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid; Phenotype; Tumor Cells, Cultured | 1991 |
Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine.
Topics: Cell Line; Cell Survival; Colony-Forming Units Assay; Cytarabine; DNA Damage; DNA, Neoplasm; Humans; Leukemia, Myeloid; Nucleosomes; RNA, Neoplasm | 1991 |
Nodular regenerative hyperplasia: a cause of ascites and hepatomegaly after chemotherapy for leukemia.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Cytarabine; Daunorubicin; Female; Hepatomegaly; Humans; Hyperplasia; Leukemia, Myeloid; Liver | 1991 |
Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine.
Topics: Cell Survival; Cycloheximide; Cytarabine; Dose-Response Relationship, Drug; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; Protein Biosynthesis; Proto-Oncogenes; RNA, Messenger; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1991 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors | 1991 |
Mechanism of inhibition of DNA ligase in Ara-C treated cells.
Topics: Adenosine Monophosphate; Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA Ligases; Humans; Hydroxyurea; Leukemia, Myeloid; Tumor Cells, Cultured | 1991 |
Circulating immune complexes correlate with remission duration in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Bone Marrow; Bone Marrow Cells; Complement C1q; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Sex Factors; Survival Analysis | 1991 |
Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1991 |
Improved prognosis in mice with advanced myeloid leukemia following administration of GM-CSF and cytosine arabinoside.
Topics: Animals; Bone Marrow; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Leukemia, Experimental; Leukemia, Myeloid; Male; Mice; Mice, Inbred BALB C; Recombinant Proteins | 1991 |
Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
Topics: Bone Marrow; Cell Division; Clone Cells; Cytarabine; Granulocytes; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Macrophages; Neoplastic Stem Cells; Stem Cells; Tumor Cells, Cultured | 1991 |
Regulation of jun-B gene expression by 1-beta-D-arabinofuranosyl-cytosine in human myeloid leukemia cells.
Topics: Cycloheximide; Cytarabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Oncogene Protein p65(gag-jun); Oncogenes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Retroviridae Proteins, Oncogenic; Transcription, Genetic; Tumor Cells, Cultured | 1990 |
Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells.
Topics: Cell Division; Cell Line; Cell Membrane; Cell Transformation, Neoplastic; Cobalt Radioisotopes; Cytarabine; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Experimental; Leukemia, Myeloid; Receptors, Cell Surface; Transcobalamins; Trypsin; Up-Regulation; Vitamin B 12 | 1990 |
Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
Topics: Animals; Cell Survival; Chromosome Aberrations; Cytarabine; Deoxycytidine Kinase; Deoxyribonucleotides; Drug Resistance; Isoenzymes; Leukemia, Myeloid; Rats; Rats, Inbred BN; Substrate Specificity; Tumor Cells, Cultured | 1990 |
Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Topics: Arabinofuranosylcytosine Triphosphate; Cell Line; Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine Kinase; DNA, Neoplasm; Humans; Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, T-Cell; Phosphorylation | 1990 |
The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Topics: Cell Survival; Culture Media; Cyclophosphamide; Cytarabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplastic Stem Cells; Phytohemagglutinins; Suspensions; Tumor Cells, Cultured | 1990 |
Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents.
Topics: Blotting, Northern; Cytarabine; DNA Polymerase I; DNA Polymerase II; Dose-Response Relationship, Radiation; Drug Resistance; Etoposide; Hematopoietic Stem Cells; Hot Temperature; Humans; In Vitro Techniques; Leukemia, Myeloid; Tumor Cells, Cultured; X-Rays | 1990 |
Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
Topics: Adult; Blast Crisis; Cell Cycle; Child; Colony-Stimulating Factors; Cytarabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interleukin-4; Leukemia, Myeloid; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Tumor Cells, Cultured | 1990 |
Synthesis of a 60 kD nuclear DNA binding protein induced by cytosine arabinoside in the HL 60 leukemic cell line.
Topics: Cell Line; Chromatography, Affinity; Cytarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Leukemia, Experimental; Leukemia, Myeloid; Methionine; Molecular Weight | 1990 |
Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Thioguanine | 1985 |
Cytosine arabinoside-induced differentiation and killing: unresolved questions.
Topics: Aged; Cell Differentiation; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Male | 1986 |
[Differentiation of human malignant myeloid and lymphoid cells].
Topics: Cell Differentiation; Cell Line; Cytarabine; Humans; Interferons; Leukemia, Hairy Cell; Leukemia, Myeloid; Lymphocytes | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Drug Evaluation; Humans; Hydroxyurea; Interferons; Leukemia, Myeloid; Prednisone; Recombinant Proteins; Retrospective Studies; Vincristine | 1987 |
Juvenile chronic myelogenous leukaemia: report of a case with an unusually long period of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hypersplenism; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Prednisolone | 1987 |
Amsacrine is safe in patients with ventricular ectopy.
Topics: Aged; Amsacrine; Cardiac Complexes, Premature; Cytarabine; Drug Therapy, Combination; Electrocardiography; Heart Ventricles; Humans; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Middle Aged | 1988 |
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid; Rats; Rats, Inbred BN; Time Factors | 1988 |
[Effect of cytosine arabinoside on the differentiation of granulocyte-monocyte progenitors (CFU-GM) and myeloid leukemia blasts (CFU-L) in vitro].
Topics: Cell Differentiation; Cell Transformation, Neoplastic; Colony-Forming Units Assay; Cytarabine; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Monocytes; Neoplastic Stem Cells | 1988 |
Relationship between intracellular dCTP/ara-CTP ratio and cytotoxic effect of ara-C.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Deoxycytosine Nucleotides; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Leukemia, T-Cell; Mice; Spleen; Time Factors; Tumor Cells, Cultured | 1989 |
Flow cytometric correlation of the c-myc oncoprotein and cell cycle kinetics of HL60 leukaemia during induced maturation with cytosine arabinoside and dimethylsulphoxide.
Topics: Blotting, Northern; Cell Cycle; Cell Differentiation; Cytarabine; Dimethyl Sulfoxide; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1989 |
Regulation of the genes for interleukin-6 and granulocyte-macrophage colony stimulating factor by different inducers of differentiation in myeloid leukemic cells.
Topics: Cell Differentiation; Colony-Stimulating Factors; Cytarabine; Dexamethasone; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interleukin-1; Interleukin-3; Interleukin-6; Leukemia, Myeloid; Lipopolysaccharides | 1989 |
Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cytarabine; Drug Administration Schedule; Female; Injections, Intraperitoneal; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Neoplasm Transplantation | 1989 |
[Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cell Survival; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission Induction; Tumor Cells, Cultured | 1989 |
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Statistics as Topic | 1989 |
[A case of granulocytic sarcoma preceding acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Lymph Nodes; Mercaptopurine; Prednisolone | 1989 |
[Therapy of the preleukemic state: effect of androgens on refractory anemia].
Topics: Adult; Aged; Androgens; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blast Crisis; Cholecalciferol; Chromosome Aberrations; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Preleukemia; Prognosis | 1988 |
[Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1988 |
Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
Topics: Adult; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Harringtonines; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vincristine | 1987 |
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction | 1988 |
Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia.
Topics: Adult; Bone Marrow; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Philadelphia Chromosome; Pilot Projects; Remission Induction | 1988 |
Busulfan-induced sideroblastic anemia.
Topics: Anemia, Sideroblastic; Bone Marrow; Busulfan; Chronic Disease; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Pancytopenia | 1988 |
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1988 |
Enhancement by hemin of the sensitivity of K562 human leukemic cells to 1-beta-D-arabinofuranosylcytosine.
Topics: Aminolevulinic Acid; Butyrates; Cell Differentiation; Cell Line; Cytarabine; Daunorubicin; Deoxyguanosine; Doxorubicin; Drug Synergism; Erythropoiesis; Heme; Hemin; Humans; Hydroxyurea; Leukemia, Myeloid; Methotrexate; Thymidine; Vincristine | 1986 |
Neurotoxicity associated with systemic high-dose cytosine arabinoside.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Nervous System Diseases | 1986 |
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
Topics: Acute Disease; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Biotransformation; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1986 |
[Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
The treatment of chronic myelogenous leukemia in blastic crisis with the chemotherapy incorporating vindesine-prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone; Vindesine | 1986 |
Prediction of remission induction in childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow; Child; Child, Preschool; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid; Prognosis; Recurrence; Tumor Stem Cell Assay | 1986 |
High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
Topics: Adult; Brain Diseases; Cytarabine; Drug Evaluation; Female; Hemorrhage; Humans; Infections; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Thrombocytopenia; Time Factors | 1986 |
Monocytic skin infiltration in chronic myelomonocytic leukaemia.
Topics: Aged; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Monocytes; Razoxane; Skin Neoplasms | 1986 |
[The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Vincristine | 1986 |
[An unusual way of manifesting acute granulocytic leukemia: granulocytic sarcoma of the breast. Apropos of a case with trisomy 22].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, 21-22 and Y; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms, Multiple Primary; Trisomy | 1986 |
[Cytogenetic and therapeutic results of a protocol including splenectomy and intensive polychemotherapy in Ph'-positive chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clone Cells; Combined Modality Therapy; Cytarabine; Humans; Leukemia, Myeloid; Philadelphia Chromosome; Prednisone; Splenectomy; Thioguanine; Vincristine | 1986 |
[Complete remission achieved by high dose cytosine arabinoside therapy in the 4th relapse of AML].
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid; Middle Aged; Recurrence | 1986 |
Pulmonary involvement in Sweet's syndrome (acute febrile neutrophilic dermatosis). Preleukemic and leukemic phases of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dermatitis; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Neutrophils; Pneumonia; Prednisone; Preleukemia; Radiography; Syndrome | 1986 |
Leukemic cell maturation: variability of the myeloid leukemic cell phenotype.
Topics: Butyrates; Butyric Acid; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Dimethyl Sulfoxide; Drug Resistance; Histocytochemistry; Humans; Leukemia, Myeloid; Phenotype; Tetradecanoylphorbol Acetate; Vitamin A | 1986 |
Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia.
Topics: Cell Division; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplastic Stem Cells; Tumor Stem Cell Assay | 1987 |
[Investigation of hepatic reserve in patients with severe liver dysfunction in the treatment of acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Deoxycytidine Monophosphate; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Liver; Liver Diseases; Male; Middle Aged | 1986 |
[Mechanisms of resistance of anticancer drugs and trials for overcoming their resistance].
Topics: Animals; Cytarabine; Drug Resistance; Extracellular Space; Humans; Kinetics; Leukemia L1210; Leukemia, Myeloid; Methotrexate; Mice | 1986 |
Histone mRNA degradation in vivo: the first detectable step occurs at or near the 3' terminus.
Topics: Base Sequence; Cell Line; Cloning, Molecular; Cytarabine; DNA Replication; Genes; Histones; Humans; Hydroxyurea; Kinetics; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Nucleic Acid Hybridization; RNA, Messenger | 1986 |
Low dose cytosar in the treatment of chronic granulocytic leukaemia--blast crisis.
Topics: Adult; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid | 1987 |
[Retrospective study of 30 cases of myelodysplastic syndrome according to the French-American-British classification].
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Bone Marrow; Cytarabine; Female; Hematopoietic Stem Cells; Humans; International Cooperation; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Retrospective Studies | 1987 |
Treatment of juvenile chronic myelocytic leukemia with multidrug chemotherapy including aclacinomycin and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Humans; Leukemia, Myeloid; Male; Naphthacenes | 1986 |
Cytarabine-induced cerebellar syndrome: case report and literature review.
Topics: Cerebellar Diseases; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged | 1987 |
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Metabolic Clearance Rate | 1987 |
A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults.
Topics: Acute Disease; Adult; Aged; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Middle Aged; Time Factors | 1987 |
Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid | 1987 |
[Granulocytic sarcoma (chloroma) with bladder and breast localizations preceding acute myeloblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Drug Combinations; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Time Factors; Urinary Bladder Neoplasms; Vincristine | 1987 |
[Round table: Differentiation of human malignant lymphoid and myeloid cells].
Topics: Cell Differentiation; Cell Line; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplastic Stem Cells | 1987 |
Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562.
Topics: Cell Differentiation; Cell Line; Cytarabine; Daunorubicin; DNA; Erythrocytes; Gene Expression Regulation; Globins; Humans; Leukemia, Myeloid; Proto-Oncogenes; RNA, Messenger | 1987 |
[Successful treatment with low-dose Ara-C in a case of chronic myelomonocytic leukemia].
Topics: Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged | 1987 |
Clostridium difficile colitis induced by cytarabine.
Topics: Aged; Cytarabine; Enterocolitis, Pseudomembranous; Humans; Leukemia, Myeloid; Male; Vancomycin | 1987 |
[A successful topical administration of prostaglandin E2 (PGE2) for the prophylaxis of chemotherapy associated oral mucosal lesions in a case of monocytic leukemia].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dinoprostone; Female; Humans; Leukemia, Myeloid; Mercaptopurine; Middle Aged; Mouth Mucosa; Prednisolone; Prostaglandins E; Stomatitis | 1987 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
[High doses of cytosine arabinoside in the treatment of refractory leukemia].
Topics: Blast Crisis; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1987 |
Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells.
Topics: Antigens, Differentiation; Arabinonucleosides; Cell Differentiation; Cell Division; Clone Cells; Cytarabine; Humans; Kinetics; Leukemia, Myeloid; Nitroblue Tetrazolium; Pyrimidines; Tumor Cells, Cultured | 1987 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Heart Diseases; Humans; Infant; Infusions, Intravenous; Leukemia, Lymphoid; Leukemia, Myeloid; Mitoxantrone; Nausea; Pancytopenia; Vomiting | 1987 |
[Daunomycin-induced cardiogenic shock in a case of acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Prednisolone; Shock, Cardiogenic | 1987 |
[Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1987 |
Autologous marrow transplantation for patients with chronic myeloid leukemia in accelerated or blastic phase: report of 14 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid; Lomustine; Male; Middle Aged; Platelet Transfusion; Thioguanine; Transplantation, Autologous | 1986 |
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, 21-22 and Y; Combined Modality Therapy; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Prognosis; Splenectomy; Translocation, Genetic; Vincristine | 1985 |
The blast crisis of chronic granulocytic leukaemia: a new approach to treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Male; Middle Aged; Thioguanine | 1985 |
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, 21-22 and Y; Cytarabine; Daunorubicin; Humans; Isotretinoin; Leukemia, Myeloid; Leukopenia; Liver; Middle Aged; Stomatitis; Thioguanine; Thrombocytopenia; Time Factors; Tretinoin | 1985 |
Treatment of refractory leukemia with high-dose cytosine arabinoside.
Topics: Acute Disease; Adult; Aged; Cytarabine; Female; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells.
Topics: Cell Differentiation; Cell Line; Cytarabine; DNA Replication; Globins; Glycophorins; Heme; Humans; Kinetics; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Nucleic Acid Hybridization; Phorbols; RNA, Messenger; Tetradecanoylphorbol Acetate; Transcription, Genetic | 1985 |
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Topics: Acute Disease; Adult; Aged; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Injections, Subcutaneous; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Preleukemia | 1985 |
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Humans; Hydroxyurea; Interphase; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1985 |
High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Child; Cytarabine; Drug Resistance; Female; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Time Factors | 1985 |
Drug association including ara-C in myeloid leukemia cell differentiation: in vitro studies.
Topics: Cell Differentiation; Cell Line; Cytarabine; Drug Synergism; Humans; Kinetics; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Tretinoin | 1985 |
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
Topics: Arabinofuranosylcytosine Triphosphate; Chromosome Aberrations; Cytarabine; Drug Evaluation; Drug Resistance; Half-Life; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prognosis; Time Factors | 1985 |
Low dose cytosine arabinoside in acute myeloid leukemia: remission is not due to differentiation induction.
Topics: Aged; Cell Differentiation; Cytarabine; Humans; Leukemia, Myeloid; Male | 1985 |
Treatment of CML blast crisis with low dose ARA-C.
Topics: Cytarabine; Humans; Leukemia, Myeloid | 1985 |
Acute myelomonocytic leukemia (M-4 subtype) with abnormal marrow eosinophilia and a normal chromosome 16.
Topics: Antigens, Surface; Bone Marrow; Chromosomes, Human, 16-18; Cytarabine; Daunorubicin; Eosinophilia; Humans; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia | 1985 |
Acute granulocytic leukemia following systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aspirin; Cyclophosphamide; Cytarabine; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Male | 1985 |
Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia: no relationship to the phenotype of the blast cells.
Topics: Adult; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyurea; Hypercalcemia; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Phenotype; Primary Myelofibrosis | 1985 |
Control of acute transformation in chronic granulocytic leukaemia with low-dose cytosine arabinoside.
Topics: Acute Disease; Adult; Cell Transformation, Neoplastic; Cytarabine; Humans; Leukemia, Myeloid; Male | 1985 |
Chronic granulocytic leukaemia in accelerated stage treated with low dose cytosine arabinoside.
Topics: Chronic Disease; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Count; Body Weight; Bone Marrow Cells; Busulfan; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Philadelphia Chromosome; Prednisone; Prognosis; Risk; Vincristine | 1985 |
[High-dose cytosine arabinoside administration in the treatment of refractory leukemia].
Topics: Adolescent; Adult; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Myeloid; Lymphoma; Male; Middle Aged | 1985 |
Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias.
Topics: Animals; Autoradiography; Bone Marrow; Cells, Cultured; Cytarabine; DNA Replication; DNA, Neoplasm; Doxorubicin; Flow Cytometry; Humans; Interphase; Leukemia; Leukemia P388; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Mice | 1985 |
[Evaluation of the sensitivity to cytostatics of leukemia cells by labeling with tritiated thymidine and uridine: comparison with clinical response].
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Retrospective Studies; Tumor Stem Cell Assay | 1985 |
[Principles of high-dose cytarabinoside treatment].
Topics: Acute Disease; Bone Marrow; Cell Cycle; Cytarabine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Metabolic Clearance Rate; RNA, Neoplasm | 1985 |
[Results of therapy with high-dose cytosine arabinoside].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
[Results of high-dose cytarabine therapy. A review].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma | 1985 |
Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Central Nervous System Diseases; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Diarrhea; Graft vs Host Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Pulmonary Fibrosis; Skin Diseases; Whole-Body Irradiation | 1985 |
The combined use of cytosine arabinoside, cyclophosphamide, and total body irradiation as preparative regimen for bone marrow transplantation in patients with AML and CML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pulmonary Fibrosis; Whole-Body Irradiation | 1985 |
Central nervous system toxicity with high-dose cytosine arabinoside.
Topics: Acute Disease; Aging; Central Nervous System Diseases; Combined Modality Therapy; Cytarabine; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Middle Aged; Whole-Body Irradiation | 1985 |
In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
Topics: Adult; Aged; Bone Marrow; Bromodeoxyuridine; Cytarabine; DNA; Drug Resistance; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Interphase; Leukemia; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Differentiation in myelodysplastic, myeloid leukaemic and normal haemopoietic cells: a new approach exploiting the synergistic interaction between differentiation inducers and DNA synthesis inhibitors.
Topics: Antineoplastic Agents; Aphidicolin; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cytarabine; Diterpenes; DNA Replication; Formamides; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Mercaptopurine; Myeloproliferative Disorders; Reference Values; Tretinoin | 1985 |
Bone marrow transplantation in accelerated chronic granulocytic leukaemia using dibromomannitol-preconditioning instead of total-body irradiation.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid; Male; Mannitol; Mitobronitol; Neutrophils; Premedication; Splenectomy; Whole-Body Irradiation | 1985 |
Cytosine arabinoside and herpes zoster.
Topics: Acute Disease; Adolescent; Adult; Child, Preschool; Cytarabine; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous; Time Factors | 1971 |
Cytosine arabinoside in the treatment of acute myeloblastic leukaemia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amino Sugars; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Synergism; Female; Follow-Up Studies; Glycosides; Humans; Injections, Intravenous; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Pregnancy; Remission, Spontaneous; Time Factors | 1971 |
Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.
Topics: Aminohydrolases; Azacitidine; Blood Proteins; Carbon Radioisotopes; Chromatography, Ion Exchange; Cytarabine; Cytidine; Deamination; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Leukocytes; Spectrophotometry, Ultraviolet | 1973 |
Flow microfluorometric analysis of cell killing with cytotoxic drugs.
Topics: Autoanalysis; Bleomycin; Cell Division; Cell Line; Cell Survival; Cytarabine; Dactinomycin; Demecolcine; DNA, Neoplasm; Histocytochemistry; Humans; Hydroxyurea; Leukemia, Myeloid; Methods; Microscopy, Fluorescence; Mitosis; Staining and Labeling; Thymidine; Time Factors; Tritium | 1974 |
[Activity of methionine synthetase (5-methyl-5,6,7,8-tetrahydrofolate: homocysteine methyltransferase) as a proliferation parameter in growing cells].
Topics: Cell Division; Cells, Cultured; Cytarabine; DNA Nucleotidyltransferases; Folic Acid; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Methionine; Methyltransferases; Prednisolone; Tetrahydrofolates; Thioguanine; Thymidine Kinase; Vincristine | 1973 |
Treatment of the blastic phase of chronic myeloid leukaemia. A question to solve.
Topics: Adult; Antineoplastic Agents; Child; Cytarabine; Glycine; Humans; Hydroxyurea; Leukemia, Myeloid; Purines; Remission, Spontaneous; Sulfides; Valerates; Vincristine | 1972 |
Treatment of central nervous system leukemia with intrathecal cytosine arabinoside.
Topics: Adolescent; Adult; Animals; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Dogs; Female; Haplorhini; Headache; Humans; Injections, Spinal; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Meninges; Middle Aged; Vomiting | 1973 |
[Preliminary studies on the effectiveness of the association cytosine-arabinoside, thioguanine, hydroxyureas in the treatment of blastic crisis in chronic myeloid leukemia].
Topics: Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Thioguanine | 1972 |
Human leukemia antigens: partial isolation and characterization.
Topics: Animals; Antigens, Neoplasm; Cell Line; Cell Membrane; Centrifugation; Chromatography, Gel; Cycloheximide; Cytarabine; Cytotoxicity Tests, Immunologic; Dactinomycin; Haplorhini; Histocompatibility Antigens; Humans; Immune Sera; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; Microscopy, Electron; Neuraminidase; Papain; Potassium Chloride; Pronase; Puromycin; Rabbits; Subcellular Fractions; Temperature; Trypsin | 1974 |
Pharmacodynamic and pharmacokinetic measurements of antitumor agents.
Topics: Animals; Antineoplastic Agents; Body Surface Area; Cell Division; Cricetinae; Culture Techniques; Cyclophosphamide; Cytarabine; Dogs; Half-Life; Haplorhini; Humans; Kinetics; Leukemia L1210; Leukemia, Myeloid; Methotrexate; Mice; Mice, Inbred Strains; Neoplasms; Rats; Species Specificity; Time Factors | 1974 |
Immunoglobulins in acute leukemia in children.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Immunodiffusion; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Infant; Leukemia; Leukemia, Myeloid; Lymphocytes; Male; Mercaptopurine; Methotrexate; Prednisone; Vincristine | 1974 |
Splenectomy in early chronic myeloid leukaemia: preliminary report on 37 cases.
Topics: Adolescent; Adult; Blood Cell Count; Blood Platelets; Cytarabine; Death; Drug Therapy, Combination; Hematopoiesis; Hemoperitoneum; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Organ Size; Pleural Effusion; Pneumonia; Prednisone; Pyelonephritis; Spleen; Splenectomy; Subphrenic Abscess; Thrombocytosis; Thrombophlebitis; Vincristine | 1974 |
Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man.
Topics: Adult; Carcinoma, Hepatocellular; Chromatography, Paper; Cytarabine; DNA; Female; Humans; Leukemia, Myeloid; Leukocytes; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nucleosides; RNA; RNA, Transfer; Tritium; Uracil Nucleotides; Uridine | 1966 |
Thrombocytopenia with sodium cephalothin therapy.
Topics: Agglutination Tests; Antibodies; Blood Cell Count; Blood Platelets; Cephalothin; Chromium Isotopes; Coombs Test; Cytarabine; Female; Gentamicins; Hemoglobins; Humans; Injections, Intravenous; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Pneumonia; Polymyxins; Sodium; Thrombocytopenia | 1972 |
Acute promyelocytic leukemia in pregnancy.
Topics: Acute Disease; Adult; Afibrinogenemia; Blood Cell Count; Blood Coagulation Disorders; Blood Transfusion; Bone Marrow Examination; Cytarabine; Ecchymosis; Estrogens, Conjugated (USP); Factor V Deficiency; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Pregnancy; Pregnancy Complications, Hematologic; Prothrombin Time; Remission, Spontaneous; Thioguanine; Uterine Hemorrhage | 1973 |
Busulfan lung complicated by pneumocystis carinii and cytomegalovirus infection.
Topics: Busulfan; Cytarabine; Cytomegalovirus Infections; Female; Humans; Leukemia, Myeloid; Lung; Middle Aged; Pneumonia, Pneumocystis; Prednisone; Pulmonary Fibrosis | 1974 |
Letter: Androgen role in erythroleukemia after treatment with alkylating agents.
Topics: Adult; Alkylating Agents; Androgens; Carcinoma, Intraductal, Noninfiltrating; Chlorambucil; Cytarabine; Female; Fluoxymesterone; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasm Metastasis; Thiotepa | 1974 |
[A case of spinal chloroma revealing acute leukemia].
Topics: Adult; Asparaginase; Betamethasone; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Spinal Cord Compression; Spinal Neoplasms | 1974 |
Letter: neuropathy due to cytosine arabinoside.
Topics: Cytarabine; Foot; Hand; Humans; Injections, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Peripheral Nervous System Diseases | 1974 |
In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine.
Topics: Aminohydrolases; Carbon Isotopes; Cytarabine; Deamination; Female; Humans; Kinetics; Leukemia, Myeloid; Lymphoma; Male; Mathematics; Models, Biological; Uracil | 1972 |
Combination chemotherapy of adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission, Spontaneous; Thioguanine; Vomiting | 1972 |
The generation time of human leukemic myeloblasts.
Topics: Aged; Autoradiography; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Division; Cytarabine; DNA, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone; Thymidine; Time Factors; Tritium | 1972 |
Daunorubicin. Results in childhood leukaemia.
Topics: Adolescent; Agranulocytosis; Anemia; Bone Marrow; Bone Marrow Cells; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Female; Hemorrhage; Humans; Infant; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Mercaptopurine; Neutrophils; Prednisolone; Thrombocytopenia; Vincristine | 1972 |
Observations on the myelocyte to tissue transit time (MTT) in acute leukaemia and other proliferative disorders.
Topics: Acute Disease; Adult; Cytarabine; Fluorine; Hematologic Diseases; Hematopoiesis; Humans; Isoflurophate; Leukemia, Myeloid; Leukocyte Count; Leukocytes; Myeloproliferative Disorders; Radioisotopes; Remission, Spontaneous; Thioguanine; Time Factors | 1972 |
Chronic myelogenous leukemia presenting in blastic crisis.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 21-22 and Y; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Vincristine | 1972 |
Intensive chemotherapy of acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Vincristine | 1972 |
Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Combinations; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1972 |
Decreased leukocyte alkaline phosphatase in monocytic leukemia.
Topics: Aged; Alkaline Phosphatase; Anemia; Blood Transfusion; Bone Marrow; Busulfan; Cytarabine; Female; Histocytochemistry; Humans; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Pneumonia; Purpura; Radiography; Sepsis; Splenomegaly; Staphylococcal Infections; Tetracycline; Thioguanine | 1972 |
[Clinical studies on the early diagnosis and treatment of blastic crisis of chronic myelogenous leukemia].
Topics: Alkaline Phosphatase; Busulfan; C-Reactive Protein; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone | 1972 |
Case report: acute lymphatic leukemia followed by a clinical picture indistinguishable from chronic granulocytic leukemia in the same patient.
Topics: Adult; Bone Marrow Examination; Cytarabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Protein Binding; Remission, Spontaneous; Spleen; Vitamin B 12 | 1972 |
Daunorubicin in the therapy of acute granulocytic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Platelets; Blood Transfusion; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Hyperplasia; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Thrombocytopenia; Time Factors | 1973 |
Optimism in leukemia treatment.
Topics: Acute Disease; Adult; Child; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisolone; Thioguanine; Vincristine | 1973 |
[Combined treatment of myeloid leukemia with cytosine arabinoside and 6-mercaptopurine].
Topics: Cytarabine; Drug Synergism; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine | 1973 |
Treatment of acute myeloid leukaemia according to the Hammersmith protocol: preliminary report.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; London; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine | 1973 |
Cytogenetic studies during remission of blastic crisis in a patient with chronic myelocytic leukaemia.
Topics: Adult; Aneuploidy; Blood Cell Count; Blood Platelets; Busulfan; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cytarabine; Erythrocytes, Abnormal; Female; Hematocrit; Humans; Leukemia, Myeloid; Leukocyte Count; Remission, Spontaneous | 1973 |
[Acute myelogenous leukaemia of adults: diagnosis, prognosis and treatment (author's transl)].
Topics: Adult; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Evaluation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous; Thymidine; Tritium | 1973 |
Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse.
Topics: Aminohydrolases; Animals; Bone Marrow; Bone Marrow Cells; Cytarabine; Deoxycytidine; Humans; Kidney; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Liver; Mice; Phosphotransferases; Spleen; Uridine | 1973 |
Acute granulocytic leukemia in elderly patients.
Topics: Adult; Age Factors; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Retrospective Studies; Time Factors | 1973 |
Letter: Neurotoxicity of intrathecal chemotherapy for leukaemia.
Topics: Aphonia; Cytarabine; Deglutition Disorders; Diplopia; Headache; Humans; Injections, Spinal; Leukemia, Myeloid; Male; Middle Aged; Tremor | 1973 |
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
Topics: Adult; Aged; Chromatography; Chromatography, Paper; Cytarabine; Female; Half-Life; Humans; Kinetics; Leukemia, Myeloid; Male; Middle Aged; Neoplasms; Tritium | 1974 |
Complications of cytostatic therapy in childhood leukemia.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Asparaginase; Autopsy; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Kidney Neoplasms; Leukemia; Leukemia, Myeloid; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Time Factors | 1973 |
[Meningeal leukaemia in chloroma with later generalized leukaemia (author's transl)].
Topics: Adult; Blood Cell Count; Bone Marrow Examination; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Myeloid; Lumbar Vertebrae; Methotrexate; Myelography; Recurrence; Remission, Spontaneous; Sciatica; Spinal Neoplasms | 1974 |
A case of acute myelomonocytic leukaemia associated with myelomatosis.
Topics: Aged; Autopsy; Blood Cell Count; Blood Protein Disorders; Blood Protein Electrophoresis; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Immunoelectrophoresis; Immunoglobulin G; Leukemia, Myeloid; Male; Melphalan; Multiple Myeloma; Prednisone | 1973 |
The treatment of acute myeliod leukaemia.
Topics: Adolescent; Adult; Blood Cell Count; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous | 1974 |
Management of priapism in patients with chronic granulocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Busulfan; Cytarabine; Diazepam; Humans; Hydroxyurea; Infusions, Parenteral; Leukemia, Myeloid; Male; Priapism; Splenomegaly | 1974 |
Neutralization in vivo of Lewis antibodies. Report of two cases.
Topics: Acute Disease; Aged; Antigen-Antibody Reactions; Blood Group Incompatibility; Coombs Test; Cytarabine; Hematocrit; Humans; Leukemia, Myeloid; Lewis Blood Group Antigens; Male; Middle Aged; Stomach Neoplasms; Transfusion Reaction | 1974 |
Mediastinal adenopathy in granulocytic leukemia.
Topics: Adult; Busulfan; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Lymph Nodes; Lymphoma; Male; Mediastinal Neoplasms; Thioguanine | 1974 |
[Cytosine-arabinoside in the treatment of acute leukemias].
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polycythemia | 1972 |
Chronic granulocytic leukaemia: multiple-drug chemotherapy for acute transformation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asparaginase; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1974 |
Studies of leukemic cell populations in culture.
Topics: Autoradiography; Bone Marrow Cells; Cell Adhesion; Cell Division; Cell Separation; Cells, Cultured; Culture Media; Cytarabine; Daunorubicin; Freezing; Humans; Lectins; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Middle Aged; Prednisone; Radiation Effects; Thymidine; Tritium; Ultrafiltration | 1974 |
Microfluorimetric evaluation of cell kill kinetics with 1-beta-D-arabinofuranosylcytosine.
Topics: Autoradiography; Cell Biology; Cell Division; Cell Line; Cell Survival; Cytarabine; DNA; Fluorometry; Humans; Kinetics; Leukemia, Myeloid; Mitosis; Thymidine; Tritium | 1974 |
Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II.
Topics: Antineoplastic Agents; Brain Neoplasms; Busulfan; Cell Count; Cell Division; Cytarabine; Diffusion; Drug Tolerance; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocyte Count; Lymphoma; Methotrexate; Multiple Myeloma; Neoplasms; Vincristine | 1974 |
Different blocks in the differentiation of myeloid leukemic cells.
Topics: Animals; Binding Sites, Antibody; Blood; Cell Differentiation; Cell Membrane; Cells, Cultured; Complement System Proteins; Cytarabine; Dactinomycin; Endotoxins; Erythrocytes; Granulocytes; Immune Adherence Reaction; Immunoglobulins; Leukemia, Experimental; Leukemia, Myeloid; Leukocytes; Macrophages; Mice; Prednisolone; Sheep; Uracil | 1974 |
Cytologic expressions of spontaneous tumor-specific immunity in an untreated myelomonocytic leukemia. Sustained, complete remission following minimal immunosuppressive therapy.
Topics: Acute Disease; BCG Vaccine; Cytarabine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunosuppression Therapy; Leukemia, Myeloid; Lymphocytes; Middle Aged; Remission, Spontaneous; Thioguanine | 1974 |
Symptomatic disorders of cardiac conduction in childhood leukemia.
Topics: Arrhythmias, Cardiac; Bradycardia; Child; Cyclophosphamide; Cytarabine; Female; Heart Block; Humans; Leukemia; Leukemia, Myeloid; Male; Myocardium; Prednisolone; Vincristine | 1974 |
Congenital and neonatal leukemia-- lymphocytic or myelocytic?
Topics: Blood Cell Count; Blood Transfusion; Bone Marrow; Bone Marrow Cells; Cytarabine; Diagnosis, Differential; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Prednisone; Vincristine; Vitamin K 1 | 1974 |
The management of blastic crisis of chronic myeloid leukaemia with thioguanine, rubidomycin, ARA C and prednisone (TRAP regimen).
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine | 1973 |
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examination; Cell Nucleus; Cytarabine; Drug Tolerance; Erythrocytes; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone | 1968 |
Cytogenetic and morphologie abnormalities in human bone marrow cells during cytosine arabinoside therapy.
Topics: Bone Marrow; Bone Marrow Cells; Chromosomes; Cytarabine; Humans; Leukemia, Myeloid; Neoplasms | 1966 |
Biochemical studies with 1 beta-D-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells.
Topics: Adolescent; Adult; Aged; Animals; Bone Marrow; Bone Marrow Cells; Child, Preschool; Cytarabine; DNA Replication; DNA, Neoplasm; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukocyte Count; Leukocytes; Male; Middle Aged; Neoplasm Proteins; Nucleosides; RNA, Neoplasm; Sarcoma, Experimental; Tritium | 1968 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Pipobroman; Prednisolone; Vincristine | 1968 |
Treatment of AGL.
Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans; Hydroxyzine; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukopenia; Mercaptopurine; Methotrexate; Middle Aged; Polycythemia Vera; Prednisone; Primary Myelofibrosis; Splenomegaly; Vincristine | 1969 |
Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro.
Topics: Blood Platelets; Cell Membrane Permeability; Cytarabine; Cytosine Nucleotides; Erythrocytes; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocytes; Oxidative Phosphorylation; Temperature; Tritium | 1969 |
Coordinated changes in biochemical patterns: the effect of cytosine arabinoside and methotrexate on leukocytes from patients with acute granulocytic leukemia.
Topics: Acute Disease; Cytarabine; Deoxyuridine; DNA; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Ligases; Methotrexate; Phosphotransferases; Tetrahydrofolate Dehydrogenase; Thymidine; Thymidine Kinase | 1969 |
Development of herpes zoster in a patient with acute leukemia after therapy with cytosine arabinoside (NSC-63878).
Topics: Adult; Cytarabine; Female; Herpes Zoster; Humans; Leukemia, Myeloid | 1969 |
Comparative sensitivity to various antimetabolites of several established cell lines derived from the buffy coat of normal humans and patients with neoplastic diseases.
Topics: Antimetabolites; Blood Cells; Cell Line; Culture Techniques; Cytarabine; Fluorouracil; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mitosis; Neoplasms | 1969 |
Prolonged infusion of arabinosyl cytosine in childhood leukemia.
Topics: Adolescent; Body Surface Area; Bone Marrow; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukopenia; Male; Time Factors | 1970 |
Experience with the use of cytosine arabinoside in adult acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Cyclophosphamide; Cytarabine; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1970 |
Preliminary evaluation of cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male | 1969 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Prednisone; Vincristine | 1970 |
Disseminated varicella in a patient with acute myelogenous leukemia: treatment with cytosine arabinoside.
Topics: Chickenpox; Child; Cytarabine; Female; Humans; Leukemia, Myeloid | 1971 |
Therapy of acute leukemia.
Topics: Adolescent; Animals; Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Child; Cytarabine; Daunorubicin; Disease Models, Animal; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Mice; Remission, Spontaneous; Vincristine | 1970 |
[Cytosine-arabinoside in the treatment of acute myeloblastic leukemias].
Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male | 1971 |
The effects of chemotherapeutic agents on the RNA metabolism of 90Sr-induced rat chloroleukemia.
Topics: Animals; Asparaginase; Cytarabine; Daunorubicin; Depression, Chemical; Hydrocortisone; In Vitro Techniques; Leukemia, Myeloid; Leukemia, Radiation-Induced; Poly I-C; Polynucleotides; Rats; RNA, Neoplasm; Strontium Isotopes; Tritium; Uridine; Vinblastine | 1971 |
[Treatment of acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antilymphocyte Serum; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Synergism; Female; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Prednisone; Vincristine | 1970 |
[Round table conference--present status and the future of treatment of leukemia].
Topics: Acute Disease; Asparaginase; Cytarabine; Daunorubicin; Glutaminase; Humans; Leukemia; Leukemia, Myeloid; Vinblastine; Vincristine | 1971 |
Cytarabine.
Topics: Acute Disease; Amino Sugars; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Cyclophosphamide; Cytarabine; Glycosides; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukopenia; Lymphoma; Prednisone; Remission, Spontaneous; Thioguanine; Thrombocytopenia; Vincristine | 1971 |
[Autoradiographic and enzyme-chemical studies of the DNA synthesis in leukemia cells. II. Thymidine-kinase and 3H-thymidine labelling index under cytostatic therapy].
Topics: Adolescent; Adult; Autoradiography; Cell Differentiation; Cytarabine; DNA, Neoplasm; Female; Histocytochemistry; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Thymidine; Thymidine Kinase; Tritium | 1970 |
Attempted recruitment of leukemic myeloblasts to proliferative activity by sequential drug treatment.
Topics: Adult; Autoradiography; Bone Marrow; Bone Marrow Cells; Culture Techniques; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mitosis; Models, Biological; Remission, Spontaneous; Thymidine; Tritium; Vincristine | 1971 |
Multiple pulmonary aspergillomas in acute leukemia.
Topics: Adult; Amphotericin B; Aspergillosis; Cytarabine; Female; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Nystatin; Pulmonary Embolism; Remission, Spontaneous | 1971 |
[Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Allopurinol; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Blood Transfusion; Cytarabine; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Muramidase; Nausea; Prednisolone; Thrombocytopenia; Vincristine | 1971 |
Chemotherapy-induced changes in serum vitamin B 12 binding proteins in myeloid leukemia.
Topics: Antineoplastic Agents; Asparaginase; Busulfan; Chromatography, Ion Exchange; Cobalt Isotopes; Cytarabine; Humans; Leukemia, Myeloid; Leukocyte Count; Mercaptopurine; Protein Binding; Serum Globulins; Vitamin B 12 | 1971 |
[Results of cytostatic and radiologic treatment of chronic myelocytic leukemia (analysis of 11 cases)].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Examination; Busulfan; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukocytosis; Male; Mannitol; Mercaptopurine; Middle Aged; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Splenic Neoplasms; Splenomegaly; Vincristine | 1970 |